As filed with the Securities and Exchange Commission on December 8, 2022
Registration No. 333-________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
SCRIPPS SAFE, INC.
(Exact name of registrant as specified in its charter)
Delaware | SIC: 7372 NAICS: 511210 | 88-0611514 | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
Scripps Safe, Inc.
9051 Tamiami Trail N, Suite 201
Naples, FL 34108
(844) 472-3379
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Jacqueline von Zwehl
Chief Executive Officer
Scripps Safe, Inc.
9051 Tamiami Trail N, Suite 201
Naples, FL 34108
(844) 472-3379
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Arthur Marcus, Esq.
Michael Blane, Esq.
Sichenzia Ross Ference LLP. 1185 Avenue of the Americas New York, New York 10036 (212) 930-9700 |
Robert Charron, Esq Ellenoff Grossman & Schole, LLP 1345 Avenue of the Americas New York, New York 10105 (212) 370-1300 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ | Accelerated filer ☐ | |
Non-accelerated filer ☒ | Smaller reporting company ☒ | |
Emerging growth company ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant will file a further amendment which specifically states that this registration statement will thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement will become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
PRELIMINARY PROSPECTUS | SUBJECT TO COMPLETION | DECEMBER 8, 2022 |
3,000,000 Shares of Common Stock
This is the initial public offering of shares of common stock of Scripps Safe, Inc.
Prior to this offering, there was no public market for our common stock. We currently estimate that the initial public offering price per share will be between $4.00 and $6.00. The final public offering price will be determined by us and WestPark Capital, Inc., as representative of the underwriters in connection with this offering, taking into consideration several factors at the time of pricing, including our historical performance and capital structure, prevailing market conditions, and overall assessment of our business. Therefore, the assumed public offering price used throughout this prospectus of $5.00 per share, the midpoint of the anticipated range, may not be indicative of the actual public offering price for our common stock.
We intend to apply to list our shares of common stock for trading on the Nasdaq Capital Market, or Nasdaq subject to official notice of issuance, under the symbol “SCRP”. Completion of this offering is contingent on the approval of our listing application for trading on the Nasdaq Capital Market.
The offering is being underwritten on a firm commitment basis. The underwriter may offer the shares of common stock from time to time to purchasers directly or through agents, through brokers in brokerage transactions on the Nasdaq Capital Market, to dealers in negotiated transactions or in a combination of such methods of sale, or otherwise, at fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to such prevailing market prices.
Upon completion of this offering, our Chief Executive Officer, and founder Jacqueline von Zwehl will beneficially own approximately 64.73% of our common stock (or approximately 62.18% of our common stock if the over-allotment option is exercised) and we will be a “controlled company” within the meaning of the listing rules of The Nasdaq Stock Market LLC.
We are an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, and, as such, may elect to comply with certain reduced public company reporting requirements for future filings. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company.
Investing in our securities is highly speculative and involves a high degree of risk. See “Risk Factors” beginning on page 12 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
Per Share | Total | |||||||
Initial public offering price | $ | 5.00 | $ | 15,000,000 | ||||
Underwriting discounts and commissions(1) | $ | 0.40 | $ | 1,200,000 | ||||
Proceeds, before expenses, to us | $ | 4.60 | $ | 13,800,000 |
(1) | The underwriters will be reimbursed for certain expenses incurred in the offering. See “Underwriting” for additional disclosure regarding underwriting discounts, commissions and expenses. |
We have granted to the underwriters an option to purchase up to 450,000 additional shares of common stock to cover overallotments, if any, exercisable at any time until 45 days after the date of this prospectus.
The underwriters expect to deliver the shares of common stock to purchasers in the offering on or about _______________, 20___.
WestPark Capital, Inc.
The date of this prospectus is _______________, ___
TABLE OF CONTENTS
You should rely only on the information contained in this prospectus or in any free writing prospectuses or amendments thereto that we may provide to you in connection with this offering. Neither we nor any of the underwriters have authorized anyone to provide you with information different from, or in addition to, that contained in this prospectus or in any such free writing prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. We can provide no assurance as to the reliability of any other information that others may give to you. The information in this prospectus is accurate only as of the date on the front cover of this prospectus, and the information in any free writing prospectus that we may provide you in connection with this offering is accurate only as of the date of such free writing prospectus. Our business, financial condition, results of operations and prospects may have changed since those dates. Neither we nor any of the underwriters are making an offer to sell or seeking offers to buy these securities in any jurisdiction where or to any person to whom the offer or sale is not permitted.
i |
GENERAL MATTERS
Unless otherwise indicated, all references to “dollars,” “US$,” or “$” in this prospectus are to United States dollars.
This prospectus contains various company names, product names, trade names, trademarks and service marks, all of which are the properties of their respective owners.
Unless otherwise indicated or the context otherwise requires, all information in this prospectus assumes no exercise of the over-allotment option granted to the underwriters.
Unless otherwise indicated, all references to “GAAP” in this prospectus are to United States generally accepted accounting principles.
Information contained on our websites, including www.4saferx.com and http://www.scrippssafe.com, shall not be deemed to be part of this prospectus or incorporated herein by reference and should not be relied upon by prospective investors for the purposes of determining whether to purchase the units offered hereunder.
Through and including ____________, 20___ all dealers effecting transactions in shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer’s obligation to deliver a prospectus when acting as an underwriter with respect to an unsold allotment or subscription.
For investors outside the United States, neither we nor any of our agents have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourself about and to observe any restrictions relating to this offering and the distribution of this prospectus.
USE OF MARKET AND INDUSTRY DATA
This prospectus includes market and industry data that has been obtained from third party sources, including industry publications, as well as industry data prepared by our management on the basis of its knowledge of and experience in the industries in which we operate (including our management’s estimates and assumptions relating to those industries based on that knowledge). Management’s knowledge of such industries has been developed through its experience and participation in those industries. Although our management believes such information to be reliable, neither we nor our management have independently verified any of the data from third party sources referred to in this prospectus or ascertained the underlying economic assumptions relied upon by such sources. In addition, the agents have not independently verified any of the industry data prepared by management or ascertained the underlying estimates and assumptions relied upon by management. Furthermore, references in this prospectus to any publications, reports, surveys or articles prepared by third parties should not be construed as depicting the complete findings of the entire publication, report, survey or article. The information in any such publication, report survey or article is not incorporated by reference in this prospectus.
TRADEMARKS
Scripps Safe currently owns various trademarks, service marks and trade names that we use in connection with the operation of our business. This prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks and trade names or products in this prospectus is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may appear without the ®, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names. There are no known issues, disputes, litigation, or opposition proceedings regarding the Company’s use of any marks referenced herein.
ii |
PROSPECTUS SUMMARY
This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, including the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our statements and the related notes included elsewhere in this prospectus, before making an investment decision. Unless the context otherwise requires, the terms “Scripps” “the Company,” “we,” “us” and “our” in this prospectus refer to Scripps Safe, Inc.
Company Overview
We are a pharmaceutical supply chain solutions company. We focus on the secure transport, storage, distribution and dispensing of pharmaceuticals within the lawful supply chain to healthcare providers while ensuring compliance with federal, state and industry oversight regulations. Our mission is to keep pharmaceuticals secure from the manufacturer/distributor to the patient by delivering integrated solutions across the United States and Canada.
WHO WE ARE
We are pharmaceutical security and inventory control pioneers. We bring innovation to compliance.®
WHAT WE DO
We innovate and develop integrated pharmaceutical security solutions, creating a safer healthcare environment.®
HOW WE DO IT
Protecting the chain of custody.®
Scripps Safe, Inc. plans to primarily focus on three major verticals, mobile pharmaceutical delivery including Fire-EMS; Private Ambulance operations/ home healthcare delivery; and Addiction or Medication Treatment Facilities by launching solutions with a yearly subscription recurring revenue model. These verticals represent the pharmaceutical distribution supply chain from manufacturers through distributors down to care providers. The technology solution is the Scripps System™ which was debuted at EMS (“Emergency Medical Services”) World October 2021. Scripps Safe was honored to be chosen as a 2021 EMS World Innovations Award Winner for the Scripps System™, a Drug Enforcement Agency (“DEA”) and Drug Supply Chain Security Act (“DSCSA”) compliance inventory audit and tracking solution.
The Scripps System™ is a Platform as a service (PaaS) Solution to keep pharmaceuticals secure within the lawful supply chain. This solution will deliver new releases of expanded features and functions made available on a yearly subscription revenue model. The Scripps System™ currently includes the availability of secure storage (vaults and safes) and access control system management available now on a transaction-based revenue model. New solution features are scheduled to be released in 2023 and 2024 and will include advanced inventory management, supply chain tracking, audit/tracking capability, diversion control, advanced analytics, and application programming interfaces (“API”) to common healthcare applications which will be made available on the subscription revenue model.
Scripps Safe currently has over 600 healthcare clients who have purchased DEA compliant vaults and safes.
To date, Scripps Safe has financed operations primarily through the sales of vaults and safes, founders’ contributions and an EIDL (“Economic Injury Disaster Loan”) Small Business Administration (“SBA”) Loan. Scripps Safe did record negative cash flow from operations and stockholders’ deficit which caused our independent auditor to raise doubt about our ability to continue as a growing concern.
Pharmaceutical security is REQUIRED by law. There are 1.9 million and growing state licensed and federally registered facilities and professionals that can handle regulated controlled substances. The security guidelines are mandated in the Controlled Substance Act of 1970 which is enforced by the DEA, the DSCSA under the jurisdiction of the FDA and each state has pharmaceutical jurisdiction enforced by their respective Bureau of Narcotics and/or Board of Pharmacy Department of Health and other Licensing Boards. Additionally, the recent passage of the Coronavirus Aid, Relief and Economic Security (“Cares Act of 2020”) and the Coronavirus Response and Consolidated Appropriations Act (“Cares Act of 2021”) provides funding and subsidies support for qualified healthcare treatment facilities to pay for their pharmaceutical security solutions. Scripps Safe does not have a controlled substance license nor are we required to for our business model.
The DEA enforcement of the Controlled Substance Act of 1970 is the U.S. federal statute establishing drug policy under which the manufacture, importation, possession, use, and distribution of certain substances is regulated. The FDA enforcement of the Drug Supply Chain Security Act of 2013, outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the U.S. Compliance traceability will become mandatory by November of 2023. State Pharmacy Boards, Departments of Health and/or State Bureaus of Narcotics have the option to require stricter guidelines. Many states have now implemented legal requirements for constant pharmaceutical supervision and surveillance and an “unbroken chain of custody”.
1 |
The U.S. market for Scripps Safe is estimated to be congruent with pharmaceutical distribution. The U.S. pharmaceutical market is controlled by the top 3 biggest distributors, McKesson, AmerisourceBergen, and Cardinal Health, known as the “Big 3”. In 2021 the “Big 3” reported a total of $574B in revenue, showing a steady year-to-year average growth rate of 7% over the last 10 years.1 Additionally as previously mentioned, there are currently over 1.9M controlled substance state license and DEA registrant holders with 135,000+ new entrants in the market every year.2 Based on the total pharmaceutical distribution in the U.S. and the actual number of controlled substance license and registrant holders, Scripps Safe estimates the U.S. addressable market opportunity for the Scripps SystemTM solution to be $16.5 billion a year and growing at a steady rate of 7% year-to-year.
3
This estimated market is for the U.S. ONLY. Scripps Safe does plan future expansion into international markets. This addressable market also does not account for the additional security requirements which may be mandated by the opioid litigation settlements and/or any future updates to the federal 52-year-old Controlled Substance Act and ever-changing state laws. State license holders and federal registrants must follow the stricter of the two sets of laws. We believe these future developments will dramatically increase the overall market opportunity and growth rate.
In 2023, it’s critical we hire key personnel to continue supporting the target markets and solution launches. To attract top talent, we plan to offer key executives’ equity through participation in an equity incentive plan (or similar) to be adopted by us. Other focus areas will include software development, patent protection/design filings and at least two new solutions launched in addition to re-launching our existing solutions through subscription revenue models. We just opened in May of 2022 a 5,000 square foot leased location in Jeffersonville, Indiana (sales, Eastern USA distribution, hardware innovation and customer support).
In 2023, we will continue hiring to support solutions development, marketing and sales. We’ll launch several solutions at key industry events within our targeted verticals. These events will be supported by months of pre-release public-relations campaigns, marketing tactics and launch deliverables. In 2023, we also plan strong sales and marketing expansion within these targeted verticals to grow revenue, market share and strategic positioning.
1 Compilation of Publicly reported revenues from each company
2 https://www.dealookup.com
3 Publicly reported annual revenues
2 |
Core Values
Every day we aim to change the world. To make an impactful difference. To save lives.
1. | Creating A Safer Healthcare Environment® | |
2. | We Bring Innovation to Compliance® | |
3. | Protecting the Chain of Custody® |
Drug diversion leads to drug abuse and death. We seek to keep drugs safe and save lives.
We Are…
● | Mission Driven – Inspired by our core values; we lead, collaborate and serve. | |
● | Game Changers – We provide the highest level of quality products and solutions that affordably address pharmaceutical security and compliance requirements. | |
● | Innovators – We develop and patent integrated solutions to create a seamless workflow across the supply chain and across market verticals. | |
● | Thought Leaders – We strive to be recognized as the industry thought leaders and experts in pharmaceutical security driving impactful and positive change. | |
● | Collaborators – We enjoy working in an environment that fosters participative management, ethical business practices, effective communication, encourages teamwork, stimulates creativity and promotes success through mutual trust and respect. | |
● | Influencers – We are driven to promulgate legislation at the state and federal levels to update pharmaceutical security standardization across the country providing for a safer, more secure and compliant environment. | |
● | Customer Driven – Our customers’ needs are our needs. Their success is our success. Their challenges become our challenges. We are passionately committed to serving our customers and delivering solutions/services which far exceed expectations. | |
● | Resilient – Markets, legislation and business dynamics change very fast. We strive to adapt quickly in the face of all disruptive challenges. | |
● | Positive & Inspiring – We strive to attract and retain high performing leaders and teams who inspire one another, enjoy collaboration and celebrate mutual success. | |
● | Patriotic – We are committed to sourcing and developing quality “Made in the USA” solutions and products. We love to hire veterans and those who’ve served our communities. | |
● | Profit & Growth Driven – We are driven by sound business practices, operational excellence and growing revenue to exceed the costs of doing business. We understand the balance of managing profit margin, making sound investments and taking calculated risks. We are committed to our investors and creating sustainable long-term growth. | |
● | Radical Thinkers – We believe we can and will reduce drug diversion. WE WILL SAVE LIVES. |
“Passionate, hard-working and focused determination will Impact and Change the World.”
- Jacqueline von Zwehl, Founder/CEO Scripps Safe
3 |
Scripps Safe is proud to announce several recent highlights.
Scripps Safe was granted US Patent No. 11,257,314, issued 2/22/2022 – AUDITABLE SECURITY SYSTEM FOR SECURE ENCLOSURE.
The patent has claims directed to a security system comprising a safe, covert cameras, a video management system, alarm system, database, and computing system to process system data for preventing unlawful diversion of goods and/ or services.
Scripps Safe, Inc., was named a 2021 EMS World Innovation Awards Winner at the annual 2021 EMS World Expo in Atlanta. EMS World is the most influential and trusted voice among emergency medical services professionals. The company publishes EMS World Magazine and runs North America’s largest EMS trade show/educational conference as part of HMP Global. Scripps Safe was recognized for its Scripps SystemTM, an end-to-end PaaS pharmaceutical inventory and access management system with smart analytics, a single integrated platform solution for narcotics/pharmaceutical transport, security, surveillance, access, inventory management, and analytics. A key component is the data which is held separate and aside from electronic health records, firewalled and encrypted. This monthly subscription cloud-based service connects to the inventory management system. The system will run on Verizon, T-Mobile, and/or AT&T LTE 4G/5G+ Wi-Fi networks for uninterrupted operability for first response reliability. The Scripps SystemTM will be available Fall of 2023.
Scripps Safe, Inc., was named a Top 10 Healthcare Security Solution Providers of 2022 by Healthcare Tech Outlook. Healthcare Tech Outlook is an industry leading publication with over 112,000 qualified healthcare technology subscribers focused on the current healthcare landscape, new solutions and enhanced care solutions for providers.
Owned IP - Trademarks Granted - 13
1. Scripps Safe Logo®
2. Rescue Series® |
![]() |
3. TRXP Series ® | |||
4. Guardian Series® | |||
5. SafeDispense® | |||
6. C1SAFE® | |||
7. Total Rx Protection® | |||
8. U.S. Strategic Drug Vault® | |||
9. We Bring Innovation to Compliance® | |||
10. Creating A Safer Healthcare Environment® | |||
11. We’re Ending the Opioid Crisis® | |||
12. Protecting the Chain of Custody® 13. Cross & Shield Logo Art in Scripps Safe logo® |
![]() |
Risk Factor Summary
Our business is subject to numerous risks described in the section entitled “Risk Factors” and elsewhere in this prospectus. You should carefully consider these risks before making an investment. Some of these risks include:
4 |
Risks Related to Our Business Operations, and Industry
● | The COVID-19 pandemic and the efforts to mitigate its impact may have an adverse effect on our business, liquidity, results of operations, financial condition and price of our securities. | |
● | We are an early development stage company with a limited operating history and have generated limited revenues to date. | |
● | We have a new business model, which makes it difficult for us to forecast our financial results, creates uncertainty as to how investors will evaluate our prospects, and increases the risk that we will not be successful. | |
● | We have a limited operating history and we expect a number of factors will cause our operating results to fluctuate on an annual basis, which may make it difficult to predict our future performance. | |
● | We face competition from other companies and our operating results will suffer if we fail to compete effectively. | |
● | Our business depends substantially on the continuing efforts of our executive officers and our business may be severely disrupted if we lose their services. | |
● | We currently do not own a manufacturing facility, and rely on different manufacturers and suppliers for the production of our safes; while we have obtained favorable financing arrangements in the past from these manufacturer(s) and supplier(s), there is no assurance that future suppliers would provide similar favorable financing arrangements. | |
● | Shortages of components and materials, as well as supply chain disruptions, may delay or reduce our sales and increase our costs, thereby harming our results of operations. | |
● | If we fail to manage our growth effectively, we may be unable to execute our business plan, maintain high levels of service, or adequately address competitive challenges. | |
● | We manufacture and sell products that create exposure to potential product liability, warranty liability, or personal injury claims and litigation. |
5 |
Risks Related to the Our Legal and Regulatory Requirements
● | Product defects could adversely affect the results of our operations | |
● | We could be exposed to significant liability claims if we are unable to obtain insurance at acceptable costs and adequate levels or otherwise protect ourselves against potential product liability claims. |
Risks Related to Our Financial Position and Need for Additional Capital
● | We are an early-stage company with a history of limited revenues. | |
● | We expect fluctuations in our financial results making it difficult to project future results. | |
● | The costs of being a public company could result in us being unable to continue as a going concern. | |
● | We may need to raise additional funds and these funds may not be available to us on attractive terms when we need them, or at all. | |
● | We may be subject to risks associated with potential future acquisitions. | |
● | If we are unable to establish and maintain confidence in our long-term business prospects among users, securities and industry analysts, and within our industries, or are subject to negative publicity, then our financial condition, operating results, business prospects, and access to capital may suffer materially. | |
● | Pandemics and epidemics, including the ongoing COVID-19 pandemic, natural disasters, terrorist activities, political unrest, and other outbreaks could have a material adverse impact on our business, results of operations, financial condition and cash flows or liquidity. |
Risks Related to Our Intellectual Property
● | We may become subject to litigation brought by third parties claiming infringement, misappropriation or other violation by us of their intellectual property rights. | |
● | Patent litigation is expensive and time-consuming and we may not prevail. In the event we did not prevail in any patent litigation, that could have a material adverse effect. | |
● | We have one issued utility patent and one pending design patent application, which we cannot guarantee will issue as a patent. | |
● | We also cannot provide any assurances that our issued patent or any other patents we may obtain will include claims with a scope sufficient to preclude others from competing with us. Others may develop systems that avoid infringing the claims of our issued patent or future patents. | |
● | We may also be subject to administrative proceedings challenging the validity of our issued patent or any future patents or opposing our registered trademarks or applications for registration of trademarks. Administrative proceedings challenging the validity of patents can also be expensive and time-consuming. | |
● | Our business may be adversely affected if we are unable to adequately establish, maintain, protect, and enforce our intellectual property and proprietary rights or prevent third parties from making unauthorized use of our technology and other intellectual property rights. | |
● | Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. | |
● | Our patent applications may not issue as patents, which may have a material adverse effect on our ability to prevent others from commercially exploiting products similar to ours. The patent prosecution process can be expensive, lengthy, and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. There are a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after issuance of any patent. Maintenance fees, renewal fees, annuity fees and/or various other government fees are required to be paid periodically. While an inadvertent lapse can, in some cases, be cured by payment of a late fee, or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market with similar or identical systems, which could have a material adverse effect on our business prospects and financial condition. | |
● | Any trademarks we own obtain may be challenged, infringed, diluted, circumvented or declared generic or determined to be infringing on other marks. We intend to rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During the trademark registration process, we may receive Office Actions from the USPTO or from comparable agencies in foreign jurisdictions objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against any trademark applications we file or registrations we may obtain, and our trademark applications or registrations may not survive such proceedings. If we are unable to obtain a registered trademark or establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. | |
● | We may not be able to protect our intellectual property rights throughout the world. | |
● | In addition to patented technology, we rely on our unpatented proprietary technology, trade secrets, processes, and know-how. Although we require all our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, trade secrets and know-how can be difficult to protect and we have limited control over the protection of trade secrets used by our collaborators and suppliers. We cannot be certain that we have or will obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary information. |
Risks Related to This Offering and Our Securities
● | The offering price for our common stock may not be indicative of its fair market value. | |
● | No public market for our common stock currently exists, and an active public trading market may not develop or be sustained following this offering. | |
● | There is no established trading market for our shares; further, our shares will be subject to potential delisting if we do not maintain the listing requirements of the Nasdaq Capital Market. | |
● | As a “controlled company” under the rules of the Nasdaq Capital Market, we may choose to exempt our company from certain corporate governance requirements that could have an adverse effect on our public shareholders. | |
● | We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance with our public company responsibilities and corporate governance practices. | |
● | As a result of being a public company, we are obligated to develop and maintain proper and effective internal controls over financial reporting, and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock. | |
● | Future sales of our common stock in the public market could cause the market price of our common stock to decline. | |
● | Our stock price may be volatile, and the value of our common stock may decline. | |
● | If securities or industry analysts do not publish research or publish unfavorable or inaccurate research about our business, the market price and trading volume of our common stock could decline. |
6 |
● | We will have broad discretion in the use of the net proceeds to us from this offering and may not use them effectively. | |
● | Our executive officers, directors and principal stockholders, if they choose to act together, have the ability and will continue to have the ability to control or significantly influence all matters submitted to stockholders for approval. | |
● | You will experience immediate and substantial dilution in the net tangible book value of the shares of common stock you purchase in this offering. | |
● | We anticipate that we will need to raise additional capital, and our issuance of additional capital stock in connection with financings, acquisitions, investments, our equity incentive plans or otherwise will dilute all other stockholders. | |
● | We do not intend to pay dividends for the foreseeable future and, as a result, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock. | |
● | We are an “emerging growth company,” and we cannot be certain if the reduced reporting and disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors. | |
● | Anti-takeover provisions in our charter documents may discourage our acquisition by a third party, which could limit our stockholders’ opportunity to sell their shares, at a premium. | |
● | There is currently no trading market for our common stock and warrants and we cannot ensure that one will ever develop or be sustained. | |
● | We will not consummate this offering unless our common stock will be listed on the Nasdaq Capital Market. |
Our certificate of incorporation designates the Court of Chancery of the State of Delaware and federal court within the State of Delaware as the exclusive forum for certain types of actions and proceedings that our stockholders may initiate, which could limit a stockholder’s ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Corporate Information
Scripps Safe, Inc. was originally incorporated in the State of Florida on October 1, 2012 under the name Von Zwehl & Company, Inc. On March 3, 2016, we changed our name to Scripps Safe, Inc. On August 23, 2021, we formed a Delaware entity named Scripps Safe, Inc. and entered into a share exchange agreement on May 10, 2022, wherein the Florida entity merged with and into the Delaware corporation.
Our principal business address is 9051 Tamiami Trail N, Suite 201, Naples, FL 34108. We maintain our corporate website at https://4saferx.com and https://scrippssafe.com The reference to our website is an inactive textual reference only. The information that can be accessed through our website is not part of this prospectus, and investors should not rely on any such information in deciding whether to purchase our common stock.
Our executive officers, directors and principal stockholders in the aggregate, beneficially own approximately 100% and will continue to own approximately 72.73% of our outstanding common stock upon completion of this offering (assuming no exercise of the underwriters’ option to purchase additional shares). Such persons acting together, will have the ability to control or significantly influence all matters submitted to our board of directors or stockholders for approval, as well as our management and business affairs.
Coronavirus (COVID-19) Update
Recently, there is an ongoing outbreak of a novel strain of coronavirus (“COVID-19”) first identified in China and has since spread rapidly globally. The pandemic has resulted in quarantines, travel restrictions, and the temporary closure of stores and business facilities globally for the past year. In March 2020, the World Health Organization declared the COVID-19 to be a pandemic. Given the rapidly expanding nature of the COVID-19 pandemic, and because substantially all of our business operations and our workforce are concentrated in the United States, where we have undergone several national lockdowns to contain the spread of the virus, we believe there is a risk that our business, results of operations, and financial condition will be adversely affected. Potential impact to our results of operations will also depend on future developments and new information that may emerge regarding the duration and severity of the COVID-19 pandemic and the actions taken by government authorities and other entities to contain the COVID-19 or mitigate its impact, almost all of which are beyond our control.
7 |
The measures taken to combat the COVID-19 pandemic may have certain and adverse effects on our business. Public health authorities and governments at local, national and international levels have implemented various measures to respond to this pandemic. Some measures that directly or indirectly impact our business include:
● | voluntary or mandatory quarantines; | |
● | restrictions on travel; and | |
● | limiting gatherings of people in public places. |
While we are regarded as an “essential business”, such factors could nonetheless have a negative effect on our business and our ability to effectively and efficiently run our business. During the COVID-19 pandemic, we have undertaken certain measures in an effort to mitigate the spread of COVID-19, including, having our employees work remotely where possible, which may make maintaining our corporate operations, quality controls and internal controls difficult.
As events are rapidly changing, we do not know how long the COVID-19 pandemic and the measures that have been introduced to respond to it will disrupt our operations or the full extent of that disruption. We also cannot predict how long the effects of COVID-19 and the efforts to contain it will continue to impact our business after the pandemic is under control. Governments could take additional restrictive measures to combat the pandemic that could further impact our business or the economy in the geographies in which we operate. It is also possible that the impact of the pandemic and response on our customers and markets will persist for some time after governments ease their restrictions. These measures may impact our business and financial condition as the responses to control COVID-19 continue. We will continue to closely monitor our operations throughout 2022.
Controlled Company
Upon completion of this offering, our Chief Executive Officer, and founder Jacqueline von Zwehl will beneficially own approximately 64.73% of our common stock (or approximately 62.18% of our common stock if the over-allotment option is exercised) and we will be a “controlled company” within the meaning of the listing rules of The Nasdaq Stock Market LLC.
As long as our principal shareholder owns at least 50% of the voting power of our Company, we are a “controlled company” as defined under Nasdaq Listing Rules.
As a controlled company, we are permitted to rely on certain exemptions from Nasdaq’s corporate governance rules, including:
● | an exemption from the rule that a majority of our board of directors must be independent directors; | |
● | an exemption from the rule that the compensation of our chief executive officer must be determined or recommended solely by independent directors; and | |
● | an exemption from the rule that our director nominees must be selected or recommended solely by independent directors. |
As a result, you will not have the same protection afforded to shareholders of companies that are subject to these corporate governance requirements.
Implications of Being a Smaller Reporting Company
We are a “smaller reporting company” because the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during our most recently completed fiscal year. We may continue to be a smaller reporting company if either (a) the market value of our stock held by non-affiliates is less than $250 million or (b) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. We may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as we remain a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to public companies that are not smaller reporting companies.
8 |
THE OFFERING
Securities offered: | We are offering 3,000,000 shares of common stock (3,450,000 shares if the underwriters exercise their over-allotment option). | |
Initial Public offering price: | The assumed initial public offering price is $5.00 per share of common stock (the midpoint of the price range listed on the cover page of this prospectus). | |
Common Stock outstanding before this offering: | 7,120,000 shares of Common Stock. | |
Common Stock to be outstanding immediately after this offering: | 11,000,000 shares of Common Stock. | |
Option to purchase additional shares: | We have granted the underwriters a 45-day option to purchase up to additional 15% of the total number of shares of our common stock to be offered by the company in this offering. | |
Use of proceeds: | Based on an assumed initial public offering price of $5.00 per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, we expect to receive gross proceeds of $15,000,000 and net proceeds of $13,100,000 (or gross proceeds of $17,250,000 and net proceeds of $15,170,000 if the over-allotment option is exercised in full). We intend to use the net proceeds from this offering for expanding our existing product offerings, expansion into new markets, purchasing inventory, expanding our workforce and for working capital, repaying our note to Greentree Financial Group, Inc. and other general corporate purposes. | |
See “Use of Proceeds” on page 30 for a more complete description of the intended use of proceeds from this offering. | ||
Underwriter Warrants: | The registration statement of which this prospectus is a part also registers the Underwriter Warrants that will be issued to the representative to purchase up to 9% of the total number of shares of our common stock to be offered by the company in this offering, (excluding any shares of common stock sold pursuant to the option to be issued to the underwriters), as a portion of the underwriting compensation payable in connection with this offering. The Underwriter Warrants will be exercisable immediately upon issuance, and from time to time, in whole or in part, and will expire five years from the commencement of sales at an exercise price of $6.00 (120% of the initial public offering price of the shares of common stock). Please see “Underwriting Underwriter Warrants” for a more complete description of these warrants. | |
Risk Factors: | Investing in our securities is highly speculative and involves a high degree of risk. You should carefully consider the information set forth in this prospectus and, in particular, the specific factors set forth in the “Risk Factors” section beginning on page 12 of this prospectus before deciding whether or not to invest in our securities | |
Proposed Nasdaq Ticker Symbol: | We have applied to list our common stock on the Nasdaq Capital Market under the symbol “SCRP”. This offering will not be consummated until we have received Nasdaq Capital Market approval of our application. No assurance can be given that our application will be approved. | |
Lock-ups: | We and our directors, officers, employees and holders of at least 1% of our outstanding securities have agreed with the underwriters not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock for a period of one year from the closing of this offering in the case of the Company and 180 days in the case of our directors, officers, employees and 1% shareholders. See “Underwriting” on page 63. |
9 |
The number of shares of our common stock to be outstanding after this offering is based on 7,120,000 shares of our common stock outstanding as of December 8, 2022. Unless we indicate otherwise or the context otherwise requires, all information in this prospectus:
● | assumes the shares of common stock are offered at $5.00 per share (the midpoint of the price range listed on the cover page of this prospectus); | |
● | assumes no exercise by the underwriters of their overallotment option; | |
● | assumes no exercise of 600,000 outstanding warrants; | |
● | assumes no exercise of the warrants issued to the representative of the underwriters; and | |
● | does not include 880,000 shares of Common Stock that will be issued to consultants within 30 days prior to the offering. |
Emerging Growth Company under the JOBS Act
We qualify as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we have elected to take advantage of reduced reporting requirements and are relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company:
● | we may present only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations; | |
● | we are exempt from the requirement to obtain an attestation and report from our auditors on whether we maintained effective internal control over financial reporting under the Sarbanes-Oxley Act; | |
● | we are permitted to provide less extensive disclosure about our executive compensation arrangements; and | |
● | we are not required to give our stockholders non-binding advisory votes on executive compensation or golden parachute arrangements. |
We may take advantage of these provisions until December 31, 2027 (the last day of the fiscal year following the fifth anniversary of our initial public offering) if we continue to be an emerging growth company. We would cease to be an emerging growth company if we have more than $1.235 billion in annual revenue, have more than $700 million in market value of our shares held by non-affiliates or issue more than $1.0 billion of non-convertible debt over a three-year period. We may choose to take advantage of some but not all of these reduced burdens. We have elected to provide two years of audited financial statements. Additionally, we have elected to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act.
10 |
SUMMARY FINANCIAL AND OTHER DATA
The following tables present our summary financial data and should be read together with our audited financial statements and accompanying notes and information in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing elsewhere in this prospectus. We derived the summary statements of operations data for the nine months ended September 30, 2022 and for the year ended December 31, 2021 and the balance sheet data as of September 30, 2022 and December 31, 2021 from the audited financial statements of Scripps Safe, Inc. included elsewhere in this prospectus. Our financial statements are prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Our historical results are not necessarily indicative of our future results.
UNAUDITED | AUDITED | |||||||
Period Ended | Year Ended | |||||||
September 30, | December 31, | |||||||
2022 | 2021 | |||||||
Summary Statements of Operations Data | ||||||||
Revenue | $ | 511,249 | $ | 505,143 | ||||
Cost of revenue: | (325,057 | ) | (354,768 | ) | ||||
Total operating expenses | (495,927 | ) | (438,675 | ) | ||||
Income (loss) from operations | (309,735 | ) | (288,300 | ) | ||||
Other (expense) income | 2,402 | 26,416 | ||||||
Interest (expense) income | (16,078 | ) | (6,720 | ) | ||||
Amortization of debt discount | (3,654 | ) | - | |||||
Total other (expense) income | (17,330 | ) | 19,696 | |||||
Net income (loss) | $ | (327,065 | ) | $ | (268,604 | ) | ||
Basic income (loss) per share attributable to common stockholders, basic and diluted | $ | (32.71 | ) | $ | (26.86 | ) | ||
Weighted average shares used in computing basic income per share attributable to common stockholders, basic and diluted | 10,000 | 10,000 |
September 30, 2022 | December 31, 2021 | |||||||
Summary Balance Sheet Data | (Unaudited) | (Audited) | ||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 31,365 | $ | 227,932 | ||||
Accounts receivable, net | 60,522 | 56,964 | ||||||
Other current assets | 26,464 | 647 | ||||||
Right-of-Use Lease Asset | 114,460 | - | ||||||
Other asset | 3,000 | - | ||||||
Property, plant and equipment, net | 5,775 | 7,963 | ||||||
Total assets | $ | 241,586 | $ | 293,506 | ||||
Total current liabilities | 239,717 | 175,702 | ||||||
Long-term payables | 655,814 | 445,300 | ||||||
Total liabilities | $ | 859,531 | $ | 621,002 | ||||
Total stockholders’ deficit | (653,945 | ) | (327,496 | ) | ||||
Total liabilities and stockholders’ deficit | $ | 241,586 | $ | 293,506 |
11 |
RISK FACTORS
Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this prospectus, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes, before making a decision to invest in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of or that we deem immaterial may also become important factors that adversely affect our business. Our business, financial condition, results of operations and prospects could be adversely affected by these risks. In that event, the market price of our common stock could decline, and you could lose part or all of your investment. Our business, financial condition, results of operations or prospects could also be harmed by risks and uncertainties not currently known to us or that we currently do not believe are material.
Risks Related to Our Business Operations, and Industry
The COVID-19 pandemic and the efforts to mitigate its impact may have an adverse effect on our business, liquidity, results of operations, financial condition and price of our securities.
The pandemic involving the novel strain of coronavirus, or COVID-19, and the measures taken to combat it, may have certain and adverse effects on our business. Public health authorities and governments at local, national and international levels have implemented various measures to respond to this pandemic. Some measures that directly or indirectly impact our business include:
● | voluntary or mandatory quarantines; | |
● | restrictions on travel; and | |
● | limiting gatherings of people in public places. |
While we are primarily a business regarded as an “essential business”, such factors could nonetheless have a negative effect on our business and our ability to effectively and efficiently run our business. During the COVID-19 pandemic, we have undertaken certain measures in an effort to mitigate the spread of COVID-19, including, having our employees work remotely where possible, which may make maintaining our corporate operations, quality controls and internal controls difficult.
As events are rapidly changing, we do not know how long the COVID-19 pandemic and the measures that have been introduced to respond to it will disrupt our operations or the full extent of that disruption. We also cannot predict how long the effects of COVID-19 and the efforts to contain it will continue to impact our business after the pandemic is under control. Governments could take additional restrictive measures to combat the pandemic that could further impact our business or the economy in the geographies in which we operate. It is also possible that the impact of the pandemic and response on our customers and markets will persist for some time after governments ease their restrictions. These measures may impact our business and financial condition as the responses to control COVID-19 continue.
We are an early development stage company with a limited operating history and have generated limited revenues to date
Although we were incorporated in Florida on October 2, 2012 and merged with and into a Delaware corporation on May 10, 2022, we began generating revenue in 2017. As a result, we are an early development stage company with a limited operating history and have generated limited revenues to date. If we cannot achieve our business objectives, investors in our shares will likely suffer a loss of their entire investment.
12 |
We have a new business model, which makes it difficult for us to forecast our financial results, creates uncertainty as to how investors will evaluate our prospects, and increases the risk that we will not be successful.
We have a new business model and are in the process of developing new offerings, seeking deeper market penetration and increasing our market shares. Accordingly, it will be difficult for us to forecast our future financial results, and it is uncertain how our new business model will affect investors’ perceptions and expectations with respect to our business and economic prospects. Additionally, our new business model may not be successful. Consequently, you should not rely upon any past financial results as indicators of our future financial performance.
We rely heavily on our suppliers and do not maintain written agreements with suppliers.
Our ability to compete and grow will be dependent on our access to software and equipment at reasonable costs and in timely manners. We sell licenses to third-party software and do not currently develop software. We do not maintain written agreements with our suppliers, and we are, therefore, dependent on the relationships we maintain with suppliers and third party software developers. Failure of suppliers and developers to deliver such software and equipment, at a reasonable cost and in a timely manner would be detrimental to our ability to maintain existing customers and obtain new customers. No assurance can be given that we will be successful in maintaining our required supply of such items.
We have a limited operating history and we expect a number of factors will cause our operating results to fluctuate on an annual basis, which may make it difficult to predict our future performance.
We are a company seeking to bring innovation to pharmaceutical compliance, transportation and storage and deal with controlled substances in a highly regulated industry and manner. Compliance with the myriad of laws and regulations concerning controlled substances and pharmaceuticals is complicated and burdensome. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history. We anticipate that our operating results will significantly fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. In particular, you should consider that we cannot provide assurance that we will be able to:
● | successfully develop and introduce our Scripps System™; | |
● | recruit and maintain our management team; | |
● | raise sufficient funds in the capital markets to effectuate our business plan; | |
● | attract, enter into or maintain contracts with, and retain customers; and/or | |
● | compete effectively in the extremely competitive environment in which we operate. |
These factors are our best estimates of possible factors that will affect our future operating results, however, they should not be considered a complete recitation of possible factors that could affect us. In addition, we do not know how the economic and societal impact of the ongoing COVID-19 global pandemic may negatively affect our current and future operations and development. Accordingly, the results of any historical quarterly or annual periods should not be relied upon as indications of future operating performance.
We face competition from other companies and our operating results will suffer if we fail to compete effectively.
There is intense competition amongst the healthcare industry. There are a number of established, well financed companies that provide pharmaceutical, security, transport, storage and tracking services that compete directly or indirectly with our services. Some competitors include Operative IQ for inventory tracking and Knox Box for security solutions in EMS. As most of our competitors have financial resources that are greater than us, they may spend more money and time on developing and testing products, systems, and undertake more extensive marketing campaigns, adopt more aggressive pricing policies or otherwise develop more commercially successful products or systems than us, which could impact our ability to win new marketing contracts. Furthermore, new competitors may enter our key market areas. If we are unable to obtain significant market presence or if we lose market share to our competitors, our results of operations and future prospects would be materially adversely affected. There are many companies with already established relationships with third parties, including hospitals, EMS/Fire/Ambulance and others that are able to introduce directly competitive products and have the potential and resources to quickly develop competitive technologies. Our success depends on our ability to develop new products and enhance existing products.
Our business depends substantially on the continuing efforts of our executive officers and our business may be severely disrupted if we lose their services.
Our future success depends substantially on the continued services of our executive officers, especially our Chief Executive Officer, and founder Jacqueline von Zwehl. If one or more of our executive officers are unable or unwilling to continue in their present positions, we may not be able to replace them readily, if at all. The loss of any of our executive officers could cause our business to be disrupted, and we may incur additional and unforeseen expenses to recruit and retain new officers.
13 |
We currently do not own a manufacturing facility, and rely on different manufacturers and suppliers for the production of our safes and solutions; while we have obtained favorable financing arrangements in the past from these manufacturer(s) and supplier(s), there is no assurance that future suppliers would provide similar favorable financing arrangements.
We currently rely on seven different manufacturers and two different suppliers for access control systems for the overall production of our safes and vaults. We do not have control over the operations of the facilities of the third-party manufacturers that we use.
The manufacturers of our safes and solutions have extended favorable financing arrangements in the past, but there is no assurance that future suppliers would provide similar favorable financing arrangements. Therefore, the continued supply and manufacturing of our sales by our current manufacturers and suppliers are critical to our success. Any event that causes a disruption of the operation of our safes’ manufacturers for even a relatively short period of time would adversely affect our ability to ship and deliver our safes and other products and to provide service to our customers. We have previously experienced, including during the first months after the spread of COVID-19 pandemic, and may in the future experience, launch and production ramp up delays for our products as a result of disruption at our supplier’s manufacturing partners.
Shortages of components and materials, as well as supply chain disruptions, may delay or reduce our sales and increase our costs, thereby harming our results of operations.
The inability to obtain sufficient quantities of raw materials and components, including those necessary for the production of our products could result in reduced or delayed sales or lost orders. Any delay in or loss of sales or orders could adversely impact our operating results. Many of the materials used in the production of our products are available only from a limited number of suppliers. We do not have long-term supply contracts with any suppliers. As a result, we could be subject to increased costs, supply interruptions, and difficulties in obtaining raw materials and components.
Our reliance on third-party suppliers for various raw materials and components for our products exposes us to volatility in the availability, quality, and price of these raw materials and components. Our orders with certain of our suppliers may represent a very small portion of their total orders. As a result, they may not give priority to our business, leading to potential delays in or cancellation of our orders. A disruption in deliveries from our third-party suppliers, capacity constraints, production disruptions, price increases, or decreased availability of raw materials or commodities could have an adverse effect on our ability to meet our commitments to customers or increase our operating costs. Quality issues experienced by third party suppliers can also adversely affect the quality and effectiveness of our products and result in liability and reputational harm.
Furthermore, the cost of safes/vaults, whether manufactured by our supplier or by us, depends in part upon the prices and availability of raw manufacturing materials such as steel, locks, fireboard, hinges, pins and other metals. The prices for these materials fluctuate and their available supply may be unstable, depending on market conditions and global demand for these materials, including as a result of increased global production of electric vehicles and energy storage products. Any reduced availability of these materials may impact our access to these parts and any increases in their prices may reduce our profitability if we cannot recoup the increased costs through increased safe prices. Moreover, any such attempts to increase product prices may harm our brand, prospects and operating results.
We have continued to maintain to relationships with multiple manufactures and suppliers within the industry to mitigate this risk.
We could be exposed to liability if we experience security breaches or other disruptions, which could harm our reputation and business.
We may be subject to cyber-attacks whereby computer hackers may attempt to access our computer systems or our third-party IT service providers’ systems and, if successful, misappropriate personal or confidential information. In addition, a contractor or other third party with whom we do business may attempt to circumvent our security measures or obtain such information, and may purposefully or inadvertently cause a breach involving sensitive information. We will continue to evaluate and implement additional protective measures to reduce the risk and detect cyber incidents, but cyber-attacks are becoming more sophisticated and frequent and the techniques used in such attacks change rapidly. Even though we take cyber-security measures that are continuously reviewed and updated, our information technology networks and infrastructure may still be vulnerable due to sophisticated attacks by hackers or breaches.
Even the most well protected IT networks, systems, and facilities remain potentially vulnerable because the techniques used in security breaches are continually evolving and generally are not recognized until launched against a target and, in fact, may not be detected. Any such compromise of our or our third party’s IT service providers’ data security and access, public disclosure, or loss of personal or confidential business information, could result in legal claims proceedings, liability under laws to protect, privacy of personal information, and regulatory penalties, disrupt our operations, require significant management attention and resources to remedy any damages that result, damage our reputation and customers willingness to transact business with us, any of which could adversely affect our business.
14 |
If we fail to manage our growth effectively, we may be unable to execute our business plan, maintain high levels of service, or adequately address competitive challenges.
We expect to invest in our growth for the foreseeable future. Any growth in our business is expected to place a significant strain on not only our managerial, administrative, operational, and financial resources, but also our infrastructure. We plan to continue to expand our operations in the future. Our success will depend in part on our ability to manage this growth effectively and execute our business plan. To manage the expected growth of our operations and personnel, we will need to continue to improve our operational, financial, and management controls and our reporting systems and procedures.
We rely heavily on information technology (“IT”) systems to manage critical business functions. To manage our growth effectively, we must continue to improve and expand our infrastructure, including our IT, financial, and administrative systems and controls. In particular, we may need to significantly expand our IT infrastructure as the amount of data we store and transmit increases over time, which will require that we both utilize existing IT products and adopt new technology. If we are not able to scale our IT infrastructure in a cost-effective and secure manner, our ability to offer competitive solutions will be harmed and our business, financial condition, and operating results may suffer.
We must also continue to manage our employees, operations, finances, research and development, and capital investments efficiently. Our productivity and the quality of our solutions may be adversely affected if we do not integrate and train our new employees quickly and effectively or if we fail to appropriately coordinate across our executive, research and development, technology, service development, analytics, finance, human resources, marketing, sales, operations, and customer support teams. As we continue to grow, we will incur additional expenses, and our growth may continue to place a strain on our resources, infrastructure, and ability to maintain the quality of our solutions. If we do not adapt to meet these evolving challenges, or if the current and future members of our management team do not effectively manage our growth, the quality of our solutions may suffer and our corporate culture may be harmed. Failure to manage our future growth effectively could cause our business to suffer, which, in turn, could have an adverse impact on our business, financial condition, and operating results.
We manufacture and sell products that create exposure to potential product liability, warranty liability, or personal injury claims and litigation.
Our products are used to store, in part, items that involve risk of personal injury and death. Our products expose us to potential product liability, warranty liability, and personal injury claims and litigation relating to the use or misuse of our products, including allegations of defects in manufacturing, defects in design, defects in security measures, data loss, a failure to warn of dangers inherent in the product, or activities associated with the product, negligence, and strict liability. If successful, any such claims could have a material adverse effect on our business, operating results, and financial condition. Defects in our products may result in a loss of sales, recall expenses, delay in market acceptance, and damage to our reputation and increased warranty costs, which could have a material adverse effect on our business, operating results, and financial condition. Although we maintain product liability insurance in amounts that we believe are reasonable, we may not be able to maintain such insurance on acceptable terms, if at all, in the future and product liability claims may exceed the amount of insurance coverage. In addition, our reputation may be adversely affected by such claims, whether or not successful, including potential negative publicity about our products.
Our profitability in part is dependent on material and other manufacturing costs. We are unable to offer any assurance that either we or a manufacturing partner will be able to reduce costs to a level that will allow production of a competitive product or that any product produced using lower cost materials and manufacturing processes will not suffer from a reduction in performance, reliability and longevity.
Risks Related to the Our Legal and Regulatory Requirements
Product defects could adversely affect the results of our operations.
The design, manufacture and marketing of our products involve certain inherent risks. Manufacturing or design defects, unanticipated use of our products, or inadequate disclosure of risks relating to the use of our products can lead to injury or other adverse events. The Company may not properly anticipate customer applications of our products and our products may fail to survive such unanticipated customer use. If the Company’s products fail to adequately perform to meet the customer’s expectations, the customer may demand refunds or replacements which will negatively affect the Company’s profitability.
15 |
We could be exposed to significant liability claims if we are unable to obtain insurance at acceptable costs and adequate levels or otherwise protect ourselves against potential product liability claims.
Our products support the use and access to highly regulated controlled and non-controlled substances and if our products are ineffective, we could require protection against potential product liability claims. Our current insurance policies may not be adequate to protect us from certain losses, which could have a material adverse effect on our business, financial condition or results of operations. There are types of losses we may incur that cannot be insured against or that we believe are not economically reasonable to insure.
Risks Related to Our Financial Position and Need for Additional Capital
We are an early-stage company with a history of limited revenues.
Since inception, we have had limited revenues. We have revenues of $511,249 and $505,143 for the nine months ended September 30, 2022, and for the year ended December 31, 2021 respectively. We have not recognized a material amount of revenue to date and have net (loss) of ($327,065) and ($268,604) for the nine months ended September 30, 2022, and for the year ended December 31, 2021 respectively. We cannot guarantee that we can increase sales and revenue at scale. Our potential profitability is dependent upon a number of factors, many of which are beyond our control. If we are unable to achieve and sustain profitability, the value of our business and common stock may significantly decrease.
Because we will incur the costs and expenses from becoming and being a publicly traded company, and otherwise growing our business, our revenues will be offset by these and other costs and expenses and will likely reduce profits and could result in losses. In addition, we may find that these efforts are more expensive than we currently anticipate or that these efforts may not result in expected revenue, which would result in reduced profit or even losses.
We expect fluctuations in our financial results making it difficult to project future results.
Our results of operations may fluctuate in the future due to a variety of factors, many of which are outside of our control. As a result, our past results may not be indicative of our future performance. In addition to the other risks described herein, factors that may affect our results of operations include the following:
● | changes in our revenue mix and related changes in revenue recognition; | |
● | changes in actual and anticipated growth rates of our revenue, customers, and key operating metrics; | |
● | fluctuations in demand for or pricing of our offering; | |
● | our ability to attract new customers; | |
● | our ability to retain our existing customers, particularly large customers; | |
● | customers and potential customers opting for alternative products, including developing their own in-house solutions; | |
● | investments in new offerings, features, and functionality; | |
● | fluctuations or delays in development, release, or adoption of new features and functionality for our offering; | |
● | delays in closing sales which may result in revenue being pushed into the next quarter; | |
● | changes in customers’ budgets and in the timing of their budget cycles and purchasing decisions; | |
● | our ability to control costs; | |
● | the amount and timing of payment for operating expenses, particularly research and development and sales and marketing expenses; | |
● | timing of hiring personnel for our research and development and sales and marketing organizations; | |
● | the amount and timing of costs associated with recruiting, educating, and integrating new employees and retaining and motivating existing employees; | |
● | the effects of acquisitions and their integration; |
16 |
● | general economic conditions, both domestically and internationally, as well as economic conditions specifically affecting industries in which our customers participate; | |
● | the impact of new accounting pronouncements; | |
● | changes in revenue recognition policies that impact our technology license revenue; | |
● | changes in regulatory or legal environments that may cause us to incur, among other things, expenses associated with compliance; | |
● | the impact of changes in tax laws or judicial or regulatory interpretations of tax laws, which are recorded in the period such laws are enacted or interpretations are issued and may significantly affect the effective tax rate of that period; | |
● | health epidemics or pandemics, such as the COVID-19 pandemic; | |
● | changes in the competitive dynamics of our market, including consolidation among competitors or customers; and | |
● | significant security breaches of, technical difficulties with, or interruptions to, the delivery and use of our products. |
Any of these and other factors, or the cumulative effect of some of these factors, may cause our results of operations to vary significantly. If our quarterly results of operations fall below the expectations of investors and securities analysts who follow our stock, the price of our common stock could decline substantially, and we could face costly lawsuits, including securities class action suits.
We may need to raise additional funds and these funds may not be available to us on attractive terms when we need them, or at all.
The commercialization of pharmaceutical transportation and storage compliance is capital intensive. This includes the costs associated with filing and protecting patents and trademarks, developing software, marketing our solutions and general compliance with the myriad of laws and regulations governing controlled and non-controlled substances. To date, we have financed our operations primarily through the sales of vaults, safes, third party software, services, founders’ contributions and an EIDL Small Business Administration (“SBA”) Loan. We may need to raise additional capital to continue to fund our commercialization activities, sales and marketing efforts, enhancement of our technology and to improve our liquidity position. Our ability to obtain the necessary financing to carry out our business plan is subject to a number of factors, including general market volatility, investor acceptance of our business plan, regulatory requirements and the successful development of our autonomous technology. These factors may make the timing, amount, terms, and conditions of such financing unattractive or unavailable to us.
We may raise these additional funds through the issuance of equity, equity related, or debt securities. To the extent that we raise additional financing by issuing equity securities or convertible debt securities, our stockholders may experience substantial dilution, and to the extent we engage in debt financing, we may become subject to restrictive covenants that could limit our flexibility in conducting future business activities. Financial institutions may request credit enhancement such as third-party guarantee and pledge of equity interest in order to extend loans to us. We cannot be certain that additional funds will be available to us on attractive terms when required, or at all. If we cannot raise additional funds when we need them, our financial condition, results of operations, business, and prospects could be materially adversely affected.
17 |
We may be subject to risks associated with potential future acquisitions.
Although we have no current acquisition plans, if appropriate opportunities arise, we may acquire additional assets, products, technology or businesses that are complementary to our existing business. Any future acquisitions and the subsequent integration of new assets and businesses would require significant attention from our management and could result in a diversion of resources from our existing business, which in turn could have an adverse effect on our operations, and consequently our results of operations and financial condition. Acquired assets or businesses may not generate the financial results we expect. Acquisitions could result in the use of substantial amounts of cash, potentially dilutive issuances of equity securities, significant goodwill impairment charges, amortization expenses for other intangible assets and exposure to potential unknown liabilities of the acquired business. Moreover, the costs of identifying and consummating acquisitions may be significant.
If we are unable to establish and maintain confidence in our long-term business prospects among users, securities and industry analysts, and within our industries, or are subject to negative publicity, then our financial condition, operating results, business prospects, and access to capital may suffer materially.
Users may be less likely to purchase or use our technology and the industrial vehicles it is deployed on if they are not convinced that our business will succeed or that our service and support and other operations will continue in the long term. Similarly, suppliers and other third parties will be less likely to invest time and resources in developing business relationships with us if they are not convinced that our business will succeed. Accordingly, in order to build and maintain our business, we must maintain confidence among users, suppliers, securities and industry analysts, and other parties in our long-term financial viability and business prospects. Maintaining such confidence may be particularly complicated by certain factors including those that are largely outside of our control, such as our limited operating history at scale, user unfamiliarity with our solutions, any delays in scaling manufacturing, delivery, and service operations to meet demand, competition, and our performance compared with market expectations.
Pandemics and epidemics, including the ongoing COVID-19 pandemic, natural disasters, terrorist activities, political unrest, and other outbreaks could have a material adverse impact on our business, results of operations, financial condition and cash flows or liquidity.
During the ongoing global COVID-19 pandemic, the capital markets are experiencing pronounced volatility, which may adversely affect investor’s confidence and, in turn may affect our initial public offering.
In addition, the COVID-19 pandemic has caused us to modify our business practices (such as employee travel plan and cancellation of physical participation in meetings, events, and conference), and we may take further actions as required by governmental authorities or that we determine are in the best interests of our employees, users, and business partners. In addition, the business and operations of our manufacturers, suppliers, and other business partners have also been adversely impacted by the COVID-19 pandemic and may be further adversely impacted in the future, which could result in delays in our ability to commercialize our suite of pharmaceutical supply chain solutions.
As a result of social distancing, travel bans, and quarantine measures, access to our facilities, users, management, support staff, and professional advisors has been limited, which in turn has impacted, and will continue to impact, our operations, and financial condition.
The extent to which COVID-19 impacts our, and those of our partners and potential users, business, results of operations, and financial condition will depend on future developments, which are uncertain and cannot be predicted, including, but not limited to, the occurrence of a “second wave,” duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. Even if the COVID-19 outbreak subsides, we may continue to experience materially adverse impacts to our business as a result of its global economic impact, including any recession that has occurred or may occur in the future.
18 |
We are also vulnerable to natural disasters and other calamities. We cannot assure you that any backup systems will be adequate to protect us from the effects of fire, floods, typhoons, earthquakes, power loss, telecommunications failures, break-ins, war, riots, terrorist attacks or similar events. Any of the foregoing events may give rise to interruptions, breakdowns, system failures, technology platform failures or internet failures, which could cause the loss or corruption of data or malfunctions of software or hardware as well as adversely affect our ability to provide services.
Risks Related to Our Intellectual Property
We may become subject to litigation brought by third parties claiming infringement, misappropriation or other violation by us of their intellectual property rights.
There is a significant amount of uncertainty in the industry regarding patent protection and infringement. In recent years, there has been significant litigation globally involving patents and other intellectual property rights. Third parties may in the future assert, that we have infringed, misappropriated or otherwise violated their intellectual property rights. As we face increasing competition and as a public company, the possibility of intellectual property rights claims against us grows. Such claims and litigation may involve one or more of our competitors focused on using their patents and other intellectual property to obtain competitive advantage, or patent holding companies or other adverse intellectual property rights holders who have no relevant product revenue, and therefore our own pending patents and other intellectual property rights may provide little or no deterrence to these rights holders in bringing intellectual property rights claims against us. There may be intellectual property rights held by others, including issued or pending patents and trademarks, that cover significant aspects of our technologies or business methods, and we cannot assure that we are not infringing or violating, and have not infringed or violated, any third-party intellectual property rights or that we will not be held to have done so or be accused of doing so in the future. In addition, because patent applications can take many years until the patents issue, there may be applications now pending of which we are unaware, which may later result in issued patents that our products may infringe. We expect that in the future we may receive notices that claim we or our suppliers or customers have misappropriated or misused other parties’ intellectual property rights, particularly as the number of competitors in our market grows.
To defend ourselves against any intellectual property claims brought by third parties, whether with or without merits, can be time-consuming and could result in substantial costs and a diversion of our resources. These claims and any resulting lawsuits, if resolved adversely to us, could subject us to significant liability for damages, impose temporary or permanent injunctions against our products, technologies or business operations, or invalidate or render unenforceable our intellectual property.
If our technology is determined to infringe a valid and enforceable patent, or if we wish to avoid potential intellectual property litigation on any alleged infringement, misappropriation or other violation of third party intellectual property rights, we may be required to do one or more of the following: (i) cease development, sales, or use of our systems that incorporate or use the asserted intellectual property right; (ii) obtain a license from the owner of the asserted intellectual property right, which may be unavailable on commercially reasonable terms, or at all, or which may be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us; (iii) pay substantial royalties or other damages; or (iv) redesign our technology to avoid any infringement or allegations thereof. The aforementioned options sometimes may not be commercially feasible. Additionally, in our ordinary course of business, we agree to indemnify our customers, partners, and other commercial counterparties for any infringement arising out of their use of our intellectual property, along with providing standard indemnification provisions, so we may face liability to our users, business partners or third parties for indemnification or other remedies in the event that they are sued for infringement.
We may also in the future license third party technology or other intellectual property, and we may face claims that our use of such in-licensed technology or other intellectual property infringes, misappropriates or otherwise violates the intellectual property rights of others. In such cases, we will seek indemnification from our licensors. However, our rights to indemnification may be unavailable or insufficient to cover our costs and losses.
19 |
We also may not be successful in any attempt to redesign our technology to avoid any alleged infringement. A successful claim of infringement against us, or our failure or inability to develop and implement non-infringing technology, or license the infringed technology on acceptable terms and on a timely basis, could materially adversely affect our business and results of operations. Furthermore, such lawsuits, regardless of their success, would likely be time-consuming and expensive to resolve and would divert management’s time and attention from our business, which could seriously harm our business. Also, such lawsuits, regardless of their success, could seriously harm our reputation with users and in the industry at large.
Our business may be adversely affected if we are unable to adequately establish, maintain, protect, and enforce our intellectual property and proprietary rights or prevent third parties from making unauthorized use of our technology and other intellectual property rights.
Our intellectual property is an essential asset of our business. Failure to adequately protect our intellectual property rights could result in our competitors offering similar products, potentially resulting in the loss of our competitive advantage, and a decrease in our revenue which would adversely affect our business prospects, financial condition, and operating results. Our success depends, at least in part, on our ability to protect our core technology and intellectual property. We rely on a combination of intellectual property rights, such as patents, trademarks, copyrights, and trade secrets (including know-how), in addition to employee and third-party nondisclosure agreements, intellectual property licenses, and other contractual rights, to establish, maintain, protect, and enforce our rights in our technology, proprietary information, and processes. Intellectual property laws and our procedures and restrictions provide only limited protection and any of our intellectual property rights may be challenged, invalidated, circumvented, infringed or misappropriated. Others may also invent around and avoid infringing any patents If we fail to protect our intellectual property rights adequately, we may lose an important advantage in the markets in which we compete. While we take measures to protect our intellectual property, such efforts may be insufficient or ineffective, and any of our intellectual property rights may be challenged, which could result in them being narrowed in scope or declared invalid or unenforceable. Other parties may also independently develop technologies that are substantially similar or superior to ours. We also may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. However, the measures we take to protect our intellectual property from unauthorized use by others may not be effective and there can be no assurance that our intellectual property rights will be sufficient to protect against others offering products, services, or technologies that are substantially similar or superior to ours and that compete with our business.
Litigation may be necessary in the future to enforce our intellectual property rights and to protect our trade secrets. Our efforts to enforce our intellectual property rights may be met with defenses, counterclaims, and countersuits attacking the validity and enforceability of our intellectual property. Any litigation initiated by us concerning the violation by third parties of our intellectual property rights is likely to be expensive and time-consuming and could lead to the invalidation of, or render unenforceable, our intellectual property, or could otherwise have negative consequences for us. Furthermore, it could result in a court or governmental agency invalidating or rendering unenforceable our patents or other intellectual property rights upon which the suit is based or finding that there is no infringement. We will not be able to protect our intellectual property if we are unable to enforce our rights or if we do not detect unauthorized use of our intellectual property. Our inability to protect our proprietary technology against unauthorized copying or use, as well as any costly litigation or diversion of our management’s attention and resources, could delay the introduction and implementation of new technologies, result in our substituting inferior or more costly technologies into our products or injure our reputation. Moreover, policing unauthorized use of our technologies, trade secrets, and intellectual property may be difficult, expensive, and time-consuming, particularly in foreign countries where the laws may not be as protective of intellectual property rights as those in the United States and where mechanisms for enforcement of intellectual property rights may be weak. If we fail to meaningfully establish, maintain, protect, and enforce our intellectual property and proprietary rights, our business, operating results, and financial condition could be adversely affected.
Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
There are a number of recent changes to the patent laws that may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act (the “AIA”) enacted in September 2011, resulted in significant changes in patent legislation. An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned from a “first-to-invent” to a “first-to-file” system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a “first-to-file” system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the United States Patent and Trademark Office (“USPTO”) after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. Circumstances could prevent us from promptly filing patent applications on our inventions.
20 |
The AIA also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.
Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable for business methods. As such, we do not know the degree of future protection that we will have on our technologies, products, and services. While we will endeavor to try to protect our technologies, products, and services with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive, and sometimes unpredictable.
Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
Our patent applications may not issue as patents, which may have a material adverse effect on our ability to prevent others from commercially exploiting systems similar to ours.
We cannot be certain that we are the first inventor of the subject matter to which we have filed a particular patent application, or if we are the first party to file such a patent application. If another party has filed a patent application to the same subject matter as we have, we may not be entitled to the protection sought by the patent application. Further, the scope of protection of issued patent claims is often difficult to determine. As a result, we cannot be certain that the patent applications that we file will issue, or that our issued patents will be broad enough to protect our proprietary rights or otherwise afford protection against competitors with similar technology. In addition, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Our competitors may challenge or seek to invalidate our issued patents, or design around our issued patents, which may adversely affect our business, prospects, financial condition or operating results. Also, the costs associated with enforcing patents, confidentiality and invention agreements, or other intellectual property rights may make aggressive enforcement impracticable.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting, maintaining, defending, and enforcing patents and other intellectual property rights in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. We have no foreign intellectual property rights. Competitors may use our technologies in jurisdictions where we have not obtained patent protection or other intellectual property rights to develop their own systems. These systems may compete with our systems candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
21 |
In addition to patented technology, we rely on our unpatented proprietary technology, trade secrets, processes, and know-how.
We rely on proprietary information (such as trade secrets, know-how, and confidential information) to protect intellectual property that may not be patentable, or that we believe is best protected by means that do not require public disclosure. We generally seek to protect this proprietary information by entering into confidentiality agreements, or consulting, services, or employment agreements that contain non-disclosure and non-use provisions with our employees, consultants, contractors, scientific advisors, and third parties. However, we cannot guarantee that we have entered into such agreements with each party that has or may have had access to our trade secrets or proprietary information and, even if entered into, these agreements may be breached or may otherwise fail to prevent disclosure, third-party infringement or misappropriation of our proprietary information, may be limited as to their term and may not provide an adequate remedy in the event of unauthorized disclosure or use of proprietary information. In addition, our proprietary information may otherwise become known or be independently developed by our competitors or other third parties. To the extent that our employees, consultants, contractors, and other third parties use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain protection for our proprietary information could adversely affect our competitive business position. Furthermore, laws regarding trade secret rights in certain markets where we operate may afford little or no protection to our trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that trade secret to compete with us. If any of our trade secrets were to be disclosed (whether lawfully or otherwise) to or independently developed by a competitor or other third party, it could have a material adverse effect on our business, operating results, and financial condition.
We also rely on physical and electronic security measures to protect our proprietary information but we cannot guarantee that these security measures provide adequate protection for such proprietary information or will never be breached. There is a risk that third parties may obtain unauthorized access to and improperly utilize or disclose our proprietary information, which would harm our competitive advantages. We may not be able to detect or prevent the unauthorized access to or use of our information by third parties, and we may not be able to take appropriate and timely steps to mitigate the damages (or the damages may not be capable of being mitigated or remedied).
22 |
Risks Related to This Offering and Our Securities
The offering price for our common stock may not be indicative of its fair market value.
The offering price for our common stock was determined in the context of negotiations between us and the underwriters. Accordingly, the offering price may not be indicative of the true fair market value of the Company or the fair market value of our common stock. We are making no representations that the offering price of our common stock under this prospectus bears any relationship to our assets, book value, net worth or any other recognized criteria of our value.
No public market for our common stock currently exists, and an active public trading market may not develop or be sustained following this offering.
Prior to this offering, there has been no public market for our common stock. Although we have applied to list our common stock on the Nasdaq Capital Market, an active public trading market for our common stock may not develop following the completion of this offering or, if developed, it may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair value of your shares. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.
There is no established trading market for our shares; further, our shares will be subject to potential delisting if we do not maintain the listing requirements of the Nasdaq Capital Market.
This offering constitutes our initial public offering of our shares. No public market for these shares currently exists. We have applied to list the shares of our common stock on the Nasdaq Capital Market, or Nasdaq. An approval of our listing application by Nasdaq will be subject to, among other things, our fulfilling all of the listing requirements of Nasdaq. Even if these shares are listed on Nasdaq, there can be no assurance that an active trading market for these securities will develop or be sustained after this offering is completed.
In addition, Nasdaq has rules for continued listing, including, without limitation, minimum market capitalization and other requirements. Failure to maintain our listing, or de-listing from Nasdaq, would make it more difficult for shareholders to dispose of our common stock and more difficult to obtain accurate price quotations on our common stock. This could have an adverse effect on the price of our common stock. Our ability to issue additional securities for financing or other purposes, or otherwise to arrange for any financing we may need in the future, may also be materially and adversely affected if our common stock is not traded on a national securities exchange.
We will be a “controlled company” within the meaning of the Nasdaq Stock Market Rules and Nasdaq Capital Market rules if, after this offering, our insiders continue to beneficially own more than 50% of our outstanding shares of common stock.
Upon completion of this offering, our Chief Executive Officer, and founder Jacqueline von Zwehl will beneficially own approximately 64.73% of our common stock (or approximately 62.18% of our common stock if the over-allotment option is exercised). Accordingly, the Company will be a “controlled company” under applicable Nasdaq listing standards after this offering. We may rely on certain exemptions from corporate governance rules, on including an exemption from the rule that a majority of our board of directors must be independent directors. Although we currently do not intend to rely on the “controlled company” exemption under the Nasdaq listing rules, we could elect to rely on this exemption in the future. In the event that we elected to rely on the “controlled company” exemption, a majority of the members of our board of directors might not be independent directors, and our nominating and corporate governance and compensation committees might not consist entirely of independent directors. Our status as a controlled company could cause our shares of common stock to be less attractive to certain investors or otherwise harm our trading price. As a result, you will not have the same protection afforded to shareholders of companies that are subject to these corporate governance requirements.
We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance with our public company responsibilities and corporate governance practices.
As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company, which we expect to further increase after we are no longer an “emerging growth company.” The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Capital Market, and other applicable securities rules and regulations impose various requirements on public companies. Our management and other personnel will devote a substantial amount of time to compliance with these requirements. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. We cannot predict or estimate the amount of additional costs we will incur as a public company or the specific timing of such costs.
23 |
As a result of being a public company, we are obligated to develop and maintain proper and effective internal controls over financial reporting, and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.
We will be required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting as of the end of the fiscal year that coincides with the filing of our second annual report on Form 10-K. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. In addition, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting in our first annual report required to be filed with the SEC following the date we are no longer an “emerging growth company.” We have not yet commenced the costly and time-consuming process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404, and we may not be able to complete our evaluation, testing and any required remediation in a timely fashion once initiated. Our compliance with Section 404 will require that we incur substantial expenses and expend significant management efforts. We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404.
Our current controls and any new controls that we develop may become inadequate because of changes in conditions in our business. In addition, changes in accounting principles or interpretations could also challenge our internal controls and require that we establish new business processes, systems and controls to accommodate such changes. Additionally, if these new systems, controls or standards and the associated process changes do not give rise to the benefits that we expect or do not operate as intended, it could adversely affect our financial reporting systems and processes, our ability to produce timely and accurate financial reports or the effectiveness of internal control over financial reporting. Moreover, our business may be harmed if we experience problems with any new systems and controls that result in delays in their implementation or increased costs to correct any post-implementation issues that may arise.
During the assessment of the effectiveness of our internal controls over financial reporting, the following were identified as material weaknesses: i) the inability to prepare complete and accurate financial statements in accordance with GAAP: ii) lack of personnel with requisite expertise to prepare complete and accurate financial statements in accordance with GAAP and; iii) lack of documentation surrounding components of the Company’s entity level and process level control environment. The SEC defines ‘material weakness’ as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the registrant’s annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls. While we have adopted remediation procedures related to these identified material weaknesses, there can be no assurance that such remedies will be effective. In addition, if we identify one or more additional material weaknesses in our internal control over financial reporting in the future, we will be unable to certify that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.
The growth and expansion of our business places a continuous, significant strain on our operational and financial resources. Further growth of our operations to support our customer base, our information technology systems and our internal controls and procedures may not be adequate to support our operations. For example, we are still in the process of implementing information technology and accounting systems to help manage critical functions such as billing and revenue recognition and financial forecasts. As we continue to grow, we may not be able to successfully implement requisite improvements to these systems, controls and processes, such as system access and change management controls, in a timely or efficient manner. Our failure to improve our systems and processes, or their failure to operate in the intended manner, whether as a result of the growth of our business or otherwise, may result in our inability to accurately forecast our revenue and expenses, or to prevent certain losses. Moreover, the failure of our systems and processes could undermine our ability to provide accurate, timely and reliable reports on our financial and operating results and could impact the effectiveness of our internal control over financial reporting. In addition, our systems and processes may not prevent or detect all errors, omissions or fraud.
24 |
Future sales of our common stock in the public market could cause the market price of our common stock to decline.
Sales of a substantial number of shares of our common stock in the public market following the completion of this offering, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. Many of our existing equity holders have substantial unrecognized gains on the value of the equity they hold based upon the price of this offering, and therefore, they may take steps to sell their shares or otherwise secure the unrecognized gains on those shares. We are unable to predict the timing of or the effect that such sales may have on the prevailing market price of our common stock.
Our stock price may be volatile, and the value of our common stock may decline.
We cannot predict the prices at which our common stock will trade. The initial public offering price of our common stock will be determined by negotiations between us and the underwriters and may not bear any relationship to the market price at which our common stock will trade after this offering or to any other established criteria of the value of our business and prospects, and the market price of our common stock following this offering may fluctuate substantially and may be lower than the initial public offering price. In addition, the trading price of our common stock following this offering is likely to be volatile and could be subject to fluctuations in response to various factors, some of which are beyond our control. These fluctuations could cause you to lose all or part of your investment in our common stock as you might be unable to sell your shares at or above the price you paid in this offering. Factors that could cause fluctuations in the trading price of our common stock include the following:
● | actual or anticipated fluctuations in our financial condition or results of operations; | |
● | variance in our financial performance from expectations of securities analysts; | |
● | changes in the pricing of the solutions on our platforms; | |
● | changes in our projected operating and financial results; | |
● | changes in laws or regulations applicable to our technology; | |
● | announcements by us or our competitors of significant business developments, acquisitions or new offerings; | |
● | sales of shares of our common stock by us or our shareholders; | |
● | significant data breaches, disruptions to or other incidents involving our technology; | |
● | our involvement in litigation; | |
● | future sales of our common stock by us or our stockholders, as well as the anticipation of lock-up releases; | |
● | changes in senior management or key personnel; | |
● | the trading volume of our common stock; | |
● | changes in the anticipated future size and growth rate of our market; | |
● | general economic and market conditions; and | |
● | other events or factors, including those resulting from war, incidents of terrorism, global pandemics or responses to these events. |
25 |
Broad market and industry fluctuations, as well as general economic, political, regulatory and market conditions, may also negatively impact the market price of our common stock. In addition, technology stocks have historically experienced high levels of volatility. In the past, companies who have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future, which could result in substantial expenses and divert our management’s attention.
If securities or industry analysts do not publish research or publish unfavorable or inaccurate research about our business, the market price and trading volume of our common stock could decline.
The market price and trading volume of our common stock following the completion of this offering will be heavily influenced by the way analysts interpret our financial information and other disclosures. We do not have control over these analysts. If few securities analysts commence coverage of us, or if industry analysts cease coverage of us, our stock price would be negatively affected. If securities or industry analysts do not publish research or reports about our business, downgrade our common stock, or publish negative reports about our business, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price to decline and could decrease the trading volume of our common stock.
We will have broad discretion in the use of the net proceeds to us from this offering and may not use them effectively.
We will have broad discretion in the application of the net proceeds to us from this offering, including for any of the purposes described in the section titled “Use of Proceeds,” and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, our ultimate use may vary substantially from our currently intended use. Investors will need to rely upon the judgment of our management with respect to the use of proceeds. Pending use, we may invest the net proceeds from this offering in investment-grade, interest-bearing securities, such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government that may not generate a high yield for our stockholders. If we do not use the net proceeds that we receive in this offering effectively, our business, financial condition, results of operations and prospects could be harmed, and the market price of our common stock could decline.
Our executive officers, directors and principal stockholders, if they choose to act together, have the ability and will continue to have the ability to control or significantly influence all matters submitted to stockholders for approval.
Our executive officers, directors and principal stockholders in the aggregate, beneficially own approximately 100% of our common stock and will continue to own approximately 72.73% of our outstanding common stock upon completion of this offering (assuming no exercise of the underwriters’ option to purchase additional shares), Such persons acting together, will have the ability to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders.
You will experience immediate and substantial dilution in the net tangible book value of the shares of common stock you purchase in this offering.
The initial public offering price of our common stock is substantially higher than the adjusted net tangible book value per share of our common stock immediately after this offering. If you purchase shares of our common stock in this offering, your shares will experience immediate dilution of $3.86 per share, or $3.72 per share if the underwriters exercise their over-allotment option in full, representing the difference between our as adjusted net tangible book value per share after giving effect to the sale of common stock in this offering and an assumed initial public offering price of $5.00 per share, the midpoint of the estimated price range set forth on the cover page of this prospectus. See the section titled “Dilution.”
26 |
The issuance of our common stock in connection with the Company’s outstanding warrants and promissory note could cause substantial dilution, which could materially affect the trading price of our common stock.
The GT Warrants and the warrants pursuant to the GreenTree service agreement are exercisable for up to 600,000 shares of the Company’s common stock and the Note is convertible at a price equal to 70% of the lowest closing price for the last five (5) trading days immediately prior to but not including the date of conversion. The additional shares of common stock issued pursuant to these instruments will result in dilution to the then existing holders of common stock of the Company and increase the number of shares eligible for resale in the public market. Sales of a substantial numbers of such shares in the public market could adversely affect the market price of our common stock.
The sale of our common stock and the warrants in this offering could result in the reset of the exercise price of certain outstanding warrants.
We have outstanding warrants to purchase 600,000 shares of our common stock with an exercise price of $2.00 per share that may be subject to further adjustment. The terms of these warrants provide that if we sell common stock, options to purchase common Stock, securities convertible into common stock or rights relating to our common stock at a price per share less than the then-current exercise price, then we are required to reduce the exercise price of the warrants to match the price per share of such sale of our common stock.
We anticipate that we will need to raise additional capital, and our issuance of additional capital stock in connection with financings, acquisitions, investments, our equity incentive plans or otherwise will dilute all other stockholders.
We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity awards to employees, directors and consultants under our equity incentive plans. We may also raise capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in companies, products or technologies and issue equity securities to pay for any such acquisition or investment. We may not be able to obtain additional capital if and when needed on terms acceptable to us, or at all. Further, if we do raise additional capital, it may cause stockholders to experience significant dilution of their ownership interests and the per share value of our common stock to decline.
27 |
We do not intend to pay dividends for the foreseeable future and, as a result, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.
We have never declared or paid any cash dividends on our capital stock, and, subject to the discretionary dividend policy described in the section entitled “Dividend Policy” of this prospectus, we do not intend to pay any cash dividends in the foreseeable future. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, you may need to rely on sales of our common stock after price appreciation, which may never occur, as the only way to realize any future gains on your investment.
We are an “emerging growth company,” and we cannot be certain if the reduced reporting and disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.
We are an “emerging-growth company,” as defined in the JOBS Act, and we have elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies,” including the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, or Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Pursuant to Section 107 of the JOBS Act, as an emerging growth company, we have elected to use the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies. As a result, our financial statements will not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make our common stock less attractive to investors. In addition, if we cease to be an emerging growth company, we will no longer be able to use the extended transition period for complying with new or revised accounting standards.
We will remain an emerging-growth company until the earliest of: (1) the last day of the fiscal year following the fifth anniversary of this offering; (2) the last day of the first fiscal year in which our annual gross revenue is $1.235 billion or more; (3) the date on which we have, during the previous rolling three-year period, issued more than $1 billion in non-convertible debt securities; and (4) the date we qualify as a “large accelerated filer,” with at least $700 million of equity securities held by non-affiliates.
We cannot predict if investors will find our common stock less attractive as a result of choosing to rely on these exemptions. For example, if we do not adopt a new or revised accounting standard, our future results of operations will not be as comparable to the results of operations of certain other companies in our industry that adopted such standards. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile.
28 |
Anti-takeover provisions in our charter documents may discourage our acquisition by a third party, which could limit our stockholders’ opportunity to sell their shares, at a premium.
Our certificate of incorporation effective immediately prior to the completion of this offering include provisions that could limit the ability of others to acquire control of our company. These provisions could have the effect of depriving our stockholders of an opportunity to sell their shares at a premium over prevailing market prices by discouraging third parties from seeking to obtain control in a tender offer or similar transaction. Among other things, the charter documents will provide:
● | certain amendments to our bylaws that will require the approval of two-thirds of the combined vote of our then-outstanding shares of our common stock; | |
● | directors will be able to be removed only for cause and only by the affirmative vote of the holders of at least two-thirds of the voting power of our common stock; | |
● | our board of directors will be classified into three classes of directors with staggered three-year terms; and | |
● | our board of directors has the authority, without further action by our stockholders, to issue preferred stock in one or more series and to fix their designations, powers, preferences, privileges, and relative participating, optional, or special rights, and the qualifications, limitations, or restrictions, including dividend rights, conversion rights, voting rights, terms. |
Our certificate of incorporation designates the Court of Chancery of the State of Delaware and federal court within the State of Delaware as the exclusive forum for certain types of actions and proceedings that our stockholders may initiate, which could limit a stockholder’s ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Our certificate of incorporation provides that, subject to limited exceptions, the Court of Chancery of the State of Delaware will be exclusive forums for any:
● | derivative action or proceeding brought on our behalf; | |
● | action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; | |
● | action asserting a claim against us, our directors or officers or employees arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or amended and restated bylaws; or | |
● | other action asserting a claim against us, our directors or officers or employees that is governed by the internal affairs doctrine. |
This choice of forum provision does not apply to actions brought to enforce a duty or liability created under the Exchange Act. Our amended and restated certificate of incorporation to be in effect after this offering also provides that the federal district courts of the United States are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. We intend for this provision to apply to any complaints asserting a cause of action under the Securities Act despite the fact that Section 22 of the Securities Act creates concurrent jurisdiction for the federal and state courts over all actions brought to enforce any duty or liability created by the Securities Act or the rules and regulations promulgated thereunder. There is uncertainty as to whether a court would enforce such a provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above.
These choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.
29 |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains, in addition to historical information, forward-looking statements. These statements are based on our management’s beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained principally under the headings “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Use of Proceeds” and “Business.” Forward-looking statements include statements concerning:
● | our possible or assumed future results of operations; | |
● | our business strategies; | |
● | our ability to attract and retain customers; | |
● | our ability to sell additional products and services to customers; | |
● | our cash needs and financing plans; | |
● | our competitive position; | |
● | our industry environment; | |
● | our potential growth opportunities; | |
● | expected technological advances by us or by third parties and our ability to integrate and commercialize them; | |
● | the effects of future regulation; and | |
● | the effects of competition |
.
All statements in this prospectus that are not historical facts are forward-looking statements. We may, in some cases, use terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions that convey uncertainty of future events or outcomes to identify forward-looking statements.
The outcome of the events described in these forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These important factors include our financial performance and the other important factors we discuss in greater detail in “Risk Factors.” You should read these factors and the other cautionary statements made in this prospectus as applying to all related forward-looking statements wherever they appear in this prospectus. Given these factors, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date on which the statements are made. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we currently expect.
USE OF PROCEEDS
We estimate that we will receive net proceeds from this offering of approximately $13,100,000 (or approximately $15,170,000 if the underwriters’ option to purchase additional shares is exercised in full) based on an assumed initial public offering price of $5.00 per share of common stock, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
Each $1.00 increase (decrease) in the assumed initial public offering price of $5.00 per share of common stock would increase (decrease) the net proceeds to us from this offering by approximately $2,760,000 assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares of common stock offered by us would increase (decrease) the net proceeds to us from this offering by approximately $4,600,000 assuming the assumed initial public offering price of $5.00 per share of common stock remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.
We intend to use net proceeds from this offering for expanding our existing product offerings, expansion into new markets, purchasing inventory, expanding our workforce, repaying our note with Greentree Financial Group, Inc. in full, working capital and other general corporate purposes, as follows:
Without over allotment | With over allotment | |||||||
Expanding Product Offerings | $ | 3,237,500 | $ | 3,792,500 | ||||
Marketing | 3,237,500 | 3,792,500 | ||||||
Expanding Workforce | 5,327,000 | 6,121,400 | ||||||
D&O insurance | 300,000 | 300,000 | ||||||
Working Capital and Other General Operation | 748,000 | 913,600 | ||||||
GT Group Loan Repayment | 250,000 | 250,000 | ||||||
Total | $ | 13,100,000 | $ | 15,170,000 |
We believe that the net proceeds from this offering and our existing cash will be sufficient to fund our operations through at least the next 30 months. This expected use of the net proceeds from the offering represents our intentions based upon our current plans and business conditions. We cannot specify with certainty all of the particular uses of the net proceeds that we will receive from this offering, or the amounts that we will actually spend on the uses set forth above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in using these proceeds. Investors will be relying on our judgment regarding the use of the net proceeds from this offering. Pending the use of proceeds as described above, we plan to invest the net proceeds that we receive in short-term and intermediate-term interest-bearing obligations, investment-grade investments, certificates of deposit or direct or guaranteed obligations of the U.S. government. We cannot predict whether the invested proceeds will yield a favorable return.
30 |
We may also use a portion of our net proceeds to acquire or invest in complementary products, technologies, or businesses. However, we currently have no agreements or commitments to complete any such transactions.
On August 4, 2022, we entered into a loan agreement (the “Loan Agreement”) with Greentree Financial Group, Inc. (the “Investor”) for a loan of up to $250,000 to help us pay certain offering expenses. As funds are advanced, the Company will issue a promissory note (the “Note”) for the amount advanced plus a 10% original issue discount. The Note matures on February 15, 2023, subject to the Company’s right to extend the note two times for three months each by issuing the investor 10,000 shares of the Company’s common stock on each extension. The Investor has the right to convert the unpaid principal amount and interest on the Note into shares of common stock at a price equal to 70% of the lowest closing price for the last five (5) trading days immediately prior to but not including the date of conversion. In connection with the Loan Agreement, the Investor will receive warrants to purchase up to 200,000 shares of common stock (based on a $200,000 investment) at $2.00 per share for a period of five years (the “GT Warrant”). The Investor was granted registration rights for a registration statement in connection with a subsequent offering, subject to certain exceptions. If after sixty (60) days of this offering (i) a registration statement for the common stock underlying the GT Warrants has gone effective, and is still effective, (ii) the 20-day volume-weighted daily average price of the Company’s common stock exceeds $6 per share, (iii) the average daily trading volume is at least 500,000 shares during such 20-day period, and (iv) an event of default under the Note has not occurred, then the Company will have the option for thirty (30) days to elect to call the Investor’s unexercised GT Warrants at a price per GT Warrant equal to $0.10 per GT Warrant; provided that, the Company provides the Investor with written notice of its intent to redeem, and the Investor has thirty (30) days after receipt of notice to elect to exercise the GT Warrants. The GT Warrants also contain an anti-dilution provision which proportionately adjusts the exercise price of the GT Warrants if the Company issues common stock or securities convertible into common stock at a price per share less than the exercise price.
On November 16, 2022, the Company and the Investor entered into amendment to the Note, pursuant to which the balance under the note may be converted into the Company’s common stock immediately upon the completion of the Company’s initial public offering or some other event that results in the Company’s common stock becoming publicly traded as opposed to the balance under the note being convertible into common stock immediately upon issuance.
On November 16, 2022, the Company and the Investor entered into amendment to the GT Warrant, pursuant to which the GT Warrants will not be exercisable until the Company’s initial public offering or some other event that results in the Company’s common stock becoming publicly traded as opposed to the GT Warrant being exercisable into common stock immediately upon issuance.
DIVIDEND POLICY
We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future.
Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant. In addition, our ability to pay dividends may be restricted by any agreements we may enter into in the future.
CAPITALIZATION
The following table sets forth our cash and cash equivalents as of September 30, 2022:
● | on an actual basis; | |
● | a pro forma basis to give effect to the sale of 3,000,000 shares in this offering at the assumed initial public offering price of $5.00 per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us; and | |
● | gives effect to the cancellation of 10,000 shares of common stocks and issuance of 7,120,000 shares of common stocks to an executive officer, and 880,000 shares of common stocks to third parties, respectively, for services rendered prior to the closing of this offering. |
The foregoing pro forma information as adjusted is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read the following table in conjunction with the “Use of Proceeds” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of this prospectus and our financial statements and related notes appearing elsewhere in this prospectus.
As of September 30, 2022 | ||||||||
Actual | Pro Forma As Adjusted | |||||||
(unaudited) | ||||||||
Cash and cash equivalents | 31,365 | 13,131,365 | ||||||
Debt: | ||||||||
Accounts payable and accrued liabilities | 193,612 | 193,612 | ||||||
Short-term payables | 25,055 | 25,055 | ||||||
Long-term payables | 561,554 | 561,554 | ||||||
Total debt | 780,221 | 780,221 | ||||||
Members’ equity | - | - | ||||||
Stockholders’ equity (deficit): | ||||||||
Common stock | 100 | 110,000 | ||||||
Additional paid-in capital | 6,582 | 13,076,582 | ||||||
Accumulated deficit | (660,627 | ) | (740,527 | ) | ||||
Total stockholders’ (deficit) equity | (653,945 | ) | 12,446,055 | |||||
Total capitalization | 126,276 | 13,226,276 |
31 |
The number of shares of our common stock to be outstanding after this offering is based on 7,120,000 shares of our common stock outstanding as of September 30, 2022. Unless we indicate otherwise or the context otherwise requires, all information in this prospectus:
● | assumes the shares of common stock are offered at $5.00 per share (the midpoint of the price range listed on the cover page of this prospectus); | |
● | assumes no exercise by the underwriters of their overallotment option; | |
● | assumes no exercise of 600,000 outstanding warrants; | |
● | assumes no exercise of the warrants issued to the representative of the underwriters; and | |
● | does not include 880,000 shares of Common Stock that will be issued to consultants within 30 days prior to the offering. |
DILUTION
If you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the initial public offering price per share of common stock and the pro forma as adjusted net tangible deficit per share of our common stock immediately after this offering.
As of September 30, 2022, we had a historical net tangible deficit of approximately $(653,945) or $(64.39) per share. Our historical net tangible deficit per share represents total tangible assets of $241,586 less total liabilities of $895,531.
Our pro forma net tangible deficit as of September 30, 2022 was $(653,945) or $(0.08) per share. Pro forma net tangible deficit represents the amount of our total tangible assets less total liabilities, after giving effect to the cancellation of 10,000 shares of common stocks, 7,120,000 shares of common stocks to an executive officer, and 880,000 shares of common stocks to third parties, respectively, for services rendered prior to the closing of this offering.
After giving effect to the cancellation of 10,000 shares of common stocks, the issuance of 7,120,000 shares of common stocks to an executive officer, and 880,000 shares of common stocks to third parties, respectively, for services surrender prior to the closing of this offering, the receipt of the net proceeds from our sale of common stock in this offering, at an assumed initial public offering price of $5.00 per share, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses, our pro forma as adjusted net tangible book value as of September 30, 2022 would have been approximately $12,446,055 or $1.13 per share. This amount represents an immediate increase in pro forma as adjusted net tangible book value of $1.21 per share to our existing stockholders and an immediate dilution of $3.87 per share to new investors participating in this offering.
The number of shares of our common stock to be outstanding after this offering is based on 7,120,000 shares of our common stock outstanding as of September 30, 2022. Unless we indicate otherwise or the context otherwise requires, all information in this prospectus:
● | assumes the shares of common stock are offered at $5.00 per share (the midpoint of the price range listed on the cover page of this prospectus); | |
● | assumes no exercise by the underwriters of their overallotment option; | |
● | assumes no exercise of 600,000 outstanding warrants; | |
● | assumes no exercise of the warrants issued to the representative of the underwriters; and | |
● | does not include 880,000 shares of Common Stock that will be issued to consultants within 30 days prior to the offering. |
We determine dilution per share to investors participating in this offering by subtracting pro forma as adjusted net tangible deficit per share after this offering from the assumed initial public offering price per share paid by investors participating in this offering. The following table illustrates this dilution on a per share basis to new investors:
Assumed initial public offering price per share | $ | 5.00 | ||
Pro forma net tangible deficit per share as of September 30, 2022 | $ | (0.08 | ) | |
Increase per share to existing stockholders attributable to investors in this offering | $ | 1.21 | ||
Pro forma as adjusted net tangible book value per share, to give effect to this offering | $ | 1.13 | ||
Dilution in pro forma net tangible book value per share to new investors in this offering | $ | 3.87 |
The pro forma information discussed above is illustrative only and will change based on the actual initial public offering price, number of shares and other terms of this offering determined at pricing.
Each $1.00 increase or decrease in the assumed initial public offering price of $5.00 per share (which is the midpoint of the price range set forth on the cover page of this prospectus), would increase or decrease, as applicable, our pro forma as adjusted net tangible book value per share after this offering by $0.25 and dilution per share to new investors purchasing shares of common stock in this offering by $0.75, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase of one million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by $0.29 and decrease the dilution per share to new investors purchasing shares of common stock in this offering by $0.29, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A decrease of one million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease our pro forma as adjusted net tangible book value per share after this offering by $0.35 and increase the dilution per share to new investors purchasing shares of common stock in this offering by $0.35, assuming no change in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
If the underwriters exercises their over-allotment option in full, our pro forma adjusted net tangible book value would be $14,516,055, or approximately $1.27 per share, representing an immediate increase in the adjusted net tangible book value to existing stockholders of approximately $1.35 per share and immediate dilution of approximately $3.73 per share to new investors purchasing shares of our common stock in this offering, assuming an initial public offering price of 5.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
32 |
The table below summarizes as of September 30, 2022, adjusted pro forma basis described above, the number of shares of our common stock, the total consideration and the average price per share (i) paid to us by existing stockholders and (ii) to be paid by new investors purchasing shares in this offering at an assumed initial public offering price of $5.00 per share, before deducting underwriting discounts and commissions and estimated offering expenses.
Shares Purchased | Total Consideration | Average Price Per | ||||||||||||||||||
Number (1) | Percent | Amount | Percent | Share | ||||||||||||||||
Existing stockholders | 8,000,000 | 72.73 | % | $ | 80,000 | 0.61 | % | $ | 0.01 | |||||||||||
New investors | 3,000,000 | 27.27 | % | $ | 13,100,000 | 99.39 | % | $ | 5.00 | |||||||||||
Total | 11,000,000 | 100.00 | % | $ | 13,180,000 | 100.00 | % | $ |
In addition, if the underwriters exercise their option to purchase additional shares of common stock in full, the percentage of shares held by existing stockholders will be reduced to 69.87% of the total number of shares of common stock to be outstanding upon the closing of this offering, and the number of shares of common stock held by new investors participating in this offering will be further increased by 450,000 shares, or 2.86% of the total number of shares of common stock to be outstanding upon the closing of this offering.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis of financial condition and results of operations in conjunction with our financial statements and related notes appearing elsewhere in this prospectus. In addition to historical information, the following discussion and analysis includes forward looking statements that involve risks, uncertainties and assumptions. Our actual results and the timing of events could differ materially from those anticipated in these forward looking statements as a result of a variety of factors, including those discussed in “Risk Factors” and elsewhere in this prospectus. See the discussion under “Special Note Regarding Forward Looking Statements” beginning on page 30 of this prospectus. Our fiscal year ends on December 31.
Overview
Scripps Safe is a pharmaceutical supply chain solutions company. Our company focuses on developing solutions for the transport, security, storage, distribution and dispensing of pharmaceuticals within the lawful supply chain and compliant with federal and state regulations. Our mission is to keep pharmaceuticals secure from the manufacturer/distributor to the patient by delivering integrated security solutions across the United States and Canada. Our solutions prevent drug diversion, reduce attempts to minimize drug abuse and ensure required compliance with the myriad of healthcare and pharmaceutical laws and regulations.
33 |
Critical Accounting Policies and Estimates and Recent Accounting Pronouncements
Basis of Presentation
The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). While our significant accounting policies are more fully described in our financial statements, we believe the following accounting policies are the most critical to aid in fully understanding and evaluating this management discussion and analysis.
Use of Accounting Estimates
The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments include but are not limited to share-based compensation. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.
Revenue Recognition
The Company adopted Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”) and recognizes revenue upon the transfer of goods or services in an amount that reflects the expected consideration received in exchange for those goods or services. The Company recognized $511,247 and $505,143 of revenue for the nine months ended September 30, 2022 and for the year ended December 31, 2021, respectively. The Company expects to derive revenue similarly in 2022. Recognition of this future revenue will be subject to the terms of any arrangements with our clients.
Recently Issued Pronouncements
For information on recently issued accounting pronouncements, refer to Note 2 to our financial statements included elsewhere in this prospectus.
34 |
Results of Operations for the Nine Months Ended September 30, 2022 and 2021,
Revenue
Revenue increased $76,972, or 17.72% from $434,277 for the nine months ended September 30, 2021, to $511,249 for the nine months ended September 30, 2022. The increase was due to the growth of our business and closing deals in the pipeline.
Cost of Revenue
Cost of revenue increased $147,016, or 82.57% from $178,041 for the nine months ended September 30, 2021, to $325,057 for the nine months ended September 30, 2022. The increase was due to the increase in costs of raw materials.
Selling, General and Administrative
Selling, General and administrative costs increased $225,021, or 83.74% from $268,718 for the nine months ended September 30, 2021, to $493,739 for the nine months ended September 30, 2022. The increase was mainly due to the increases in legal and professional services.
Results of Operations for the Year Ended December 31, 2021, and 2020,
Revenue
Revenue decreased $43,048, or 7.85% from $548,191 for the year ended December 31, 2020, to $505,143 for the year ended December 31, 2021. The decrease was due to supply chain challenges and delayed delivery of finished goods.
Cost of Revenue
Cost of revenue increased $85,881, or 31.94% from $268,887 for the year ended December 31, 2020, to $354,768 for the year ended December 31, 2021. The increase was due to the increase in costs of raw materials.
Selling, General and Administrative
Selling, General and administrative costs increased $190,647, or 77.31% from $246,614 for the year ended December 31, 2020, to $437,261 for the year ended December 31, 2021. The increase was primarily due to additional office and safety expenses to meet new COVID-19 guidelines and new staffing requirements.
Non-GAAP Financial Measures
Off-Balance Sheet Arrangements
We did not have, during the periods presented, any off-balance sheet financing arrangements or any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.
Liquidity and Capital Resources
We have financed our operations primarily through the founder’s equity, revenue from sales and an EIDL SBA loan which has historically been sufficient to meet our working capital and capital expenditure requirements. As of September 30, 2022 and December 31, 2021, our principal sources of liquidity were $31,365 and $227,932, respectively of cash and cash equivalents. Cash and cash equivalents consist primarily of cash on deposit.
On August 4, 2022, we entered into a loan agreement (the “Loan Agreement”) with Greentree Financial Group, Inc. (the “Investor”) for a loan of up to $250,000 to help us pay certain offering expenses. As funds are advanced, the Company will issue a promissory note (the “Note”) for the amount advanced plus a 10% original issue discount. The Note matures on February 15, 2023, subject to the Company’s right to extend the note two times for three months each by issuing the investor 10,000 shares of the Company’s common stock on each extension. The Investor has the right to convert the unpaid principal amount and interest on the Note into shares of common stock at a price equal to 70% of the lowest closing price for the last five (5) trading days immediately prior to but not including the date of conversion. In connection with the Loan Agreement, the Investor will receive warrants to purchase up to 200,000 shares of common stock (based on a $200,000 investment) at $2.00 per share for a period of five years (the “GT Warrant”). The Investor was granted registration rights for a registration statement in connection with a subsequent offering, subject to certain exceptions. If after sixty (60) days of this offering (i) a registration statement for the common stock underlying the GT Warrants has gone effective, and is still effective, (ii) the 20-day volume-weighted daily average price of the Company’s common stock exceeds $6 per share, (iii) the average daily trading volume is at least 500,000 shares during such 20-day period, and (iv) an event of default under the Note has not occurred, then the Company will have the option for thirty (30) days to elect to call the Investor’s unexercised GT Warrants at a price per GT Warrant equal to $0.10 per GT Warrant; provided that, the Company provides the Investor with written notice of its intent to redeem, and the Investor has thirty (30) days after receipt of notice to elect to exercise the GT Warrants. The GT Warrants also contain an anti-dilution provision which proportionately adjusts the exercise price of the GT Warrants if the Company issues common stock or securities convertible into common stock at a price per share less than the exercise price.
On November 16, 2022, the Note was the Company and the Investor entered into amendment to the Note, pursuant to which the balance under the note may be converted into the Company’s common stock immediately upon the completion of the Company’s initial public offering or some other event that results in the Company’s common stock becoming publicly traded as opposed to the balance under the note being convertible into common stock immediately upon issuance.
On November 16, 2022, the Note was the Company and the Investor entered into amendment to the GT Warrant, pursuant to which the GT Warrants will not be exercisable until the Company’s initial public offering or some other event that results in the Company’s common stock becoming publicly traded as opposed to the GT Warrant being exercisable into common stock immediately upon issuance.
Based on our current operating plan, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents and anticipated cash generated from sales of our services, will be sufficient to meet our anticipated cash needs for at least the next 30 months following the date of this prospectus.
Our future capital requirements will depend on many factors, including, but not limited to, the rate of our growth, our ability to attract and retain customers, and the timing and extent of spending to support our efforts to develop our software platform. Further, we may enter into future arrangements to acquire or invest in businesses, products, services, strategic partnerships, and technologies. As such, we may be required to seek additional equity and/or debt financing. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. The incurrence of indebtedness would result in increased fixed obligations and could result in operating covenants that would restrict our operations. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations may be materially and adversely affected.
Cash Flows
Operating activities
Net cash used in operating activities was $334,838 and $56,211 for the nine months ended September 30, 2022 and 2021, respectively. The negative cash flows from operating activities for the nine months ended September 30, 2022 was primarily due to the net loss of 327,065, plus mainly the right of use asset of $114,460, offsetting mainly by increase in right of use liabilities of $115,310. Comparatively, the negative cash flows from operating activities for the nine months ended September 30, 2021 was primarily due to the net loss of $1,124, which mainly increased by the increase in accounts receivable of $69,731.
35 |
Investing activities
Net cash used in investing activities was $0 for the nine months ended September 30, 2022 and 2021.
Financing activities
Net cash provided by financing activities was $138,271 and $307,407 for the nine months ended September 30, 2022 and 2021. The positive cash flows from financing activities for nine months ended September 30, 2022 was primarily due the $112,500 of the net proceeds from borrowings in debt. Comparatively, the positive cash flows from financing activities for the nine months ended September 30, 2021 was primarily due to the $314,700 proceeds from SBA EIDL loan.
Emerging Growth Company Status
We are an “emerging-growth company”, as defined in the JOBS Act, and, for as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging growth companies, including, but not limited to, not being required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As an emerging growth company we can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to avail ourselves of these options. Once adopted, we must continue to report on that basis until we no longer qualify as an emerging growth company.
We will cease to be an emerging growth company upon the earliest of: (i) the end of the fiscal year following the fifth anniversary of this offering; (ii) the first fiscal year after our annual gross revenue are $1.235 billion or more; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; or (iv) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million as of the end of the second quarter of that fiscal year. We cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. If, as a result of our decision to reduce future disclosure, investors find our common shares less attractive, there may be a less active trading market for our common shares and the price of our common shares may be more volatile.
BUSINESS
Overview
The U.S. pharmaceuticals market is the world’s largest national market and represents over 45% of the world’s global pharmaceuticals with sales exceeding $584B in 2021.4 U.S. pharmaceuticals are divided into two categories: controlled and non-controlled substances. The Controlled Substances Act (CSA) of 1970 is the statute establishing federal U.S. drug policy under which the manufacture, importation, possession, use, transport, security, storage, distribution and dispensing of controlled substances is regulated. The Drug Enforcement Administration (“DEA”) enforces these policies at the federal level and State Pharmacy Boards, Bureau of Narcotics and Departments of Health have enforcement authority at the state level. The stricter of the two regulations must be always be followed.
Our mission focuses on developing integrated solutions for the professionals who are required to manage the transport, security, storage and distribution of pharmaceuticals within the lawful supply chain and be compliant with federal and state regulations. Our mission is to keep pharmaceuticals secure from the manufacturer/distributor to the patient by delivering integrated security solutions across the United States and Canada.
The Scripps System™ is a Platform as a service (PaaS) Solution to keep pharmaceuticals secure within the lawful supply chain. Currently, we sell DEA compliant safes and vaults with integrated access control system management. We anticipate adding new solution features in the near term that will include advanced inventory management, supply chain tracking, audit tracking capability and diversion control. Within two years we anticipate adding advanced analytics, and application programming interfaces (“API”) to common healthcare applications.
Scripps Safe currently has over 600 healthcare clients who have purchased our currently available DEA compliant vaults and safes with integrated access control/management systems. To date, our revenue has not been concentrated to any one particular vertical or among a small number of customers.
4 https://www.statista.com/topics/1719/pharmaceutical-industry/
36 |
Market Need and Opportunity
Pharmaceutical Drug Diversion
In 2021 over 18,278 opioid related overdose deaths were reported, directly attributable to diverted pharmaceuticals. 5 In 2021 a total of 107,521 people died in the USA to a drug overdose with 75% related to an opioid according to the CDC.
Pharmaceutical Drug Diversion is defined as the transfer of a drug from a lawful to an unlawful channel of distribution or abuse. The impact of drug diversion in the U.S. is:
● | $72.65 billion a year – Economic Cost6 | |
● | $120 billion a year – Lost Labor and Productivity2 | |
● | $45 - $150 billion – Litigation & Settlement Costs7 | |
● | Pharmacy / Healthcare Facility Risks: |
○ | Risk of violent crime | |
○ | Risk to patient health and security | |
○ | Workplace risk to employees | |
○ | Negative publicity | |
○ | Remediation costs | |
○ | Regulatory and civil liability | |
○ | Loss of federal funding (Medicaid) | |
○ | Loss of license |
○ | Destroying lives, families and communities |
Drug diversion is not uncommon and can result in substantial risk not only to the individual who is diverting the drugs but also to patients, co-workers, and employers. Drug diversion can occur at any point along the supply chain. The true devastation of drug diversion and economic impact is immeasurable.
Market Opportunity and Growth
This market is primarily driven by the growth and distribution of pharmaceuticals. Pharmaceutical security solutions ARE REQUIRED BY LAW.
Three companies—McKesson, AmerisourceBergen, and Cardinal Health—account for approximately 90% of drug distribution revenue in the United States. Each of the Big 3 distributors appear in the top 15 companies ranked in the 2021 Fortune 500 list, and each recorded revenue of over $162 billion for 2021, following years of steady growth.8
5 https://nida.nih.gov/drug-topics/trends-statistics/overdose-death-rates
6 Source: National Drug Control Budget: FY 2018 Funding Highlights
7 https://www.bloomberg.com/news/articles
8 Publicly reported revenues
37 |
Figure 1
From 2011 – 2021 the pharmaceutical market has grown approximately 95.2% and continues to show a steady upward trajectory.
Based on the overall size of the pharmaceutical market, the current U.S. federal and state security requirements and the number of controlled substance license holders, Scripps Safe estimates the addressable pharmaceutical security market for the Scripps SystemTM to be $16.5B in the United States. Based on the current laws, market dynamics and growth, pharmaceutical security is estimated to be a €6.14B/year9 opportunity within the European Union (EU).
Target Verticals
Pharmaceuticals are divided into two categories: controlled and non-controlled substances. There are many high value non-controlled substances that need to be protected in the supply chain. These include but are not limited to OTC medications, vaccines, Viagra, birth control pills, steroids and pet medications. However, the target verticals will generally be focused on securing and protecting controlled substances.
In order to manufacture, carry, dispense, handle or prescribe controlled substances an individual must register with the DEA, their State Pharmacy Board, Bureau of Narcotics and/or Department of Health. Upon approval registrants are awarded their license as a practitioner, mid-level practitioner or non-practitioner. The laws regarding the security and handling of controlled substances varies by each of these groups. Scripps Safe is not a medical practitioner, mid-level practitioner or non-practitioner and is not required to have a state or federal controlled substance license.
Controlled substances are categorized by the DEA into five (5) distinct categories or schedules depending upon the drug’s acceptable medical use and the drug’s abuse or dependency potential. The abuse rate is a determinate factor in the scheduling of the drug; for example, Schedule I drugs have a high potential for abuse and the potential to create severe psychological and/or physical dependence. As the drug schedule changes— Schedule II, Schedule III, etc., so does the abuse potential— Schedule V drugs represents the least potential for abuse. Drugs may include the parent chemical and do not necessarily describe the salts, isomers and salts of isomers, esters, ethers and derivatives which may also be classified as controlled substances.10
There are currently 1.9 million DEA controlled substance licenses, broken out as follows:11
9 EFPIA (European Federation of Pharmaceutical Industries and Associations), 2020
10 https://www.dea.gov/drug-scheduling
11 https://www.dealookup.com/
38 |
● | Physicians | 1,352,890 | |
● | Nurses/PAs | 446,573 | |
● | Pharmacy | 70,905 | |
● | Hospital/Clinic | 18,722 | |
● | Researcher | 11,919 |
Net new licenses are currently growing about 7% per year. Several market dynamics can and will dramatically increase this number. One, is the opioid settlements and litigation. The massive infusion of opioid settlement funds is expected to funnel billions of dollars in grants to open new opioid treatment facilities within the next few years. Two, is the massive approval of medical marijuana across many states, creating a virtually new industry and expanded add-on business for many existing providers. Narcotic treatment providers and medical marijuana (schedule I) would be held to the highest government standards for security and handling. Scripps Safe breaks out our current target vertical markets and priority as follows:
|
![]() |
● | Scripps Safe’s top three target strategic verticals are mobile pharmacy including EMS/Fire/ RescuePharmacy/ Home Health Delivery, Addiction/ Medication Treatment Facilities and Distributed Supply Chain plus those needing the Highest Security Requirements Required by Law |
○ | Government, Law Enforcement, Military, Prisons | |
○ | Hospitals, Research, Universities, Independent Testing Labs, Medical and Veterinary Practices | |
○ | Manufacturers, Distributors, Reverse Distributors, Importers, Exporters, Compounders | |
○ | Narcotic/ Medication Treatment Facilities, Bio & Life Sciences, Assisted/ Acute Care |
● | Maximum Crime and Anti-Diversion Risk |
○ | Chain & Independent Pharmacies | |
○ | Mobile Pharmacy: First Responders/ EMS/Fire/Delivered Home Health Care – | |
○ | Animal Handlers/ Veterinary Care | |
○ | Hospice & Assisted/ Acute Care Facilities |
● | Solution Launch Priority by Vertical in 2023 |
○ | Scripps System™ Mobile Pharmacy – 1H2023 | |
○ | SafeDispense® for Hospitals – 1H2023 | |
○ | Guardian Series® for Addiction/ Medication Treatment Facilities – 1H2023 | |
○ | TRXP Series® for Assisted Care Facilities and Chain Pharmacies 2H2023 | |
○ | SMART Series™ Vaults for Manufactures & Distributors 2H2023 C1SAFE®Analytical & Research Labs 2H2023 |
● | Future Verticals/Opportunities – 2024 - 2025 |
○ | Vaccine Transportation & Storage Solutions (2024) | |
○ | Cold Chain Storage Solutions (2024) | |
○ | Scripps Pharma Tracking Command Center (2025) | |
○ | U.S. Strategic Drug Vault® (2025) |
39 |
These priorities were chosen based on highest market/legislative need, competitive advantage, lowest barriers to entry, solution availability and strongest market opportunity.
Competition
The competitive environment for pharmaceutical security is disparate, fragmented, non-integrated commodity products and/or general non-compliance.
By target vertical the competitive solutions currently serving the market are as follows:
● | Hospitals – 1) Very expensive medication management and dispensing solutions which are not DEA compliant for storage. No integration to secure enclosures. | |
● | Pharmacy – 1) No solution at all 2) Commodity products 3) Not integrated | |
● | Mobile Pharmacy: EMS/Fire Rescue/ Home Health Care – 1) Very fragmented solution options 2) Non-UL/Non-compliant disparate systems 3) Commodity products. The biggest competitor in this space has stopped servicing their product opening a tremendous opportunity for Scripps Safe. | |
● | Bio & Life Sciences – 1) Great market opportunity, currently no leaders in this space. | |
● | Narcotic/ Medication Assisted Treatment Clinics, Animal Handlers – | |
1) Commodity products with no software or technology integration | ||
● | Assisted/ Long-Term/ Acute Care Facilities – No competitors in this space. Currently only using commodity products. |
The greatest competitive “challenges” are complacent non-compliance, no solution at all, and addressing customer purchasing behavior. Our top 2 target verticals are EMS/Fire/Ambulance and Addiction Treatment Facilities. The competitive opportunity in Mobile Pharmacy: EMS/Fire/Ambulance is our biggest competitor has stopped servicing their product. The competitive opportunity for Addiction Treatment facilities is two-fold. One, there are no market leaders addressing this vertical and two, the cost of pharmaceutical security solutions for treatment providers (up to $8,000 for facilities and $250,000 for mobile treatment operations) are covered by SAMSHA (Substance Abuse and Mental Services Health Administration) grants.
40 |
Solutions and Products
I. | The Scripps System™ PaaS Solution |
The patent approved Scripps System™ is designed to eliminate drug diversion throughout the supply chain. This is an integrated system of transport, storage, dispensing and inventory management with direct supervision surveillance and access control system management connected to track and trace serialization requirements. This system will integrate to advanced diversion analytics, customer’s pharmacy management and inventory systems, customized reporting, advanced artificial intelligence and machine learning to empower real time knowledge leading to smarter decisions.
The Scripps System™ keeps drugs safe from manufacturer to the patient with end-to-end chain of custody solutions. This system currently includes the following brand segments and product lines: Rescue Series®, TRXP Series®, Guardian Series®, C1SAFE® and SafeDispense®.
On-going R&D is planned for each of these product lines to development competitive, game changing and patented solutions to continue bringing innovation to compliance.
41 |
Turnkey System
The Chief Pharmacist will have the ability to manage permissions and access across the entire pharmacy narcotics workflow. Permissions can be centrally managed, audited, revoked and issued across each of the narcotics vaults. The central administrator will have 24/7 administrative supervision and audit control backed by video technology.
Pre-Integrated & Tested
The Scripps System™ integrates all these components to work together to significantly reduce the risk of internal diversion, tampering, narcotics substitutions or theft.
Growth is Easy
When your needs grow so does your system. Seamless turnkey future growth and expansion make growth easy at minimal cost. Whether you need to add one vault to the new surgery unit or inpatient facility, your plug-in security system easily expands.
Compliant Monitoring Technology
The Chief Pharmacist now can monitor all flow and usage no matter the day or time. In compliance with State and Federal law, the Chief Pharmacist will have constant supervisory view over the entire pharmacy narcotics workflow with the patented Scripps System™ covert digital video camera solution.
42 |
Customer Benefits
Pharmaceutical security solutions lower drug diversion while reducing healthcare costs and keeping everyone safe. Scripps Safe solutions go beyond security to bring smart innovation to compliance. The Scripps System™ patented solution uniquely integrates the DEA’s Controlled Substance Act to the FDA’s Drug Supply Chain Security Act for a seamless workflow environment.
Healthcare facilities will have integrated systems, chain of custody management, streamlined operations, reduced costs and reduced risks of drug diversion. This creates a safer healthcare environment for patients, staff and communities.
Creating a Safer Healthcare Environment®
Integrated Pharmaceutical Security Benefits
Competitive Advantage
We believe Scripps Safe presents the only vertically integrated system that integrates across healthcare systems meeting all federal and state security requirements including constant supervision surveillance.
43 |
In 2021, NASCSA (National Association of State Controlled Substance Authorities) chose Scripps Safe Executive to be honored with the Annual President’s Award, a significant industry recognition.
We Bring Innovation to Compliance®
44 |
We believe our competitive advantage is a fully integrated and autonomous system that has patent protection.
Pricing - Subscription Recurring Revenue Model
Scripps Safe currently has a flat rate transactional pricing model. With the support of the capital raise, we plan to re-launch/launch our new solutions with a recurring subscription revenue monthly pricing model.
Monthly - Per Unit/User Pricing for Access Control System Automated Dispatch System
This is a standard PaaS pricing model, where users pay different amounts based on the number of individuals using the hardware, software and requiring dispatch codes. Accounts would have 3 to 10-year service contracts.
Monthly Subscription License - Feature Based Pricing for Solution Bundles
PaaS pricing model customized to a customer’s feature requirements, offering different tiers of support on services and upgrades available. Accounts would have 3 to 10-year service contracts.
Scripps Safe will make money through the following:
○ | Sale and/ or Leasing of Hardware | |
○ | Long-Term/ Ongoing Service and Support Contracts | |
○ | Extended Warranty Packages | |
○ | Consulting Services | |
○ | Data & Analytics Revenue Stream |
Intellectual Property
● | Utility Patent Granted – 1 |
Scripps Safe was issued United States Patent No. US11,257,314 - – AUDITABLE SECURITY SYSTEM FOR SECURE ENCLOSURE.
In summary, this approved patent is directed to an auditable security system for preventing unlawful diversion of goods and/ or services.
45 |
■ | We believe this patent’s claims cover having the ONLY fully networked secure enclosure with camera surveillance in the US. | |
■ | We believe this patent potentially allows Scripps Safe to be the ONLY vendor who can offer this fully integrated solution meeting the Controlled Substance Act of 1970, the FDA’s Drug Supply Chain Security Act of 2013 and State Pharmacy Board security requirements for constant supervision. | |
■ | Currently NY & Illinois DO require constant supervision technology, which we believe only Scripps Safe would be able to provide through a single integrated solution. |
● | Trademarks Granted - 13 |
○ ○ |
1. Scripps Safe Logo® 2. Rescue Series® |
![]() |
○ | 3. TRXP Series ® | ||
○ | 4. Guardian Series® | ||
○ | 5. SafeDispense ® | ||
○ | 6. C1SAFE® | ||
○ | 7. Total Rx Protection® | ||
○ | 8. U.S. Strategic Drug Vault® | ||
○ | 9. We Bring Innovation to Compliance® | ||
○ | 10. Creating A Safer Healthcare Environment® | ||
○ | 11. We’re Ending The Opioid Crisis® | ||
○ ○ |
12. Protecting the Chain of Custody® 13. Cross & Shield Logo Art in Scripps Safe logo® |
![]() |
● | Trademarks Filed & Pending - 3 |
○ | Scripps SystemTM | |
Smart SeriesTM | ||
Central DispenseTM |
● | Patents Design Pending – 1 |
○ | Design patent application number: 29761955 – Product design in support of The Scripps System™ |
Marketing
Solutions Managers, Market Managers, Marketing Operations & Analytics leaders empowered to drive a fully integrated marketing ecosystem by decision maker, influencer and industry executives.
46 |
Direct & Partner Sales
Ambulance Manufacturers, Medical Supply Distributors, Northwell GPO (already a Member), MHA GPO, LabRepCo GPO, Hospital GPO’s, Federal & State GSA, Healthcare Engineering & Design Firms, Healthcare Consulting Firms
Vertical Channel Strategy
Channel Campaigns, Buying Alliances, Manufacturers, Service Providers, Healthcare Compliance Officers, Consultants, GC’s, Mobile Briefing Centers, CE Education, Business Partners – Co-Marketing/ Joint Campaigns
Go to Market Channels
SEO, PPC, Mobile, Affiliate, Display, Social Media, Blogs, Apps, Video, Web Design, Events Calendar
Content Marketing
Unique Content, Customer References, Testimonials, Case Studies, Articles, Newsletters, Blog, Webinars, Deliverables, Language Translations
Influencers
DEA, NADDI, NASCA, State Pharmacy Boards, Vertical Industry Associations, Educational Institutions, Dept of Health |
![]() |
Advocacy
Promulgate legislation through Coalition for 21st Controlled Substances Act (CSA 21)
Promotion
PR Partner Team – Press Releases, Run Print Ads, Broadcast Media, Detail PR Plans to support solution launch events.
47 |
Associations
Scripps Safe currently has marketing agreements with the following associations:
● | AAP – American Associated Pharmacists | |
● | APhA – American Pharmacy Association | |
● | APPA – American Pharmacy Purchasing Alliance | |
● | CARE – Pharmacy Cooperative | |
● | IPA – Independent Pharmacy Alliance | |
● | Keystone – Pharmacy Purchasing Alliance | |
● | PFOA – Pharmacy Practitioners & Owners Association | |
● | Pharmacist Mutual Insurance (PHMIC) | |
● | RxPlus Pharmacies | |
● | Southern Drug Store Solutions | |
● | SPC Southern Pharmacy | |
● | WSPC – Western States Pharmacy Coalition |
Facilities
Our corporate headquarters is located in 9051 Tamiami Trail N, Suite 201, Naples, FL 34108. We have entered into a lease agreement, for our corporate headquarters which lease provides for monthly base rent of $2,200 and expired in April 2022. The lease is currently $2,300 per month on a month-to-month basis. We have entered into a three-year lease agreement for distribution, customer support and order processing for 5,000 sq feet of office space at 100 Technology Way, Jeffersonville, IN 47130 for a monthly base rent of $2,291.67 beginning 5/1/2022, with an option to renew.
Legal Proceedings
We are not a party to any pending legal proceeding, nor is our property the subject of a pending legal proceeding, that is not in the ordinary course of business or otherwise material to the financial condition of our business. None of our directors, officers or affiliates are involved in a proceeding adverse to our business or have a material interest adverse to our business.
Impact of COVID-19
The COVID-19 pandemic affected our company, partners, customers, and the industry at large in many ways. Namely, we saw decreased interest in new deployments due to travel restrictions and social distancing precautions. In addition, it was not feasible for us to engage in new on-site discussions and product demonstrations with the pandemic safety measures that were in place during most of 2020 and early 2021. Furthermore, many potential customers and partners paused their investment into new technologies as they focused on keeping their core business running under the extenuating circumstances of the pandemic. These factors delayed our progress, particular with respect to sales and business development activities. However, we believe this negative impact will be transient. In fact, we believe many of the industries that have positive feedback characteristics to the industrial vehicle market (e-commerce, construction mechanization, etc.) have entered a new stage of growth during the COVID-19 pandemic. The need to support these global markets and the desire to reduce human interactions, enable social distancing as a preventative measure in future operations has spawned new use cases and opportunities for our products.
MANAGEMENT
The following table provides information regarding our executive officers and directors as of the date of this prospectus:
Name | Age | Position(s) | ||
Executive Officers: | ||||
Jacqueline von Zwehl | 47 | Chief Executive Officer, Chairman of the Board of Directors and Director | ||
Craig Steinhoff | 45 | Chief Financial Officer | ||
James Egan | 73 | Director, Audit Chair, Independent Board | ||
Tim Theriault | 66 | Director, Human Capital and Compensation Chair, Independent Board | ||
Steven Ruhl | 65 | Director, Independent Board | ||
Doug Balog | 61 | Director, Nominating & Governance Chair, Independent Board |
48 |
Executive Officers and Directors
Jacqueline von Zwehl, Chief Executive Officer & Chairman of the Board
Ms. Von Zwehl founded Scripps Safe, Inc. in 2016. She is passionate about pharmaceutical security and creating a safer healthcare environment. In her current role, she consults hospitals, pharmacies, federal healthcare, EMS, private ambulance, law enforcement, opioid treatment clinics, manufactures and others on the compliance and safe handling, transportation, storage and dispensing of pharmaceuticals. She is an expert on DEA, SAMHSA regulations and State Board/Bureau of Narcotic guidelines. Ms. Von Zwehl is an advisor to State and Federal lawmakers on controlled substance trends, legislation and drug diversion risks.
Career Highlights
● | 20+ Years Global Healthcare Technology & SW Solutions Leader | |
● | 11+ Years Executive & Management Career at IBM focused on Healthcare Solutions | |
● | Managed 220+ Employees, managed Global P&L and influenced Billions in Revenue | |
● | Led software development teams in CA, Austin, Canada, Israel and India | |
● | Consulted clients in healthcare software solutions in over 25 countries | |
● | BA, Film & English Literature, New York University | |
● | MBA, Marketing & Finance, Penn State University |
Ms. Von Zwehl lives in Naples, FL. She is proud to support her family’s charitable foundation and philanthropic work around the world. The Family Foundation has funded and built 44 medical clinics around the world, St Joseph’s Hospital in Jerusalem, four primary schools in Vietnam and three orphanages in Russia.
Craig Steinhoff, Chief Financial Officer
Craig Steinhoff has been a Principal at HBK CPA’s & Consultants for over 14 years. Craig is acting as Scripps Safe’s interim CFO on a full-time basis as we conduct an executive search for a permanent Chief Financial and Operating Officer (CFOO). Craig does not have any conflicts of interest in performing the duties of this role. He manages a wide range of tax, accounting, audit, business advisory, financial planning, and other business operational and support with expertise across multiple industries. His experience is backed by a B.S. in Accounting from Capital University.
James Egan, Director, Audit Chair, Independent Board
Jim Egan has served as the Non-Executive Chairman of PHH Corporation (NYSE: PHH), a mortgage origination and servicing business, from 2009 to 2020. He was a Chairman of the Audit Committee and a member of the Compensation and Governance committees.
Jim recently served as Board Advisor and Executive Coach to a privately-owned master plan community, real estate developer. He currently serves as the Chairman of the Audit Committee of a privately owned and operated hospital system. He served as a Managing Director of Investcorp International, Inc, an alternative asset management firm specializing in private equity, hedge fund and real estate investments, from 1998 through 2008. Jim was the partner-in-charge, M&A Practice, U.S. Northeast Region for KPMG LLP from 1997 to 1998.
He also served as the Senior Vice President and Chief Financial Officer of Riverwood International, Inc. (currently Graphic Packaging Holding Co.); a global paper, packaging and machinery company from 1996 to 1997. Jim began his career with PricewaterhouseCoopers (formerly Coopers & Lybrand) in 1971 and served as a partner from 1982 to 1996 and a member of the Board of Partners from 1995 to 1996.
Jim possesses over forty years of business experience involving companies of varying sizes from start-ups to Fortune 500 public companies operating across numerous industries, including, among others, retail, consumer, distribution, industrial and financial services.
As a director, Jim brings to the board of directors a wide range of skills and experience in strategy development; operations, financial expertise; governance; risk management, and regulatory compliance.
Tim Theriault, Director, Human Capital and Compensation Chair, Independent Board
Tim Theriault is an executive with more than 30 years of experience in various leadership roles for publicly traded and private companies. Tim currently serves on the Boards of Directors for Alliance Data Systems (NYSE:ADS) and previously the Vitamin Shoppe (NYSE:VSI). Alliance Data Systems, where Tim serves on the Audit and Nominating and Governance Committees, provides a portfolio of integrated outsourced marketing solutions, including customer loyalty programs, database marketing services, end-to-end marketing services, analytics and creative services, direct marketing services, and private label and co-brand retail credit card programs. Vitamin Shoppe, where Tim served on the Audit, Compensation, and IT Committees, operates as an omni-channel specialty retailer of nutritional products in the United States and internationally. Tim left the Board when the Vitamin Shoppe was sold in December, 2019.
Tim most recently served as Executive Vice President and Global Chief Information Officer for Walgreens Boots Alliance, Inc. a Fortune 20 company. During his career he has held leadership positions within information technology, business leadership with P/L responsibility, global operations, innovation, and continuous improvement at companies with annual revenues ranging from $4B to over $100b. His experience includes a wide variety of industries, including healthcare, financial services, retail, and manufacturing. He consistently served as a key advisor to CEOs and boards, as well as strategic partner to the business, helping to provide proactive advice designed to further business objectives while managing risk.
He has applied his skill set to a variety of challenges facing executive teams and boards over the course of his career. Tim has gained significant recognition for his leadership in technology, financial services, retail, and healthcare. At the same time, Tim provided key leadership around cyber security, Cloud, Analytics, Mobile, and other progressive technology solutions. Tim is an avid reader of emerging technologies and how they drive business value. Tim has also led significant mergers and acquisitions in retail, healthcare, and financial services. Having participated in hundreds of board and board committee meetings as an executive or as a board member, Tim has a wealth of practical knowledge and experiences and a common sense approach to board service.
49 |
Steven Ruhl , Director, Independent Board
Steven Ruhl joined Scripps Safe Board in March 2022. He currently serves as the Chief Scientific Officer for Forte Biosciences. In this role, he is responsible for Forte’s technology and scientific needs and issues. He works with management to determine the short- and long-term technical requirements and investments to help the company reach its goals. He has over 35 years of experience in biopharmaceutical development and commercial manufacturing including technical roles with commercializing first in class products and commercial technology transfers associated with large capital projects. He has managed manufacturing of scheduled drug products in the US and EU. Before joining Forte, Mr. Ruhl supported a direct phase 3 transfer of a COVID warp speed monoclonal antibody downstream process at ThermoFisher, contributing to an accelerated PPQ campaign readiness with an external partnership and third-party sending site. Prior to that, Mr. Ruhl held positions of increasing responsibility and leadership at various biopharmaceutical companies, including IDEC Pharmaceuticals as Technical and Commercial Manufacturing Supply Director and Amgen as Commercial Drug Product Development Executive Director and Amgen Ireland Site Process Development Head. Mr. Ruhl received his B.Sc. in Microbiology and Chemistry from Brigham Young University.
Doug Balog, Director, Nominating & Governance Chair, Independent Board
Doug Balog is a seasoned executive in the IT industry. He currently is an investor, board member, advisor and/or consultant to numerous technology companies involved in areas such as Hybrid Cloud, Data Protection, Cybersecurity and Artificial Intelligence/Machine Learning.
Previously, Doug spent 37 years at IBM and was a senior executive for IBM’s Systems Business responsible for the portfolio innovation, sales growth and business unit performance of their Storage, Server, and Mainframe hardware businesses. In these roles, Doug traveled the world to work with some of IBM’s largest customers, business partners, ecosystem members, and cloud providers to architect next generation IT solutions.
Doug graduated from Pennsylvania State University with a B.S. in Computer Science and has maintained a close relationship with the university as an Alumni Club member as well as a member of the Penn State College of Information Sciences and Technology’s Board of Advisors. He and his wife have established the Balog Educational Grant at Penn State to help women and diverse students fulfill their dreams of a STEM degree.
Board Composition
Our board currently consists of 5 directors, Jacqueline Anz von Zwehl, Steven Ruhl, Tim Theriault, James Egan, and Doug Balog. Messrs. Ruhl, Theriault, Egan and Balog are “independent directors” within the meaning of the Listing Rules (the “Nasdaq Listing Rules”) of the Nasdaq Stock Market (“Nasdaq”).
Family Relationships
No family relationships exist between any of our officers or directors.
Role of Board of Directors in Risk Oversight Process
The board of directors has extensive involvement in the oversight of risk management related to us and our business and accomplishes this oversight through the regular reporting by the Audit Committee. The purpose of the Risk and Audit Committee is to assist the board of directors in fulfilling its fiduciary oversight responsibilities relating to (1) the integrity of the Company’s financial statements, (2) the effectiveness of the Company’s internal control over financial reporting, (3) the Company’s compliance with legal and regulatory requirements, and (4) the independent auditor’s qualifications and independence. Through its regular meetings with management, including finance and legal, the Risk and Audit Committee reviews and discusses all significant areas of our business and summarizes for the board of directors all areas of risk and the appropriate mitigating factors. In addition, our board of directors receives periodic detailed operating performance reviews from management.
Director Independence
The Board evaluates the independence of each nominee for election as a director of our Company in accordance with the Nasdaq Listing Rules. Pursuant to these rules, a majority of our Board must be “independent directors” within the meaning of the Nasdaq Listing Rules, and all directors who sit on our Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee must also be independent directors.
Committees of the Board of Directors
Our board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee. The composition and responsibilities of each of the committees of our board of directors are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. Our board of directors may establish other committees as it deems necessary or appropriate from time to time.
Audit Committee
The members of our Audit Committee are James Egan, Steven Ruhl and Tim Theriault, with James Egan serving as the Chairperson. Each of Mr. Ruhl, Mr. Theriault, and Mr. Egan are independent under the rules and regulations of the SEC and the listing standards of the Nasdaq Stock Market applicable to audit committee members. Our board of directors has determined that each of Jim Egan, Steven Ruhl, and Tim Theriault qualify as an audit committee financial expert within the meaning of SEC regulations and meet the financial sophistication requirements of the Nasdaq Stock Market.
50 |
Our Audit Committee has the responsibility for, among other things, (i) selecting, retaining and overseeing our independent registered public accounting firm, (ii) obtaining and reviewing a report by independent auditors that describe the accounting firm’s internal quality control, and any materials issues or relationships that may impact the auditors, (iii) reviewing and discussing with the independent auditors standards and responsibilities, strategy, scope and timing of audits, any significant risks, and results, (iv) ensuring the integrity of the Company’s financial statements, (v) reviewing and discussing with the Company’s independent auditors any other matters required to be discussed by PCAOB Auditing Standard No. 1301, (v1) reviewing, approving and overseeing any transaction between the Company and any related person and any other potential conflict of interest situations, (vii) overseeing the Company’s internal audit department, (v) reviewing, approving and overseeing related party transactions, and (viii) establishing and overseeing procedures for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters and the confidential, anonymous submission by Company employees of concerns regarding questionable accounting or auditing matters.
Human Capital and Compensation Committee
The members of our Compensation Committee are Tim Theriault, and James Egan, with Tim Theriault serving as the Chairperson. Our Compensation Committee has the responsibility for, among other things, (i) reviewing and approving the chief executive officer’s compensation based on an evaluation in light of corporate goals and objectives, (ii) reviewing and recommending to the Board the compensation of all other executive officers, (iii) reviewing and recommending to the Board incentive compensation plans and equity plans, (iv) reviewing and discussing with management the Company’s Compensation Discussion and Analysis and related information to be included in the annual report on Form 10-K and proxy statements.
Nominating and Corporate Governance Committee
The members of our Nominating and Corporate Governance Committee are Steven Ruhl with Steven Ruhl serving as the Chairperson. Our Nominating and Corporate Governance Committee has the responsibility relating to assisting the Board in, among other things, (i) identifying and screening individuals qualified to become members of our board of directors, consistent with criteria approved by our board of directors, (ii) recommending to the Board the approval of nominees for director, (ii) developing and recommending to our board of directors a set of corporate governance guidelines, and (iv) overseeing the evaluation of our board of director.
Code of Business Conduct and Ethics
Our board of directors has adopted a Code of Business Conduct and Ethics (the “Code”). The Code applies to all of our directors, officers and employees. Upon the completion of this offering, the full text of our code of conduct will be posted on our website under the Investor Relations section. We intend to disclose future amendments to, or waivers of, our Code, as and to the extent required by SEC regulations, at the same location on our website identified above or in public filings. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase our shares of common stock.
Board Diversity
Each year, our nominating and corporate governance committee will review, with the board of directors, the appropriate characteristics, skills and experience required for the board of directors as a whole and its individual members. In evaluating the suitability of individual candidates, our nominating and corporate governance committee will consider factors including, without limitation, an individual’s character, integrity, judgment, potential conflicts of interest, other commitments and diversity. While we have no formal policy regarding board diversity for our board of directors as a whole nor for each individual member, the nominating and corporate governance committee does consider such factors as gender, race, ethnicity, experience and area of expertise, as well as other individual attributes that contribute to the total diversity of viewpoints and experience represented on the board of directors.
51 |
Effective upon completion of this offering, our board of directors will include at least one female director.
Involvement in Certain Legal Proceedings
Our directors and executive officers have not been involved in any of the following events during the past ten years:
1. | any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; | |
2. | any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); | |
3. | being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities; | |
4. | being found by a court of competent jurisdiction in a civil action, the SEC or the Commodity Futures Trading Commission to have violated a Federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated; | |
5. | being subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or | |
6. | being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member. |
EXECUTIVE COMPENSATION
Summary Compensation Table
The amounts a represent the compensation awarded to or earned by or paid to our named executive officers for the years ended December 31, 2021 and 2020:
Name and Principal Position | Fiscal Year | Salary ($) | Bonus ($) | Stock Awards ($) | Option Award ($)(1) | Non-Equity Incentive Plan Compensation | Non-Qualified Deferred Compensation Earnings ($) | All Other Compensation ($) | Total ($) | |||||||||||||||||||||||||||
Jacqueline von Zwehl | 2021 | $ | 108,625 | $ | 0 | $ | 0 | $ | 0 | $ | 0 | $ | 0 | $ | 0 | $ | 108,625 | |||||||||||||||||||
CEO | 2020 | $ | 50,443 | $ | 0 | $ | 0 | $ | 0 | $ | 0 | $ | 0 | $ | 0 | $ | 50,443 | |||||||||||||||||||
Craig Steinhoff (2) | 2021 | $ | - | $ | - | $ | - | $ | - | $ | - | $ | - | $ | - | $ | - | |||||||||||||||||||
CFO | 2020 | $ | - | $ | - | $ | - | $ | - | $ | - | $ | - | $ | - | $ | - |
(1) | Represents the aggregate grant date fair value of equity compensation awards granted to the named executive officer, computed in accordance with FASB ASC Topic 718. See Note 9 to our financial statements included elsewhere in this prospectus for a discussion of the assumptions made by us in determining the grant date fair value of our equity awards. |
(2) | Mr. Steinhoff was not a Chief Financial Officer of the Company in 2020 or 2021. |
52 |
Executive Employment Agreements
Jacqueline von Zwehl
On April 1, 2022 Jacqueline von Zwehl executed an Employment Agreement (the “Zwehl Employment Agreement”) for her service as our Chief Executive Officer. She will be paid a base salary of $325,000 per year upon completion of the Company’s initial public offering and will be eligible to earn an annual bonus based on the achievement of certain goals and performance criteria established by our Board of Directors. For the fiscal years 2022-2025, the annual bonus will be 20% of the current base salary with a maximum payout of 150% based on target achievement. The employment is “at-will” and the Zwehl Employment Agreement can be terminated any anytime, however, if the she is terminated without cause or if she resigns for Good Reason (defined therein) she shall receive an amount equal to twelve months (12) of Executive’s then-current base salary (the “Severance Payout”). The Severance Payout is payable in equal installments over the subsequent 12 month period.
Consulting Agreements
In August 2021, the Company entered into a service agreement with Greentree Financial Group, Inc. (“Greentree”) to provide certain services to the Company, including assisting the Company in responding to comments from Nasdaq, preparing a code of conduct, preparing employment agreements, and advising the Company with financial statements. In exchange for the services, Greentree is entitled to receive an amount of shares of the Company’s common stock equal to 3.0% of the total outstanding shares prior to this offering. In addition, Greentree shall receive warrants (the “Warrants”) to purchase 200,000 shares of common stock at $2.00 per share. The Warrants also contain an anti-dilution provision which proportionately adjusts the exercise price of the Warrants if the Company issues common stock or securities convertible into common stock at a price per share less than the exercise price. Greentree was granted registration rights for a registration statement in connection with a subsequent offering, subject to certain exceptions. The shares of common stock and Warrants have not yet been issued as certain pre-conditions have not yet been met.
In August 2021, the Company entered into a Business Service Development Agreement (the “Business Service Development Agreement”) with Gerald R. Newman & Associates whereby Mr. Newman will provide certain services to the Company, including general business consulting, strategic relationships and the recruiting of certain key personnel. Pursuant to the agreement, Newman is entitled to receive shares of common stock equal to 8% of the total shares outstanding prior to this offering. Commencing upon the closing of the offering, Newman shall be entitled to a fee of $5,000 per month for twelve months, less the $10,000 fee that was prepaid. The shares have not yet been issued as certain pre-conditions have not yet been met. On July 13, 2022, the Business Service Development Agreement was amended to include a lock up period commencing as of the date the shares are issued and ending six (6) months from the date the Company is listed as a public company.
Compensation of Directors
With the exception of Mrs. von Zwehl, our directors do not currently receive any compensation other than reimbursement for expenses incurred during the performance of their duties or their separate duties as officers of the Company. We intend to approve a compensation plan for directors that will take effect upon completion of this offering.
Equity Incentive Plans
2022 Equity Incentive Plan
On April 15, 2022 our Board and stockholders adopted the 2022 Equity Incentive Plan (the “2022 Plan”). The purpose of the 2022 Plan is to advance the interests of our stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to us and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of our stockholders.
Each stock option granted shall be exercisable at such times and terms and conditions as the Board may specify in the applicable option agreement, provided that no option will be granted with a term in excess of 10 years. Upon the adoption of the 2022 Plan, we reserved for issuance 1,200,000 shares of common stock. There are 1,200,000 shares of common stock authorized for non-statutory and incentive stock options, restricted stock units, and stock grants under the 2022 Plan, which are subject to adjustment in the event of stock splits, stock dividends, and other situations. As of August 15, 2022, we had not made any grants under the 2022 Plan.
The 2022 Plan is administered by our Board. The persons eligible to participate in the 2022 Plan are as follows: all of our employees, officers and directors, as well as consultants and advisors to the Company (as such terms consultants and advisors are defined and interpreted for purposes of Form S-8 under the Securities Act of 1933, as amended, or any successor form) are eligible to be granted Awards under the 2022 Plan. Each person who is granted an Award under the 2022 Plan is deemed a “Participant.”
The 2022 Plan will continue in effect until all of the stock available for grant or issuance has been acquired through exercise of options or grants of shares, or until April 15, 2027, whichever is earlier. The 2022 Plan may also be terminated in the event of certain corporate transactions such as a merger or consolidation or the sale, transfer or other disposition of all or substantially all of our assets.
As of the date hereof, no grants have been made or awarded under the 2022 Plan.
53 |
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Other than as set forth below and compensation arrangements, including employment, and indemnification arrangements, discussed, there have been no transactions since January 1, 2019, in which the amount involved in the transaction exceeded or will exceed the lesser of $120,000 or one percent of the average of our total assets as at the year-end for the last two completed fiscal years, and to which any of our directors, executive officers or beneficial holders of more than 5% of our capital stock, or any immediate family member of, or person sharing the household with, any of these individuals, had or will have a direct or indirect material interest.
Indemnification Agreements
Our amended and restated certificate of incorporation, which will be effective upon the completion of this offering, will contain provisions limiting the liability of directors, and provide that we will indemnify each of our directors to the fullest extent permitted under Delaware law. Our amended and restated certificate of incorporation will also provide our board of directors with discretion to indemnify our officers and employees when determined appropriate by our board of directors.
We intend to enter into indemnification agreements with each of our directors and executive officers. The indemnification agreements will provide that we will indemnify each of our directors, executive officers, and such other key employees against any and all expenses incurred by that director or executive officer because of his or her status as one of our directors or executive officers, to the fullest extent permitted by Delaware law and our amended and restated certificate of incorporation. In addition, the indemnification agreements will provide that, to the fullest extent permitted by Delaware law, we will advance all expenses incurred by our directors, executive officers, and other key employees in connection with a legal proceeding involving his or her status as a director, executive officer, or key employee.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
54 |
Limitation of Liability and Indemnification of Officers and Directors
Our certificate of incorporation, limits the liability of directors to the maximum extent permitted by Delaware General Corporation Law (the “DGCL”). The DGCL provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors.
Our bylaws provide that we will indemnify our directors and officers to the fullest extent permitted by law, and may indemnify employees and other agents. Our bylaws also provide that we are obligated to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding.
Our bylaws, subject to the provisions of the DGCL contain provisions which allow the corporation to indemnify any person against liabilities and other expenses incurred as the result of defending or administering any pending or anticipated legal issue in connection with service to us if it is determined that person acted in good faith and in a manner which he or she reasonably believed was in the best interest of the corporation. Insofar as indemnification for liabilities arising under the Securities Act of 1933 as amended, or the Securities Act, may be permitted to our directors, officers and controlling persons, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
The limitation of liability and indemnification provisions in our bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might provide a benefit to us and our stockholders. Our results of operations and financial condition may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
At present, there is no pending litigation or proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.
Policies and Procedures for Related Party Transactions
In connection with this offering, we expect to adopt a written related party transactions policy that will provide that transactions with directors, officers and holders of five percent or more of our voting securities and their affiliates, each a related party must be approved by our audit committee. This policy will become effective on the date on which the registration statement of which this prospectus is part is declared effective by the SEC. Pursuant to this policy, the audit committee will have the primary responsibility for reviewing and approving or disapproving “related party transactions,” which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed the lesser of (i) $120,000 or (ii) one percent of the average of our total assets for the last two completed fiscal years, and in which a related person has or will have a direct or indirect material interest. For purposes of this policy, a related person will be defined as a director, executive officer, nominee for director, or greater than 5% beneficial owner of our common stock, in each case since the beginning of the most recently completed year, and their immediate family members.
PRINCIPAL STOCKHOLDERS
The following table sets forth certain information with respect to the beneficial ownership of our voting securities as of December 8, 2022 by (i) any person or group beneficially owning more than 5% of any class of voting securities; (ii) our directors, and; (iii) each of our named executive officers; and (iv) all executive officers and directors as a group as of the date of this prospectus. The information presented below regarding beneficial ownership of our voting securities has been presented in accordance with the rules of the Securities and Exchange Commission and is not necessarily indicative of ownership for any other purpose. Under these rules, a person is deemed to be a “beneficial owner” of a security if that person has or shares the power to vote or direct the voting of the security or the power to dispose or direct the disposition of the security. A person is deemed to own beneficially any security as to which such person has the right to acquire sole or shared voting or investment power within 60 days through the conversion or exercise of any convertible security, warrant, option or other right. More than one person may be deemed to be a beneficial owner of the same securities. Unless otherwise indicated, the address of all listed stockholders is c/o 9051 Tamiami Trail N, Suite 201, Naples, FL 34108.
55 |
Name of Beneficial Owner | Common Stock Beneficially Owned | Percentage of Common Stock Before Offering | Percentage of Common Stock After Offering | |||||||||
Directors and Officers: | ||||||||||||
Jacqueline von Zwehl, Chief Executive Officer, Chairman of the Board of Directors and Director | 7,120,000 | 100 | % | 64.73 | % | |||||||
Craig Steinhoff, Chief Financial Officer | - | - | - | |||||||||
James Egan, Director, Audit Chair | - | - | - | |||||||||
Tim Theriault, Director, Compensation Chair | - | - | - | |||||||||
Steven Ruhl, Director, Risk & Compliance Chair | - | - | - | |||||||||
Doug Balog, Director, Nominating & Governance Chair | - | - | - | |||||||||
All Executive Officers and Directors as a Group (6 persons) | 7,120,000 | 100 | % | 64.73 | % | |||||||
Beneficial owners of more than 5%: | ||||||||||||
Jacqueline von Zwehl | 7,120,000 | (1) | 100 | % | 64.73 | % | ||||||
Gerald Newman (2) | 640,000 | (2) | 8 | % | 5.82 | % |
* | represents less than 1% |
(1) | Does not include 640,000 shares and 240,000 shares to be issued to Gerald Newman and Greentree Financial Group Inc, respectively, to be issued within 30 days prior to the offering. |
(2) | Mr. Newman is entitled to receive shares of common stock equal to 8% of the total shares outstanding or 640,000 shares to be issued within 30 days prior to the offering, |
DESCRIPTION OF SECURITIES
A description of our capital stock and the material terms and provisions of our certificate of incorporation and our amended and restated bylaws that will be in effect upon the completion of this offering and affecting the rights of holders of our capital stock is set forth below. The forms of certificate of incorporation and our amended and restated bylaws to be adopted in connection with this offering are filed as exhibits to the registration statement relating to this prospectus.
Upon completion of this offering, our authorized capital stock will consist of 15,000,000 shares of stock, all with a par value of $0.01. There is only one class of stock authorized and no preferred stock.
Common Stock
Upon completion of this offering, our authorized common stock will consist of 15,000,000 shares of common stock, par value $0.01. Immediately following the completion of this offering, the Company will have 11,000,000 shares of common stock issued and outstanding (assuming no exercise by the underwriters of their option to purchase additional shares).
Dividend Rights
The holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available at the times and in the amounts that our board of directors may determine.
Voting Rights
Each holder of our common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Our certificate of incorporation, as amended and restated, provides that there is no cumulative voting for directors.
No Preemptive or Similar Rights
Our common stock is not entitled to preemptive rights to acquire additional securities issued by the Company.
Right to Receive Liquidation Distributions
Upon our liquidation, dissolution, or winding-up, after the payment of all claims of the Company’s creditors and preferential amounts to the holders of shares of preferred stock, the remaining assets of the Company legally available for distribution to its stockholders shall be distributed among the holders of shares of common stock, pro rata based on the number of shares outstanding held by each such holder.
Preferred Stock
We have not issued any preferred stock.
56 |
Underwriter Warrants The following summary of certain terms and provisions of the Underwriter Warrants that are being issued to the representative hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Underwriter Warrants, the form of which will be filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of Underwriter Warrant for a complete description of the terms and conditions of the Underwriter Warrant.
Duration and Exercise Price
Each Underwriter Warrant offered hereby will have an initial exercise price equal to $6.00 per share of common stock (120% of the initial public offering price per share of common stock). The Underwriter Warrants will be immediately exercisable and will expire five years from the commencement of sales in this offering. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price.
Exercisability
The Underwriter Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the Underwriter to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days’ prior notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding stock after exercising the holder’s Underwriter Warrant up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Underwriter Warrants and in accordance with the rules and regulations of the SEC.
Cashless Exercise
In lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the Underwriter Warrants.
Fractional Shares
No fractional shares of common stock will be issued upon the exercise of the Underwriter Warrants. Rather, the number of shares of common stock to be issued will be rounded up to the nearest whole number.
Transferability
Subject to applicable laws and certain exceptions, the Underwriter Warrants may not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the date of commencement of sales of this offering.
Trading Market
There is no trading market available for the Underwriter Warrants on any securities exchange or nationally recognized trading system, and we do not expect a trading market to develop. We do not intend to list the Underwriter Warrants on any securities exchange or other trading market. Without a trading market, the liquidity of the Underwriter Warrants will be extremely limited. The common stock issuable upon exercise of the Underwriter Warrants will be listed on the Nasdaq Capital Market in connection with this offering.
Right as a Stockholder
Except as otherwise provided in the Underwriter Warrants or by virtue of such holder’s ownership of shares of our common stock, the holders of the Underwriter Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their Underwriter Warrants.
Fundamental Transaction
In the event of a fundamental transaction, as described in the Underwriter Warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the Underwriter Warrants will be entitled to receive upon exercise of the Underwriter Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Underwriter Warrants immediately prior to such fundamental transaction. In addition, in the event of a fundamental transaction which is approved by our Board, the holders of the Underwriter Warrants have the right to require us or a successor entity to redeem the Underwriter Warrant for cash in the amount of the Black-Scholes value of the unexercised portion of the Underwriter Warrant on the date of the consummation of the fundamental transaction. In the event of a fundamental transaction which is not approved by our Board, the holders of the Underwriter Warrants have the right to require us or a successor entity to redeem the Underwriter Warrants for the consideration paid in the fundamental transaction in the amount of the Black Scholes value of the unexercised portion of the Underwriter Warrant on the date of the consummation of the fundamental transaction.
Delaware Law
We will be governed by the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:
● | the business combination or transaction which resulted in the stockholder becoming an interested stockholder was approved by the board of directors prior to the time that the stockholder became an interested stockholder; | |
● | upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares owned by directors who are also officers of the corporation and shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or | |
● | at or subsequent to the time the stockholder became an interested stockholder, the business combination was approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. |
In general, Section 203 defines a “business combination” to include mergers, asset sales and other transactions resulting in financial benefit to a stockholder and an “interested stockholder” as a person who, together with affiliates and associates, owns, or within three years did own, 15% or more of the corporation’s outstanding voting stock. These provisions may have the effect of delaying, deferring or preventing changes in control of our company.
Choice of Forum
Our certificate of incorporation provides that unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty by any of our directors, officers or other employees to us or our stockholders; any action asserting a claim against the Company, our directors or officer or employees directors arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or amended and restated bylaws or any other action asserting a claim against us our directors or officers or employees that is governed by the internal affairs doctrine. This choice of forum provision does not apply to actions brought to enforce a duty or liability created by the Exchange Act or any other claim for which federal courts have exclusive jurisdiction.
Furthermore, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. We intend for this provision to apply to any complaints asserting a cause of action under the Securities Act despite the fact that Section 22 of the Securities Act creates concurrent jurisdiction for the federal and state courts over all actions brought to enforce any duty or liability created by the Securities Act or the rules and regulations promulgated thereunder. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions in our certificate of incorporation to be inapplicable or unenforceable
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is VStock Transfer, LLC.
Limitations of Liability and Indemnification
Our certificate of incorporation, as amended and restated, limits the liability of directors to the maximum extent permitted by the DGCL. The DGCL provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors.
57 |
Our bylaws, as amended, provide that we will indemnify our directors and officers to the fullest extent permitted by law, and may indemnify employees and other agents. Our bylaws also provide that we are obligated to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding.
Our bylaws, as amended, subject to the provisions of the DGCL, contain provisions which allow the corporation to indemnify any person against liabilities and other expenses incurred as the result of defending or administering any pending or anticipated legal issue in connection with service to us if it is determined that person acted in good faith and in a manner which he or she reasonably believed was in the best interest of the corporation. Insofar as indemnification for liabilities arising under the Securities Act of 1933 as amended, or the Securities Act, may be permitted to our directors, officers and controlling persons, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
The limitation of liability and indemnification provisions in our bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might provide a benefit to us and our stockholders. Our results of operations and financial condition may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
At present, there is no pending litigation or proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.
Listing
We have applied to list our common stock on the Nasdaq Capital Market and have reserved the symbol “SCRP”. We will not consummate this offering unless our listing application is approved.
SHARES ELIGIBLE FOR FUTURE SALE
Prior to this offering, there has been no market for our common stock. Future sales of substantial amounts of our common stock in the public market or the perception that such sales might occur could adversely affect market prices prevailing from time to time. Furthermore, because only a limited number of shares will be available for sale shortly after this offering due to existing contractual and legal restrictions on resale as described below, there may be sales of substantial amounts of our common stock in the public market after the restrictions lapse. This may adversely affect the prevailing market price of our common stock and our ability to raise equity capital in the future.
After completion of this offering, we will have 11,000,000 shares of common stock outstanding (or 11,450,000 shares if the underwriters’ option to purchase additional shares is exercised in full).
All of the shares of common stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, unless the shares are purchased by our “affiliates” as that term is defined in Rule 144 and except certain shares that will be subject to the lock-up period described below after completion of this offering. Any shares owned by our affiliates may not be resold except in compliance with Rule 144 volume limitations, manner of sale and notice requirements, pursuant to another applicable exemption from registration or pursuant to an effective registration statement.
Any of the shares held by our executive officers, directors, employees and 1% and greater stockholders will be subject to lock-up restriction for an initial period of 180 days from the closing of the offering described under “Underwriting” (Lock-Up Agreements)” beginning on page 63. Accordingly, there will be a corresponding increase in the number of shares that become eligible for sale after the lock-up period expires. As a result of these agreements, subject to the provisions of Rule 144 or Rule 701, shares will be available for sale in the public market as follows:
● | beginning on the date of this prospectus, all of the shares sold in this offering will be immediately available for sale in the public market (except as described above). | |
● | beginning 180 days and on each of the 270 days and 350 days after the date of this prospectus, for our executive officers, directors, employees, and 1% and greater stockholders, [__] additional shares will become eligible for sale in the public market. | |
● | This does not include shares of common stock that may be issuable upon exercise of outstanding options held by our officers and directors. |
58 |
Lock-Up and Market Standoff Agreements
Pursuant to certain “lock-up” agreements, we, our executive officers, directors and our 1% and greater stockholders have agreed not to, without the prior written consent of the representative, directly or indirectly, offer to sell, sell, pledge or otherwise transfer or dispose of any of shares of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) our common stock or any securities convertible into or exercisable or exchangeable for our common stock (the Lock-Up Securities”), enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of our common stock, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for shares of common stock or any other of our securities or publicly disclose the intention to do any of the foregoing, subject to customary exceptions. In the case of our officers, directors and 1% and greater stockholders, the foregoing restrictions shall apply to all Lock-Up Securities of such persons for 180 days following the date of this prospectus.
Rule 144
In general, Rule 144 provides that once we have been subject to the public company reporting requirements of Section 13 or Section 15(d) of the Exchange Act for at least 90 days, a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and who has beneficially owned the shares of our common stock proposed to be sold for at least six months is entitled to sell those shares without complying with the manner of sale, volume limitation or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then that person would be entitled to sell those shares without complying with any of the requirements of Rule 144.
In general, Rule 144 provides that our affiliates or persons selling shares of our common stock on behalf of our affiliates are entitled to sell upon expiration of the market standoff agreements and lock-up agreements described above, within any three-month period, a number of shares of our common stock that does not exceed the greater of:
● | 1% of the number of shares of our capital stock then outstanding, which will equal [__] shares (or [__] shares if the underwriters’ option to purchase additional shares is exercised in full) immediately after the completion of this offering; or | |
● | the average weekly trading volume of our common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to that sale. |
Sales of our common stock made in reliance upon Rule 144 by our affiliates or persons selling shares of our common stock on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us.
Rule 701
Rule 701 generally allows a stockholder who purchased shares of our capital stock pursuant to a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required to wait until 90 days after the date of this prospectus before selling those shares pursuant to Rule 701.
59 |
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON STOCK
The following is a general discussion of certain material U.S. federal income tax considerations with respect to the ownership and disposition of shares of our common stock and warrants applicable to non-U.S. holders who acquire our securities in this offering. This discussion is based on current provisions of the Internal Revenue Code, U.S. Treasury regulations promulgated thereunder and administrative rulings and court decisions in effect as of the date hereof, all of which are subject to change at any time, possibly with retroactive effect.
For purposes of this discussion, the term “non-U.S. holder” means a beneficial owner of our securities that is not, for U.S. federal income tax purposes, a partnership or any of the following:
● | a citizen or resident of the United States; | |
● | a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States, any state thereof or the District of Columbia; | |
● | an estate, the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or | |
● | a trust if (1) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (2) it has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person for U.S. federal income tax purposes. |
If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds shares of our securities, the tax treatment of a person treated as a partner generally will depend on the status of the partner and the activities of the partnership. Persons that for U.S. federal income tax purposes are treated as a partner in a partnership holding shares of our securities should consult their tax advisors.
This discussion assumes that a non-U.S. holder holds shares of our securities as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be important to a non-U.S. holder in light of that holder’s particular circumstances or that may be applicable to holders subject to special treatment under U.S. federal income tax law (including, for example, financial institutions, brokers or dealers in securities, “controlled foreign corporations,” “passive foreign investment companies,” traders in securities that elect mark-to-market treatment, insurance companies, tax-exempt entities, holders who acquired our securities pursuant to the exercise of employee stock options or otherwise as compensation, entities or arrangements treated as partnerships for U.S. federal income tax purposes, holders liable for the alternative minimum tax, certain former citizens or former long-term residents of the United States and holders who hold our securities as part of a hedge, straddle, constructive sale or conversion transaction). In addition, this discussion does not address U.S. federal tax laws other than those pertaining to the U.S. federal income tax, nor does it address any aspects of the unearned income Medicare contribution tax pursuant to the Health Care and Education Reconciliation Act of 2010, any U.S. federal estate and gift taxes, or any U.S. state, local or non-U.S. taxes. Accordingly, prospective investors should consult with their own tax advisors regarding the U.S. federal, state, local, non-U.S. income and other tax considerations of acquiring, holding and disposing of shares of our securities.
THIS SUMMARY IS FOR GENERAL INFORMATION ONLY AND IS NOT INTENDED TO CONSTITUTE A COMPLETE DESCRIPTION OF ALL TAX CONSEQUENCES RELATING TO THE OWNERSHIP AND DISPOSITION OF OUR SECURITIES. WE RECOMMEND THAT PROSPECTIVE HOLDERS OF OUR SECURITIES CONSULT WITH THEIR TAX ADVISORS REGARDING THE TAX CONSEQUENCES TO THEM (INCLUDING THE APPLICATION AND EFFECT OF ANY FEDERAL, STATE, LOCAL, NON-U.S. INCOME AND OTHER TAX LAWS) OF THE OWNERSHIP AND DISPOSITION OF OUR SECURITIES.
60 |
Allocation of Investment in Securities
An investor in this offering will be required to allocate cost of the acquisition of the securities between the shares of common stock and warrants acquired based on their relative fair market values.
Dividends
In general, any distributions we make to a non-U.S. holder with respect to its shares of our common stock that constitute dividends for U.S. federal income tax purposes will be subject to U.S. withholding tax at a rate of 30% of the gross amount (or a reduced rate prescribed by an applicable income tax treaty) unless the dividends are effectively connected with a trade or business carried on by the non-U.S. holder within the United States (and, if an income tax treaty applies, are attributable to a permanent establishment of the non-U.S. holder within the United States). A distribution will constitute a dividend for U.S. federal income tax purposes to the extent of our current or accumulated earnings and profits as determined for U.S. federal income tax purposes. Any distribution not constituting a dividend will be treated as first reducing the adjusted basis in the non-U.S. holder’s shares of our common stock and, to the extent it exceeds the adjusted basis in the non-U.S. holder’s shares of our common stock, as gain from the sale or exchange of such shares. Any such gain will be subject to the treatment described below under “— Gain on Sale or Other Disposition of our Common Stock.”
Subject to the discussion below regarding “— Foreign Account Tax Compliance,” dividends effectively connected with a U.S. trade or business (and, if an income tax treaty applies, attributable to a U.S. permanent establishment) of a non-U.S. holder generally will not be subject to U.S. withholding tax if the non-U.S. holder complies with applicable certification and disclosure requirements. Instead, such dividends generally will be subject to U.S. federal income tax on a net income basis, in the same manner as if the non-U.S. holder were a resident of the United States. A non-U.S. holder that is a corporation may be subject to an additional “branch profits tax” at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on its “effectively connected earnings and profits,” subject to certain adjustments.
Gain on Sale or Other Disposition of Our Securities
In general, a non-U.S. holder will not be subject to U.S. federal income or, subject to the discussion below under the headings “Information Reporting and Backup Withholding” and “Foreign Account Tax Compliance,” withholding tax on any gain realized upon the sale or other disposition of our securities unless:
● | the gain is effectively connected with a trade or business carried on by the non-U.S. holder within the United States and, if required by an applicable income tax treaty, is attributable to a U.S. permanent establishment of the non-U.S. holder; | |
● | the non-U.S. holder is an individual and is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are satisfied; or | |
● | we are or have been a U.S. real property holding corporation (a “USRPHC”) for U.S. federal income tax purposes at any time within the shorter of the five-year period ending on the date of the disposition and the non-U.S. holder’s holding period and certain other conditions are satisfied. We believe that we currently are not and we do not anticipate becoming, a USRPHC |
Gain that is effectively connected with the conduct of a trade or business in the United States generally will be subject to U.S. federal income tax, net of certain deductions, at regular U.S. federal income tax rates. If the non-U.S. holder is a foreign corporation, the branch profits tax described above also may apply to such effectively connected gain. An individual non-U.S. holder who is subject to U.S. federal income tax because the non-U.S. holder was present in the United States for 183 days or more during the year of sale or other disposition of our securities will generally be subject to a flat 30% tax on the gain derived from such sale or other disposition, which may be offset by U.S. source capital losses, provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses.
61 |
Information Reporting and Backup Withholding
We must report annually to the Internal Revenue Service and to each non-U.S. holder the amount of dividends paid to and the tax withheld with respect to, each non-U.S. holder. These reporting requirements apply regardless of whether withholding was reduced or eliminated by an applicable tax treaty. Copies of this information also may be made available under the provisions of a specific treaty or agreement with the tax authorities in the country in which the non-U.S. holder resides or is established.
U.S. backup withholding tax (currently, at a rate of 24%) is imposed on certain payments to persons that fail to furnish the information required under the U.S. information reporting rules. Dividends paid to a non-U.S. holder generally will be exempt from backup withholding if the non-U.S. holder provides a properly executed IRS Form W-8BEN or W-8BEN-E, or otherwise establishes an exemption.
Under U.S. Treasury regulations, the payment of proceeds from the disposition of our securities by a non-U.S. holder effected at a U.S. office of a broker generally will be subject to information reporting and backup withholding, unless the beneficial owner, under penalties of perjury, certifies, among other things, its status as a non-U.S. holder or otherwise establishes an exemption. The payment of proceeds from the disposition of our securities by a non-U.S. holder effected at a non-U.S. office of a broker generally will not be subject to backup withholding and information reporting, except in the case of proceeds from a disposition of our securities by a non-U.S. holder effected at a non-U.S. office of a broker that is:
● | a U.S. person; | |
● | a “controlled foreign corporation” for U.S. federal income tax purposes; | |
● | a foreign person 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business; or | |
● | a foreign partnership if at any time during its tax year (a) one or more of its partners are U.S. persons who, in the aggregate, hold more than 50% of the income or capital interests of the partnership, or (b) the foreign partnership is engaged in a U.S. trade or business. |
Information reporting will apply unless the broker has documentary evidence in its files that the owner is a non-U.S. holder and certain other conditions are satisfied, or the beneficial owner otherwise establishes an exemption (and the broker has no knowledge or reason to know to the contrary). Backup withholding will apply if the sale is subject to information reporting and the broker has actual knowledge that the owner is a U.S. person.
Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder generally can be refunded or credited against the non-U.S. holder’s U.S. federal income tax liability, if any, provided that the required information is furnished to the Internal Revenue Service in a timely manner. Non-U.S. holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them.
Foreign Account Tax Compliance
Under Sections 1471 through 1474 of the Code and the Treasury regulations and administrative guidance promulgated thereunder (collectively, “FATCA”), a U.S. federal withholding tax of 30% generally is imposed on any dividends paid on our common stock and a U.S. federal withholding tax of 30% generally will be imposed on gross proceeds from the disposition of our securities (beginning January 1, 2019) paid to (i) a “foreign financial institution” (as specifically defined under FATCA) unless such institution enters into an agreement with the U.S. tax authorities to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) and (ii) certain other foreign entities unless such entity provides the withholding agent with a certification identifying its direct and indirect “substantial U.S. owners” (as defined under FATCA) or, alternatively, provides a certification that no such owners exist and, in either case, complies with certain other requirements. The withholding tax described above will not apply if the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from the rules and properly certifies its exempt status to a withholding agent or is deemed to be in compliance with FATCA. Application of FATCA tax does not depend on whether the payment otherwise would be exempt from U.S. federal withholding tax under the other exemptions described above. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of such taxes. Foreign financial institutions and non-financial foreign entities located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. Prospective non-U.S. holders should consult with their tax advisors regarding the possible implications of FATCA on their investment in our securities.
62 |
EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, NON-U.S., OR U.S. FEDERAL NON-INCOME TAX LAWS SUCH AS ESTATE AND GIFT TAX.
UNDERWRITING
WestPark Capital, Inc. (“WestPark” or the “Representative”) is acting as the representative of the underwriters and the book-running manager of this offering. We have entered into an underwriting agreement dated [_________] with the Representative. Under the terms of an underwriting agreement, which is filed as an exhibit to the registration statement, each of the underwriters named below has severally agreed to purchase from us the respective number of shares of common stock shown opposite its name below:
Underwriter | Number of Shares | |||
WestPark Capital, Inc. | ||||
Total |
The underwriters are committed to purchase all shares of common stock offered by us other than those covered by the over-allotment option described below, if any are purchased. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters’ obligations are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers’ certificates and legal opinions.
The underwriters are offering the shares subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, and other conditions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.
The underwriters propose to offer the shares offered by us to the public at the initial public offering price set forth on the cover of the prospectus. After the shares are released for sale to the public, the underwriters may change the offering price and other selling terms at various times.
Underwriting Commissions and Discounts and Expenses
The Representative has advised us that the underwriters propose to offer the shares of common stock to the public at the initial public offering price set forth on the cover page of this prospectus. The underwriters may offer shares to securities dealers at that price less a concession of not more than $ per share.
The following table shows the per share and total underwriting discounts and commissions we will pay to WestPark. These amounts are shown assuming both no exercise and full exercise of the underwriters’ option to purchase additional shares.
Total | ||||||||||||
Per Share | No Exercise | Full Exercise | ||||||||||
Initial public offering price | $ | 5.00 | $ | 15,000,000 | $ | 17,250,000 | ||||||
Underwriting discounts and commissions to be paid by us (8.0%): | $ | 0.40 | $ | 1,200,000 | $ | 1,380,000 | ||||||
Proceeds, before expenses, to us | $ | 4.60 | $ | 13,800,000 | $ | 15,870,000 |
In addition, we have also agreed to pay all expenses in connection with the offering, including the following expenses: (a) all filing fees and communication expenses relating to the registration of the securities to be sold in the offering (including the over-allotment shares) with the SEC; (b) all FINRA public offering filing system fees associated with the review of the offering by FINRA; (c) all fees and expenses relating to the listing of such closing shares and over-allotment shares on Nasdaq; (d) all fees, expenses and disbursements relating to the registration or qualification of such securities under the “blue sky” securities laws of such states and other foreign jurisdictions as WestPark may reasonably designate the costs, if any, of all mailing and printing of the underwriting documents (including, without limitation, the underwriting agreement, any Blue Sky Surveys and, if appropriate, any agreement among underwriters, selected dealers’ agreement, underwriters’ questionnaire and power of attorney), registration statements, prospectuses and all amendments, supplements and exhibits thereto and as many preliminary and final prospectuses as the representative may reasonably deem necessary; (e) the costs of preparing, printing and delivering the securities; (f) fees and expenses of the transfer agent for the securities (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company); (g) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the underwriters; (h) the fees and expenses of the Company’s accountants; and (i) a maximum of $200,000 for fees and expenses including “road show”, diligence and reasonable legal fees and disbursements for underwriters’ counsel.
We have agreed to the payment of $50,000 to be applied against WestPark’s expenses (“the Advance”). Upon acceptance of the engagement by WestPark, the Company delivered to WestPark $25,000 of the total $50,000 Advance. The remaining $25,000 of the Advance was due and paid upon the initial filing of this registration statement. Such Advance will be applied against the representative’s expenses in connection with the offering, and to the extent not actually incurred, such Advance shall be reimbursed to us.
63 |
We estimate that the total expenses of the offering payable by us, excluding underwriting discounts and commissions, will be approximately $700,000.
Over-Allotment Option
We have granted the representative of the underwriters an option to purchase from us, up to 450,000 additional shares of common stock within 45 days from the date of this prospectus to cover over-allotments, if any. The purchase price to be paid per additional share will be equal to the initial public offering price of one share, as applicable, less the underwriting discount.
Discretionary Accounts
The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.
Lock-Up Agreements
Pursuant to certain “lock-up” agreements, the Company’s executive officers, directors and holders of at least 1% of the Company’s common stock and securities exercisable for or convertible into its common stock outstanding immediately upon the closing of this offering, have agreed, subject to certain exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, engage in any short selling of any shares of common stock or securities convertible into or exchangeable or exercisable for any common stock, whether currently owned or subsequently acquired, without the prior written consent of the underwriters. In the case of our officers, directors and 1% and greater shareholders the foregoing restrictions shall apply for 180 days from the date of this prospectus.
Underwriter Warrants
The Company has agreed to issue to WestPark or its designees warrants (“Underwriter Warrants”) to purchase up to a total of nine percent (9%) of the shares of common stock sold in this offering (excluding the shares sold through the exercise of the over-allotment option). Such warrants and underlying shares of common stock are included in this prospectus. The Underwriter Warrants are immediately exercisable upon issuance at an exercise price of $6.00 per share (120% of the initial public offering price) for a period of five (5) years from the commencement of sales of the offering in compliance with FINRA Rule 5110.
The Underwriter Warrants may be exercised as to all, or a lesser number of shares of common stock, and will provide for cashless exercise and will contain provisions for one demand and unlimited “piggyback” registration rights, for a period of no greater than five (5) years from the commencement of sales of the offering in compliance with FINRA Rule 5110. The Company will bear all fees and expenses attendant to registering the securities issuable on exercise of the Underwriter Warrants other than underwriting commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the Underwriter Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or the Company’s recapitalization, reorganization, merger or consolidation.
64 |
Pursuant to FINRA Rule 5110(e), the Underwriter Warrants and any shares of common stock issued upon exercise of the Underwriter Warrants shall not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the date of commencement of sales of this offering, except the transfer of any security: (i) by operation of law or by reason of reorganization of the issuer; (ii) to any FINRA member firm participating in the offering and the officers, partners, registered persons or affiliates thereof, if all securities so transferred remain subject to the lock-up restriction set forth above for the remainder of the time period; (iii) if the aggregate amount of our securities held by the Representative or related persons does not exceed 1% of the securities being offered; (iv) that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund and the participating members in the aggregate do not own more than 10% of the equity in the fund; (v) the exercise or conversion of any security, if all securities remain subject to the lock-up restriction set forth above for the remainder of the time period; (vi) if we meet the registration requirements of Forms S-3, F-3 or F-10; or (vii) back to us in a transaction exempt from registration with the SEC. The Underwriter Warrants and the shares of common stock underlying the Underwriter Warrants are registered on the registration statement of which this prospectus forms a part.
Securities Issuance Standstill
We have agreed, for a period of one (1) year after the date of this prospectus, that we will not, without the prior written consent of the Representative (x) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or file with the Commission a registration statement under the Securities Act relating to, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, or (y) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or any such other securities, whether any such transaction described in clause (x) or (y) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, without the prior written consent of the Representative. The foregoing restrictions will not apply with respect to (i) any shares of common stock issued under any stock option plan described as outstanding in this prospectus, (ii) any shares of common stock issued under the Company’s stock option plans, (iii) the filing by the Company of any registration statement on Form S-8, (iv) securities issued in connection with a transaction with an unaffiliated third party that includes a bona fide commercial relationship or any acquisition of assets or acquisition of not less than a majority or controlling portion of the equity of another entity, subject to certain limitations.
Indemnification
We have agreed to indemnify the underwriters against liabilities relating to this offering arising under the Securities Act and the Exchange Act, liabilities arising from breaches of some or all of the representations and warranties contained in the underwriting agreement, and to contribute to payments that the underwriters may be required to make for these liabilities.
Nasdaq Listing
We have applied to have our shares of common stock listed on Nasdaq under the symbol “SCRP”. We will not consummate this offering unless our common stock is approved for listing on Nasdaq. There is no established public trading market for the common stock and there is no assurance that a market will develop.
Electronic Offer, Sale and Distribution of Shares
A prospectus in electronic format may be made available on the websites maintained by the underwriters, if any, participating in this offering and the underwriters participating in this offering may distribute prospectuses electronically. The underwriters may agree to allocate a number of shares for sale to its online brokerage account holders. Internet distributions will be allocated by the underwriters that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or the underwriters in their capacity as underwriters, and should not be relied upon by investors.
Stabilization
In connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering transactions, penalty bids and purchases to cover positions created by short sales.
● | Stabilizing transactions permit bids to purchase shares so long as the stabilizing bids do not exceed a specified maximum and are engaged in for the purpose of preventing or retarding a decline in the market price of the shares while the offering is in progress. | |
● | Over-allotment transactions involve sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares in the over-allotment option. The underwriters may close out any short position by exercising their over-allotment option and/or purchasing shares in the open market. |
65 |
● | Syndicate covering transactions involve purchases of shares in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise of the over-allotment option. If the underwriters sell more shares than could be covered by exercise of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the open market that could adversely affect investors who purchase in the offering. | |
● | Penalty bids permits the underwriters to reclaim a selling concession from a syndicate member when the shares originally sold by that syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions. |
These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of the Company’s common stock or preventing or retarding a decline in the market price of its common stock. As a result, the price of the Company’s common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither the Company nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of the Company’s common stock. These transactions may be affected on the Nasdaq Capital Market, in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.
Passive Market Making
In connection with this offering, the underwriters may engage in passive market making transactions in the Company’s common stock on The Nasdaq Capital Market in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the shares and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker’s bid, then that bid must then be lowered when specified purchase limits are exceeded.
Other Relationships
The underwriters and their respective affiliates may, in the future provide various investment banking, commercial banking and other financial services for the Company and its affiliates for which they have received, and may in the future receive, customary fees. However, except as disclosed in this prospectus, the Company has no present arrangements with the underwriters for any further services.
Offer Restrictions Outside the United States
Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.
LEGAL MATTERS
The validity of the securities offered by this prospectus will be passed upon for us by Sichenzia Ross Ference LLP, New York, New York. Certain legal matters of U.S. federal securities law related to the offering will be passed upon for the underwriters by Ellenoff Grossman & Schole LLP, New York, New York.
66 |
EXPERTS
The financial statements included in this registration statement as of December 31, 2021 and 2020, and for each of the years in the two-year period ended December 31,2021, have been included herein in reliance upon the report of M & K CPAS, PLLC, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.
WHERE YOU CAN FIND ADDITIONAL INFORMATION
We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of our common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.
As a result of this offering, we will become subject to the information and reporting requirements of the Exchange Act and, in accordance with this law, will file periodic reports, proxy statements and other information with the SEC. We also maintain a website at www.4saferx.com and http://www.scrippssafe.com,. Upon completion of this offering, you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only.
67 |
3,000,000 Shares of Common Stock
PROSPECTUS
PROSPECTUS
WestPark Capital, Inc.
, 2022
Until and including , 2022 (25 days after the date of this prospectus), all dealers effecting transactions in our securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealer’s obligation to deliver a prospectus when acting as an underwriter and with respect to unsold allotments or subscriptions.
INDEX TO FINANCIAL STATEMENTS
F-1 |
SCRIPPS SAFE, INC
CONSOLIDATED BALANCE SHEETS
September 30, 2022 | December 31, 2021 | |||||||
(Unaudited) | (Audited) | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 31,365 | $ | 227,932 | ||||
Accounts receivable, net | 60,522 | 56,964 | ||||||
Other current assets | 26,464 | 647 | ||||||
Total current assets | 118,351 | 285,543 | ||||||
NON-CURRENT ASSETS: | ||||||||
Right-of-Use lease asset | 114,460 | |||||||
Property, plant and equipment, net | 5,775 | 7,963 | ||||||
Other asset | 3,000 | |||||||
Total non-current assets | 123,235 | 7,963 | ||||||
Total assets | $ | 241,586 | $ | 293,506 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable and accrued liabilities | $ | 193,612 | $ | 175,702 | ||||
Right-of-Use lease liability | 21,050 | |||||||
Short term debt | 25,055 | |||||||
Total current liabilities | 239,717 | 175,702 | ||||||
Non-current liabilities: | ||||||||
Right-of-Use lease liability | 94,260 | |||||||
Long-term payables | 561,554 | 445,300 | ||||||
Total non-current liabilities | 655,814 | 445,300 | ||||||
Total liabilities | 895,531 | 621,002 | ||||||
Stockholders’ deficit: | ||||||||
Common stock | 100 | 100 | ||||||
Additional paid-in capital | 6,582 | 6,582 | ||||||
Retained earnings | (660,627 | ) | (334,178 | ) | ||||
Total stockholders’ deficit | (653,945 | ) | (327,496 | ) | ||||
Total liabilities and stockholders’ deficit | $ | 241,586 | $ | 293,506 |
The accompanying notes are an integral part of these unaudited consolidated financial statements.
F-2 |
SCRIPPS SAFE, INC
CONSOLIDATED STATEMENTS OF OPERATIONS
For the nine months ended | ||||||||
September 30, 2022 | September 30, 2021 | |||||||
(Unaudited) | (Unaudited) | |||||||
Sales | $ | 511,249 | $ | 434,277 | ||||
Total revenue | 511,249 | 434,277 | ||||||
Cost of revenue | (325,057 | ) | (178,041 | ) | ||||
Gross profit | 186,192 | 256,236 | ||||||
Operating expenses: | ||||||||
Depreciation | 2,188 | 1,061 | ||||||
Selling, general and administrative | 493,739 | 268,718 | ||||||
Total operating expenses | 495,927 | 269,779 | ||||||
Loss from operations | (309,735 | ) | (13,543 | ) | ||||
Other income (expenses): | ||||||||
Other income | 2,402 | 24,909 | ||||||
Interest expense | (16,078 | ) | (12,490 | ) | ||||
Amortization of debt discount | (3,654 | ) | ||||||
Total other (expenses) | (17,330 | ) | 12,419 | |||||
Loss from operations before income taxes | (327,065 | ) | (1,124 | ) | ||||
Provision for income taxes | ||||||||
Net (loss) | (327,065 | ) | (1,124 | ) | ||||
Basic and diluted net loss per share attributable to common stockholders | (32.71 | ) | (0.11 | ) | ||||
Basic and diluted weighted average common shares | 10,000 | 10,000 |
The accompanying notes are an integral part of these unaudited consolidated financial statements.
F-3 |
SCRIPPS SAFE, INC
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
Additional | Total | |||||||||||||||||||
Common Share | Paid- in | Accumulated | Stockholders’ | |||||||||||||||||
Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||
Balance, December 31, 2019 | 10,000 | $ | 100 | $ | 6,582 | $ | (52,851 | ) | $ | (46,169 | ) | |||||||||
Shareholder’s distributions | - | (35,644 | ) | (35,644 | ) | |||||||||||||||
Net income | - | 30,243 | 30,243 | |||||||||||||||||
Balance, December 31, 2020 | 10,000 | $ | 100 | $ | 6,582 | $ | (58,252 | ) | $ | (51,570 | ) | |||||||||
Shareholder’s distributions | - | (7,322 | ) | (7,322 | ) | |||||||||||||||
Net (loss) | - | (268,604 | ) | (268,604 | ) | |||||||||||||||
Balance, December 31, 2021 | 10,000 | $ | 100 | $ | 6,582 | $ | (334,178 | ) | $ | (327,496 | ) | |||||||||
Shareholder’s contribution | - | 616 | 616 | |||||||||||||||||
Net (loss) | - | (327,065 | ) | (327,065 | ) | |||||||||||||||
Balance, September 30, 2022 | 10,000 | $ | 100 | $ | 6,582 | $ | (660,627 | ) | $ | (653,945 | ) |
The accompanying notes are an integral part of these unaudited consolidated financial statements.
F-4 |
SCRIPPS SAFE, INC
CONSOLIDATED STATEMENT OF CASHFLOWS
For the | For the | |||||||
nine months ended | nine months ended | |||||||
September 30, 2022 | September 30, 2021 | |||||||
(Unaudited) | (Unaudited) | |||||||
Cash flows from operating activities: | ||||||||
Net income (loss) | $ | (327,065 | ) | $ | (1,124 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation | 2,188 | 1,061 | ||||||
Amortization of debt discount | 3,654 | |||||||
PPP Loan forgiveness | (22,532 | ) | ||||||
Changes in operating assets and liabilities: | - | |||||||
Accounts receivable | (3,558 | ) | (69,731 | ) | ||||
Right-of-use asset | (114,460 | ) | ||||||
Other current assets | (25,817 | ) | 17,562 | |||||
Other asset | (3,000 | ) | ||||||
Accounts payable and accrued liabilities | 12,002 | 18,553 | ||||||
Deferred revenue | 5,908 | |||||||
Right-of-use liabilities | 115,310 | |||||||
Net cash (used in) operating activities | (334,838 | ) | (56,211 | ) | ||||
Cash flows from investing activities: | ||||||||
Purchase of fixed assets | ||||||||
Net cash (used in) provided by investing activities | ||||||||
Cash flows from financing activities: | ||||||||
Proceeds from notes payables | 112,500 | |||||||
Proceeds from SBA EIDL loan | 100 | 314,700 | ||||||
Shareholders contributions (distributions) | 616 | (7,293 | ) | |||||
Borrowings in debt | 29,282 | |||||||
Principal payments on debt | (4,227 | ) | ||||||
Net cash (used in) financing activities | 138,271 | 307,407 | ||||||
Net change in cash | (196,567 | ) | 251,196 | |||||
Cash, beginning of period | 227,932 | 58,941 | ||||||
Cash, end of period | $ | 31,365 | $ | 310,137 | ||||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||
Cash paid for interest | $ | 16,078 | $ | 38 | ||||
Cash paid for taxes | $ | $ |
The accompanying notes are an integral part of these unaudited consolidated financial statements.
F-5 |
SCRIPPS SAFE, INC
Notes to Financial Statements for the nine months ended
September 30, 2022 and 2021(Unaudited)
NOTE 1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION
Scripps Safe, Inc (the “Company”), was formed under the laws of the state of Florida on October 1, 2012. The Company operates as a leader of pharmaceutical security and storage solutions to prevent drug diversions in the healthcare environment. The Company is located in Naples, Florida.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
The Company’s financial statements and the notes thereto have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.
Segment Reporting
The Company operates as one segment, in which management uses one measure of profitability, and all the Company’s assets are located in the United States of America. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not have separately reportable segments.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent. There are no cash equivalents at September 30, 2022 and December 31, 2021.
Concentrations of Credit Risk
The Company, from time to time during the years covered by these financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
Accounts Receivable
Accounts receivables are carried at their estimated collectible amounts and are periodically evaluated for collectability based on past credit history with clients and other factors. The Company establishes provisions for losses on accounts receivable on the basis of loss experience, known and inherent risk in the account balance, and current economic conditions. At September 30, 2022 and December 31, 2021, the amount of the net allowances for doubtful accounts were $0. The accounts receivable amounts are reflected net of allowances of $60,522 and $56,964 at September 30, 2022 and December 31, 2021, respectively.
Other Current Assets
Other current assets are comprised of amounts paid for direct parts and materials which had not been installed on jobs in progress. As of September 30, 2022 and December 31, 2021, amounts of $17,146 and $647 were awaiting to be installed on jobs in progress.
Property and Equipment
Property and equipment is stated at the historical cost, less accumulated depreciation. Depreciation on property and equipment is provided using the straight-line method over the estimated useful lives of the assets for both financial and income tax reporting purposes as follows:
Machinery and equipment | 7 years |
F-6 |
Expenditures for renewals and betterments are capitalized while repairs and maintenance costs are normally charged to the statement of operations in the period which they are incurred. In situation where it can be clearly demonstrated that the expenditure has resulted in an increase in the future economic benefits expected to be obtained from the use of the asset, the expenditure is capitalized as an additional cost of the asset.
Upon sale or disposal of an asset, the historical cost and related accumulated depreciation or amortization of such asset were removed from their respective accounts and any gain or loss is recorded in the statements of operations.
The Company reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value of asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undisclosed expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this assessment, no impairment expenses for property and equipment were recorded in operating expenses during the nine months ended September 30, 2022 and year ended December 31, 2021.
Fair Value of Financial Instruments
Financial Accounting Standards Board guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows:
Financial Accounting Standards Board guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows:
Level 1 - | Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. | |
Level 2 - | Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). | |
Level 3 - | Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. |
The liabilities and indebtedness presented on the accompanying financial statements approximate fair values at September 30, 2022 and December 31, 2021, consistent with recent negotiations of notes payable and due to the short duration of maturities.
F-7 |
Revenue Recognition
The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers (“Topic 606”). This guidance sets forth a five-step model which depicts the recognition of revenue in an amount that reflects what the Company expect to receive in exchange for the transfer of goods or services to customers.
The Company recognizes revenue when the performance obligations under the terms of a contract with the customer are satisfied. Product sales occur once control of the products is transferred upon delivered to the location specified by its customer. Revenue is measured as the amount of consideration that expect to receive in exchange for transferring goods and is presented net of provisions for customer returns and allowances. Sales taxes and other similar taxes are excluded from revenue.
Revenue is recognized upon transfer of control of products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that may include various combinations of products and services which are generally capable of being distinct and accounted for as separate performance obligations.
Hardware. Hardware revenue from the sale of the Company’s devices is recognized when the Company transfers control to the customer, typically at the time when the product is shipped or installed, at which time the title passes to the customer, and there are no further performance obligations with regards to the hardware device. All of the Company’s revenue for the nine months ended September 30, 2022 and for the year ended December 31, 2021 were derived from the sale of hardware.
PaaS and Other Services. When the Company generates PaaS subscription revenue it will be recognized over time on a ratable basis over the contract term beginning on the date that its service is made available to the customer. Subscription periods range from monthly to multi-year, with the majority of contracts being one to three years. The Company’s customers have an option to purchase the monitoring device or lease it over the term of the contract. If the customer purchases the hardware device, the Company recognizes the revenue at a point in time as discussed above in the hardware revenue recognition disclosure. Because the Company’s rental asset lease contracts qualify as operating leases under Accounting Standards Codification (“ASC”) 842, Leases (“ASC 842”), and the contracts also include services to operate the underlying asset, and to maintain the asset, the Company has elected the practical expedient to combine the lease and the non-lease components because the service is the predominant element in the eyes of the customer and the pattern of service delivery is the same for both elements. The Company will recognize revenue over time in a ratable basis over the term of the contract.
Product Warranties. The Company, through its vendors, provides a standard warranty for one year period of time and a right of return on defective products. The Company considers the standard warranty is not providing incremental service to customers rather an assurance to the quality of the product, and therefore is not a separate performance obligation and should be accounted for in accordance with ASC 460, Guarantees.
Professional services revenue. From time to time, the Company enters into special engineering design service agreements. Revenues from engineering design services are designed to meet specifications of a particular product, and therefore do not create an asset with an alternative use. The Company will recognize revenue based on the achievement of certain applicable milestones and the amount of payment the Company believes it is entitled to at the time.
If a customer pays consideration or the Company has a right to an amount of consideration that is unconditional, before the Company transfers a good or service to the customer, the Company records the deferred revenue when the payment is made or a receivable is recorded, whichever is earlier. A deferred revenue is the Company’s obligation to transfer goods or services to a customer for which the Company has received consideration, or an amount of consideration is due, from the customer. The Company’s deferred revenue are primarily resulted from the performance obligation identified in sales order, which the revenue will be recognized when future goods or services are transferred.
F-8 |
Cost of Goods Sold
Cost of goods sold includes direct parts, material, labor cost and manufacturing overhead and reserves for estimated warranty cost.
Income Taxes
The Company elected under the Internal Revenue Code to be taxed as an S Corporation. Subchapter S Corporations do not pay entity level taxes; results of operations are reported to the member for inclusion in personal tax return. Accordingly, the Company is not subject to Federal and state income taxes and makes no provision for income taxes in its financial statements.
The Company’s tax return and the amount of allocable Company profits and losses are subject to examination by state and Federal authorities. If such examinations result in changes to the Company’s profits and losses, the tax liability of the shareholders could be changed accordingly.
In accordance with authoritative guidance under U.S. GAAP on accounting for and disclosure of uncertainty in tax positions, the Manager determines whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. For tax positions meeting this more likely than not threshold, the tax amount recognized in the combined financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement with the relevant taxing authority.
Basic net earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Potential common stock equivalents are determined using the treasury stock method. For diluted net income per share purposes, the Company excludes stock options and other stock-based awards, including shares issued as a result of option exercises that are subject to repurchase by the Company, whose effect would be anti-dilutive from the calculation. During the nine months ended September 30, 2022 and the year ended December 31, 2021, the Company has neither common stock equivalents nor stock options and other stock-based awards. Therefore, basic and diluted earnings per share was the same in all periods presented.
Advertising
The Company conducts advertising for the promotion of the products. In accordance with ASC 720-35, advertising costs are charged to operations when incurred. The Company recorded advertising expense of $56,632 and $29,911 for the nine months ended September 30, 2022 and 2021, respectively.
Recently adopted accounting pronouncements
In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The amendments in this update create Topic 842, Leases, and supersede the leases requirements in Topic 840, Leases. Topic 842 specifies the accounting for leases. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. The main difference between Topic 842 and Topic 840 is the recognition of lease assets and lease liabilities for those leases classified as operating leases under Topic 840. Topic 842 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model in Topic 842, the effect of leases in the statement of operations and the statement of cash flows is largely unchanged from previous GAAP. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that reporting period, for public business entities. In June 2020, the FASB postponed the effective date of the new lease standard, which will become effective after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022, for entities other than public and Not-for-profit entities. The Company elected to adopt the new lease standard as of the effective date applicable to non-issuers and implemented the new lease standard on January 1, 2022, using the modified retrospective method. The adoption of ASC 842 resulted in recognition of right of use (“ROU”) assets of US$135,182 and right of use liabilities of US$135,182 upon the adoption date. The Company elected the package of practical expedients permitted under the transition guidance with ASC 842, which among others, allows the Company to carry forward certain historical conclusions reached under Topic 840 regarding lease identification, classification, and the accounting treatment of initial direct costs. The Company is elected not to record assets and liabilities on its consolidated balance sheet for new or existing lease arrangements with terms of 12 months or less. The Company recognizes lease expenses for such leases on a straight-line basis over the lease term. In addition, the Company elected the land easement transition practical expedient and does not reassess whether an existing or expired land easement is a lease or contains a lease if it has not historically been accounted for as a lease.
Going Concern
The Company has incurred continuing losses from its operations and has an accumulated deficit of $660,627. There are no assurances the Company will be able to raise capital on acceptable terms or that cash flows generated from its operations will be sufficient to meet its current operating costs and required debt service. If the Company is unable to obtain sufficient amounts of additional capital, it may be required to reduce the scope of its business, which could harm its financial condition and operating results. These conditions raise substantial doubt about the Company’s ability to continue ongoing operations. These consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
NOTE 3. ACCOUNTS RECEIVABLE
Accounts receivable and allowance for doubtful accounts consisted of the following:
September 30, | December 31, | |||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Accounts receivable | $ | 60,522 | $ | 56,964 | ||||
Less: allowance for doubtful accounts | ||||||||
Net accounts receivable | $ | 60,522 | $ | 56,964 |
F-9 |
NOTE 4. OTHER CURRENT ASSETS
Other current assets consisted of the following:
September 30, 2022 | December 31, 2021 | |||||||
(Unaudited) | ||||||||
Deferred cost of goods sold | $ | 26,464 | $ | 647 | ||||
Less: allowance for doubtful accounts | ||||||||
Deferred cost of goods sold, net balance | 26,464 | 647 | ||||||
Other asset | $ | $ | ||||||
Total | 26,464 | 647 |
NOTE 5. PROPERTY AND EQUIPMENT
Property and equity consisted of the following:
September 30, | December 31, | |||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Machinery and equipment, at cost | $ | 9,900 | $ | 9,900 | ||||
Accumulated depreciation | (4,125 | ) | (1,937 | ) | ||||
Property and equipment, net | $ | 5,775 | $ | 7,963 |
Depreciation expense totaled $2,188 and $1,414 for the nine months ended September 30, 2022 and for the twelve months ended December 31, 2021, respectively.
NOTE 6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable and accrued liabilities amounted to $193,612 and $175,702 as of September 30, 2022 and December 31, 2021, respectively. Accounts payable is consisted of payroll liabilities and related costs. Accrued liability is mainly accrued interest of the Economic Injury Disaster Loan (“EIDL”) loan (see Note 8), credit cards, refund liability and deferred revenue (see Note 7).
September 30, 2022 | December 31, 2021 | |||||||
(Unaudited) | ||||||||
Credit Cards | $ | 40,301 | $ | 21,451 | ||||
Refund Liability | 50,121 | 74,384 | ||||||
Deferred Revenue | 68,917 | 63,009 | ||||||
Payroll liabilities | 9,128 | |||||||
Payroll tax liabilities | 84 | 7,441 | ||||||
Accrued interest | 23,243 | 9,417 | ||||||
Other liabilities | 1,818 | |||||||
Net balance | $ | 193,612 | $ | 175,702 |
F-10 |
NOTE 7. DEFERRED REVENUE
Deferred revenue primarily consisted of advance payments from customers prior to the transfer of goods or services by the Company. The payment amounts and timing vary depending on the product, and the location of delivery. Deferred revenue is included in current liabilities until refunded or performance obligations have met.
September 30, | December 31, | |||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Deferred revenue - beginning of year | $ | 63,009 | $ | |||||
A change in time frame for a performance obligation to be satisfied | 5,908 | 63,009 | ||||||
Deferred revenue - end of year | $ | 68,917 | $ | 63,009 |
NOTE 8. NOTES PAYABLE
On June 24, 2020, the Company was approved to receive a loan of $130,600 under the Economic Injury Disaster Loan (“EIDL”). The EIDL is a Small Business Administration (“SBA”) loan that provides qualifying businesses with 6 months of working capital. The first payment has been deferred by the SBA for twelve months from the date of the note. The EIDL has a fixed annual interest rate of 3.75% for 30 years.
On May 1, 2020, the Company received loan proceeds of $22,532 under the Payroll Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities. The Company used the proceeds for eligible purposes and was informed in April 2021 that the Small Business Administration approved their loan forgiveness applicable, and the loan balance was forgiven in full.
On September 28, 2021, the Company received loan proceeds of $314,700 under the EIDL. The EIDL is a SBA loan that provides qualifying businesses with 6 months of working capital. The first payment has been deferred by the SBA for twelve months from the date of the note. The EIDL has a fixed interest rate of 3.75% APR for 30 years.
On June 15, 2022, the Company established a line of credit with Headway Capital for a maximum draw of up to $60,600. This line of credit is to cover working capital. The balance as of September 30, 2022 was $25,055, with a periodic monthly interest rate of 3.33%.
On August 4, 2022, we entered into a loan agreement (the “Loan Agreement”) with Greentree Financial Group, Inc. (the “Investor”) for a loan of up to $250,000 to help us pay certain offering expenses. As funds are advanced, the Company will issue a promissory note (the “Note”) for the amount advanced plus a 10% original issue discount. The Note is on February 15, 2023, subject to the Company’s right to extend the note two times for three months each by issuing the investor shares of the Company’s common stock on each extension. The Investor has the right to convert the unpaid principal amount and interest on the Note into shares of common stock at a price equal to 70% of the lowest closing price for the last five (5) trading days immediately prior to but not including the date of conversion. In connection with the Loan Agreement, the Investor will receive warrants to purchase up to 200,000 shares of common stock (based on a $200,000 investment) at $ per share for a period of five years (the “Warrant”). The Investor was granted registration rights for a registration statement in connection with a subsequent offering, subject to certain exceptions. If after sixty (60) days of this offering (i) a registration statement for the common stock underlying the Warrants has gone effective, and is still effective, (ii) the 20-day volume-weighted daily average price of the Company’s common stock exceeds $6 per share, (iii) the average daily trading volume is at least 500,000 shares during such 20-day period, and (iv) an event of default under the Note has not occurred, then the Company will have the option for thirty (30) days to elect to call the Investor’s unexercised Warrants at a price per Warrant equal to $0.10 per Warrant; provided that, the Company provides the Investor with written notice of its intent to redeem, and the Investor has thirty (30) days after receipt of notice to elect to exercise the Warrants. The Warrants also contain an anti-dilution provision which proportionately adjusts the exercise price of the Warrants if the Company issues common stock or securities convertible into common stock at a price per share less than the exercise price. During the third quarter of 2022, the company received loan proceeds of $125,000, with an original issuance discount of $12,500. The balance of the debt and unamortized debt discount as of September 30, 2022 was $125,000 and $8,846, respectively. And during the three months ended September 30, 2022, the company recorded amortization of debt discount of $3,654.
On November 16, 2022, the Note was the Company and the Investor entered into amendment to the Note, pursuant to which the balance under the note may be converted into the Company’s common stock immediately upon the completion of the Company’s initial public offering or some other event that results in the Company’s common stock becoming publicly traded as opposed to the balance under the note being convertible into common stock immediately upon issuance.
On November 16, 2022, the Note was the Company and the Investor entered into amendment to the GT Warrant, pursuant to which the GT Warrants will not be exercisable until the Company’s initial public offering or some other event that results in the Company’s common stock becoming publicly traded as opposed to the GT Warrant being exercisable into common stock immediately upon issuance.
F-11 |
NOTE 9. MARKET AND OTHER RISK FACTORS
COVID-19
On March 11, 2020, the World Health Organization declared the spread of COVID-19 pandemic. Several governments in jurisdictions that encompass the Company’s offices and operations have implemented extended strict social distancing measures. In response, the Company has implemented remote work arrangements for virtually all of its employees and restricted business travel. These arrangements have not materially affected our ability to maintain and conduct our business operations, including the operation of financial reporting systems, internal controls over financial reporting, and disclosure controls and procedures. While the COVID-19 pandemic has adversely affected the global economy, the nature and extent of COVID-19’s effect on the Company’s operational and financial performance will depend on future developments, including the course of the pandemic, the success of governments in relaxing social distancing measures and restarting economic activity, the efficacy of monetary and fiscal measures taken or that may be taken in the future, and the potential for structural damage to the economy due to the sharp drop in aggregate demand and, particularly in the U.S., a high level of unemployment, all of which are uncertain and difficult to predict considering the rapidly evolving landscape. It is unclear whether these challenges will be contained and what effects they each may have. The Company could be materially adversely affected by a prolonged recession in the U.S. and other major markets.
NOTE 10. COMMITMENTS AND CONTINGENCIES
Leases
The Company has an operating lease for an office lease in Naples, Florida with an initial term of 24 months. Base monthly rent was approximately $2,100 per month plus net operating expenses and expires in April 2022. The company currently leases their space in Naples, FL month-to-month for $2,300 per month.
The company also has a -year lease agreement for 5,000 sq feet of office space at 100 Technology Way, Jeffersonville, IN 47130 for a monthly base rent of $2,291.67 beginning May 1, 2022, with an option to renew. The total amount of rental payments due over the lease term is being charged to rent expense according to the straight-line method over the term of the lease. As of September 30, 2022, the Company recorded right of use liabilities of $115,310 and right of use asset of $114,460, respectively.
Legal Proceedings
From time to time, we may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect our financial condition, results of operations and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect us due to legal costs and expenses, diversion of management attention and other factors. We expense legal costs in the period incurred. We cannot assure you that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against us in the future, and these matters could relate to prior, current or future transactions or events. As of September 30, 2022 and December 31, 2021, there were no pending or threatened litigation against the Company.
NOTE 11. INCOME TAXES
The Company is elected to be taxed as an S Corporation for federal income tax purposes. As a result, its taxable income and loss are passed through to the shareholders at the end of each tax year.
On December 20, 2017, the US Congress passed the Tax Cut and Jobs Act. The new law was effective in 2018 and among its many provisions may impose additional reporting requirements on the Company. ASC Topic 740 provides guidance on the accounting for uncertainty in income taxes recognized in a company’s financial statements. Topic 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. At September 30, 2022, the Company had net operating loss carry forwards of $660,627 that maybe offset against future taxable income. No tax benefit has been reported in the September 30, 2022 and December 31, 2021 financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.
NOTE 12. SUBSEQUENT EVENTS
The Company has evaluated subsequent events through the date of the financial statements were issued and determined there were no such events to report.
F-12 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the Board of Directors and
Stockholders of Scripps Safe, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Scripps Safe, Inc. (the Company) as of December 31, 2021 and 2020, and the related statements of operations, change in stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2021, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.
Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has negative cash flow from operations and stockholders’ deficiency, which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Revenue Recognition
As discussed in Note 2, the Company recognizes revenue upon transfer of control of promised services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services.
Auditing management’s evaluation of agreements with customers involves significant judgment, given the fact that some agreements require management’s evaluation and allocation of the standalone transaction prices to the performance obligations.
To evaluate the appropriateness and accuracy of the assessment by management, we evaluated management’s assessment in relationship to the relevant agreements.
/s/ M&K CPAS, PLLC | |
We have served as the Company’s auditor since 2020. | |
Houston, TX | |
August 22, 2022 |
F-13 |
SCRIPPS SAFE, INC
CONSOLIDATED BALANCE SHEETS
December 31, 2021 | December 31, 2020 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 227,932 | $ | 58,941 | ||||
Accounts receivable, net | 56,964 | 26,110 | ||||||
Other current assets | 647 | 17,562 | ||||||
Total current assets | 285,543 | 102,613 | ||||||
Property, plant and equipment, net | 7,963 | 9,377 | ||||||
Total assets | $ | 293,506 | $ | 111,990 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable and accrued liabilities | $ | 175,702 | $ | 10,428 | ||||
Total current liabilities | 175,702 | 10,428 | ||||||
Non-current liabilities: | ||||||||
Long-term payables | 445,300 | 153,132 | ||||||
Total liabilities | 621,002 | 163,560 | ||||||
Stockholders’ deficit: | ||||||||
Common stock | 100 | 100 | ||||||
Additional paid-in capital | 6,582 | 6,582 | ||||||
Retained earnings | (334,178 | ) | (58,252 | ) | ||||
Total stockholders’ deficit | (327,496 | ) | (51,570 | ) | ||||
Total liabilities and stockholders’ deficit | $ | 293,506 | $ | 111,990 |
The accompanying notes are an integral part of these financial statements.
F-14 |
SCRIPPS SAFE, INC
CONSOLIDATED STATEMENTS OF OPERATIONS
For the year | For the year | |||||||
ended | ended | |||||||
December 31, 2021 | December 31, 2020 | |||||||
Sales | $ | 505,143 | $ | 548,191 | ||||
Total revenue | 505,143 | 548,191 | ||||||
Cost of revenue | (354,768 | ) | (268,887 | ) | ||||
Gross profit | 150,375 | 279,304 | ||||||
Operating expenses: | ||||||||
Depreciation | 1,414 | 523 | ||||||
Selling, general and administrative | 437,261 | 246,614 | ||||||
Total operating expenses | 438,675 | 247,137 | ||||||
(Loss)/Profit from operations | (288,300 | ) | 32,167 | |||||
Other income (expenses): | ||||||||
Other income | 26,416 | 773 | ||||||
Interest expense | (6,720 | ) | (2,697 | ) | ||||
Total other income | 19,696 | (1,924 | ) | |||||
(Loss)/Income from operations before income taxes | (268,604 | ) | 30,243 | |||||
Provision for income taxes | ||||||||
Net (loss)/income | (268,604 | ) | 30,243 | |||||
Basic and diluted net loss per share attributable to common stockholders | (26.86 | ) | 3.02 | |||||
Basic and diluted weighted average common shares | 10,000 | 10,000 |
The accompanying notes are an integral part of these financial statements.
F-15 |
SCRIPPS SAFE, INC
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
Additional | Total | |||||||||||||||||||
Common Share | Paid- in | Accumulated | Stockholders’ | |||||||||||||||||
Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||
Balance, December 31, 2019 | 10,000 | $ | 100 | $ | 6,582 | $ | (52,851 | ) | $ | (46,169 | ) | |||||||||
Shareholder’s distributions | - | (35,644 | ) | (35,644 | ) | |||||||||||||||
Net income | - | 30,243 | 30,243 | |||||||||||||||||
Balance, December 31, 2020 | 10,000 | $ | 100 | $ | 6,582 | $ | (58,252 | ) | $ | (51,570 | ) | |||||||||
Shareholder’s distributions | - | (7,322 | ) | (7,322 | ) | |||||||||||||||
Net loss | - | (268,604 | ) | (268,604 | ) | |||||||||||||||
Balance, December 31, 2021 | 10,000 | $ | 100 | $ | 6,582 | $ | (334,178 | ) | $ | (327,496 | ) |
The accompanying notes are an integral part of these financial statements.
F-16 |
SCRIPPS SAFE, INC
CONSOLIDATED STATEMENT OF CASH FLOWS
For the year | For the year | |||||||
ended | ended | |||||||
December 31, 2021 | December 31, 2020 | |||||||
Cash flows from operating activities: | ||||||||
Net income (loss) | $ | (268,604 | ) | $ | 30,243 | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation | 1,414 | 523 | ||||||
PPP Loan forgiveness | (22,532 | ) | ||||||
Changes in operating assets and liabilities: | - | |||||||
Accounts receivable | (30,854 | ) | (1,770 | ) | ||||
Other current assets | 16,915 | 36,098 | ||||||
Accounts payable and accrued liabilities | 102,265 | 380 | ||||||
Deferred revenue | 63,009 | (114,602 | ) | |||||
Net cash (used in) operating activities | (138,387 | ) | (49,128 | ) | ||||
Cash flows from investing activities: | ||||||||
Purchase of fixed assets | (9,900 | ) | ||||||
Net cash (used in) provided by investing activities | (9,900 | ) | ||||||
Cash flows from financing activities: | ||||||||
Proceeds from SBA PPP loan | 22,532 | |||||||
Proceeds from SBA EIDL loan | 314,700 | 130,600 | ||||||
Shareholders distributions | (7,322 | ) | (35,644 | ) | ||||
Net cash (used in) financing activities | 307,378 | 117,488 | ||||||
Net change in cash | 168,991 | 58,460 | ||||||
Cash, beginning of period | 58,941 | 481 | ||||||
Cash, end of period | $ | 227,932 | $ | 58,941 | ||||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||
Cash paid for interest | $ | $ | ||||||
Cash paid for taxes | $ | $ |
The accompanying notes are an integral part of these financial statements.
F-17 |
SCRIPPS SAFE, INC
Notes to Financial Statements for the year ended
December 31, 2021 and December 31, 2022
NOTE 1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION
Scripps Safe, Inc (the “Company”), was formed under the laws of the state of Florida on October 1, 2012. The Company operates as a leader of pharmaceutical security and storage solutions to prevent drug diversions in the healthcare environment. The Company is located in Naples, Florida.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
The Company’s financial statements and the notes thereto have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.
Segment Reporting
The Company operates as one segment, in which management uses one measure of profitability, and all the Company’s assets are located in the United States of America. The Company does not operate separate lines of business or separate business entities with respect to any of its product brands. Accordingly, the Company does not have separately reportable segments.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent. There are no cash equivalents at December 31, 2021 and December 31, 2020.
Concentrations of Credit Risk
The Company, from time to time during the years covered by these financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
Accounts Receivable
Accounts receivables are carried at their estimated collectible amounts and are periodically evaluated for collectability based on past credit history with clients and other factors. The Company establishes provisions for losses on accounts receivable on the basis of loss experience, known and inherent risk in the account balance, and current economic conditions. At December 31, 2021 and 2020, the amount of the net allowances for doubtful accounts were $0. And the accounts receivable amounts are reflected as net of allowances for doubtful accounts of $56,964 and $26,110 at December 31, 2021 and 2020, respectively.
Other Current Assets
Other current assets are comprised of amounts paid for direct parts and materials which had not been installed on jobs in progress. As of December 31, 2021 and 2020, amounts of $647 and $17,562 were awaiting to be installed on jobs in progress.
Property and Equipment
Property and equipment is stated at the historical cost, less accumulated depreciation. Depreciation on property and equipment is provided using the straight-line method over the estimated useful lives of the assets for both financial reporting purposes as follows:
Machinery and equipment | 7 years |
F-18 |
Expenditures for renewals and betterments are capitalized while repairs and maintenance costs are normally charged to the statement of operations in the period which they are incurred. In situations where it can be clearly demonstrated that the expenditure has resulted in an increase in the future economic benefits expected to be obtained from the use of the asset, the expenditure is capitalized as an additional cost of the asset.
Upon sale or disposal of an asset, the historical cost and related accumulated depreciation or amortization of such asset were removed from their respective accounts and any gain or loss is recorded in the statements of operations.
The Company reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value of asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this assessment, no impairment expenses for property and equipment were recorded in operating expenses during the years ended December 31, 2021 and 2020.
Fair Value of Financial Instruments
Financial Accounting Standards Board guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows:
Level 1 - | Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. | |
Level 2 - | Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). | |
Level 3 - | Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. |
The liabilities and indebtedness presented on the accompanying financial statements approximate fair values at December 31, 2021 and December 31, 2020, consistent with recent negotiations of notes payable and due to the short duration of maturities.
Revenue Recognition
The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers (“Topic 606”). This guidance sets forth a five-step model which depicts the recognition of revenue in an amount that reflects what the Company expect to receive in exchange for the transfer of goods or services to customers.
The Company recognizes revenue when the performance obligations under the terms of a contract with the customer are satisfied. Product sales occur once control of the products is transferred upon delivered to the location specified by its customer. Revenue is measured as the amount of consideration that expect to receive in exchange for transferring goods and is presented net of provisions for customer returns and allowances. Sales taxes and other similar taxes are excluded from revenue.
Revenue is recognized upon transfer of control of products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that may include various combinations of products and services which are generally capable of being distinct and accounted for as separate performance obligations.
Hardware. Hardware revenue from the sale of the Company’s devices is recognized when the Company transfers control to the customer, typically at the time when the product is shipped or installed, at which time the title passes to the customer, and there are no further performance obligations with regards to the hardware device. All of the Company’s revenue for the years ended December 31, 2021 and 2020 were derived from the sale of hardware.
PaaS and Other Services. When the Company generates PaaS subscription revenue it will be recognized over time on a ratable basis over the contract term beginning on the date that its service is made available to the customer. Subscription periods range from monthly to multi-year, with the majority of contracts being one to three years. The Company’s customers have an option to purchase the monitoring device or lease it over the term of the contract. If the customer purchases the hardware device, the Company recognizes the revenue at a point in time as discussed above in the hardware revenue recognition disclosure. Because the Company’s rental asset lease contracts qualify as operating leases under Accounting Standards Codification (“ASC”) 842, Leases (“ASC 842”), and the contracts also include services to operate the underlying asset, and to maintain the asset, the Company has elected the practical expedient to combine the lease and the non-lease components because the service is the predominant element in the eyes of the customer and the pattern of service delivery is the same for both elements. The Company will recognize revenue over time in a ratable basis over the term of the contract.
Product Warranties.
The Company, through its vendors, provides a standard warranty for one year period of time and a right of return on defective products. The Company considers the standard warranty is not providing incremental service to customers rather an assurance to the quality of the product, and therefore is not a separate performance obligation and should be accounted for in accordance with ASC 460, Guarantees.
Professional services revenue. From time to time, the Company enters into special engineering design service agreements. Revenues from engineering design services are designed to meet specifications of a particular product, and therefore do not create an asset with an alternative use. The Company will recognize revenue based on the achievement of certain applicable milestones and the amount of payment the Company believes it is entitled to at the time.
F-19 |
If a customer pays consideration or the Company has a right to an amount of consideration that is unconditional, before the Company transfers a good or service to the customer, the Company records the deferred revenue when the payment is made or a receivable is recorded, whichever is earlier. A deferred revenue is the Company’s obligation to transfer goods or services to a customer for which the Company has received consideration, or an amount of consideration is due, from the customer. The Company’s deferred revenue are primarily resulted from the performance obligation identified in sales order, which the revenue will be recognized when future goods or services are transferred.
Cost of Goods Sold
Cost of goods sold includes direct parts, material, labor cost and manufacturing overhead and reserves for estimated warranty cost.
Income Taxes
The Company elected under the Internal Revenue Code to be taxed as an S Corporation. Subchapter S Corporations do not pay entity level taxes; results of operations are reported to the member for inclusion in personal tax return. Accordingly, the Company is not subject to Federal and state income taxes and makes no provision for income taxes in its financial statements.
The Company’s tax return and the amount of allocable Company profits and losses are subject to examination by state and Federal authorities. If such examinations result in changes to the Company’s profits and losses, the tax liability of the shareholders could be changed accordingly.
In accordance with authoritative guidance under U.S. GAAP on accounting for and disclosure of uncertainty in tax positions, the CFO determines whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. For tax positions meeting this more likely than not threshold, the tax amount recognized in the combined financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement with the relevant taxing authority.
Basic net earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Potential common stock equivalents are determined using the treasury stock method. For diluted net income per share purposes, the Company excludes stock options and other stock-based awards, including shares issued as a result of option exercises that are subject to repurchase by the Company, whose effect would be anti-dilutive from the calculation. During the years ended December 31, 2021 and 2020, the Company has neither common stock equivalents nor stock options and other stock-based awards. Therefore, basic and diluted earnings per share was the same in all periods presented.
Advertising
The Company conducts advertising for the promotion of the products. In accordance with ASC 720-35, advertising costs are charged to operations when incurred. The Company recorded advertising expense of $47,799 and $27,570 for the years ended December 31, 2021 and 2020, respectively.
F-20 |
Recent Accounting Pronouncements
The Financial Accounting Standards Board (“FASB”) and other entities issued new or modifications to, or interpretations of, existing accounting guidance during 2021 and 2020. The Company has carefully considered the new pronouncements that altered GAAP, and, other than those disclosed in these notes to financial statements, does not believe that any other new or modified principles will have a material impact on the reported financial position or results of operations of the Company’s financial statements.
Going Concern
The Company has incurred continuing losses from its operations and has an accumulated deficit of $334,178. There are no assurances the Company will be able to raise capital on acceptable terms or that cash flows generated from its operations will be sufficient to meet its current operating costs and required debt service. If the Company is unable to obtain sufficient amounts of additional capital, it may be required to reduce the scope of its business, which could harm its financial condition and operating results. These conditions raise substantial doubt about the Company’s ability to continue ongoing operations. These consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
NOTE 3. ACCOUNTS RECEIVABLE
Accounts receivable and allowance for doubtful accounts consisted of the following:
December 31, | December 31, | |||||||
2021 | 2020 | |||||||
Accounts receivable | $ | 56,964 | $ | 26,110 | ||||
Less: allowance for doubtful accounts | ||||||||
Net accounts receivable | $ | 56,964 | $ | 26,110 |
NOTE 4. PROPERTY AND EQUIPMENT
Property and equity consisted of the following:
December 31, | December 31, | |||||||
2021 | 2020 | |||||||
Machinery and equipment, at cost | $ | 9,900 | $ | 9,900 | ||||
Accumulated depreciation | (1,937 | ) | (523 | ) | ||||
Property and equipment, net | $ | 7,963 | $ | 9,377 |
Depreciation expense totaled $1,414 and $523 for the years ended December 31, 2021 and 2020, respectively.
F-21 |
NOTE 5. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable and accrued liabilities amounted to $175,702 and $10,428 as of December 31, 2021 and 2020, respectively. Accounts payable is consisted of payroll liabilities and related costs. Accrued liability is mainly accrued interest of the Economic Injury Disaster Loan (“EIDL”) loan (see Note 8), credit cards, refund liability and deferred revenue (see Note 7).
December 31, | December 31, | |||||||
2021 | 2020 | |||||||
Credit Cards | $ | 21,451 | $ | |||||
Refund Liability | 74,384 | |||||||
Deferred Revenue | 63,009 | |||||||
Payroll liabilities | 6,945 | |||||||
Payroll tax liabilities | 7,441 | 786 | ||||||
Accrued interest | 9,417 | 2,697 | ||||||
Net balance | $ | 175,702 | $ | 10,428 |
NOTE 6. DEFERRED REVENUE
Deferred revenue primarily consisted of advance payments from customers prior to the transfer of goods or services by the Company. The payment amounts and timing vary depending on the product, and the location of delivery. Deferred revenue is included in current liabilities until refunded or performance obligations have met.
December 31, | ||||
2021 | ||||
Deferred revenue - beginning of year | $ | |||
A change in time frame for a performance obligation to be satisfied | 63,009 | |||
Deferred revenue - end of year | $ | 63,009 |
NOTE 7. NOTES PAYABLE
On June 24, 2020, the Company was approved to receive a loan of $130,600 under the Economic Injury Disaster Loan (“EIDL”). The EIDL is a Small Business Administration (“SBA”) loan that provides qualifying businesses with 6 months of working capital. The first payment has been deferred by the SBA for twelve months from the date of the note. The EIDL has a fixed annual interest rate of 3.75% for 30 years.
On May 1, 2020, the Company received loan proceeds of $22,532 under the Payroll Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly payroll expenses of the qualifying business.
The loans and accrued interest are forgivable as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities. The Company used the proceeds for eligible purposes and was informed in April 2021 that the Small Business Administration approved their loan forgiveness applicable, and the loan balance was forgiven in full.
On September 28, 2021, the Company received loan proceeds of $314,700 under the EIDL. The EIDL is a SBA loan that provides qualifying businesses with 6 months of working capital. The first payment has been deferred by the SBA for twelve months from the date of the note. The EIDL has a fixed interest rate of 3.75% APR for 30 years.
NOTE 8. MARKET AND OTHER RISK FACTORS
COVID-19
On March 11, 2020, the World Health Organization declared the spread of COVID-19 pandemic. Several governments in jurisdictions that encompass the Company’s offices and operations have implemented extended strict social distancing measures. In response, the Company has implemented remote work arrangements for virtually all of its employees and restricted business travel. These arrangements have not materially affected our ability to maintain and conduct our business operations, including the operation of financial reporting systems, internal controls over financial reporting, and disclosure controls and procedures. While the COVID-19 pandemic has adversely affected the global economy, the nature and extent of COVID-19’s effect on the Company’s operational and financial performance will depend on future developments, including the course of the pandemic, the success of governments in relaxing social distancing measures and restarting economic activity, the efficacy of monetary and fiscal measures taken or that may be taken in the future, and the potential for structural damage to the economy due to the sharp drop in aggregate demand and, particularly in the U.S., a high level of unemployment, all of which are uncertain and difficult to predict considering the rapidly evolving landscape. It is unclear whether these challenges will be contained and what effects they each may have. The Company could be materially adversely affected by a prolonged recession in the U.S. and other major markets.
F-22 |
NOTE 9. COMMITMENTS AND CONTINGENCIES
Leases
The Company has an operating lease for an office lease in Naples, Florida with an initial term of 24 months. Base monthly rent was approximately $2,100 per month plus net operating expenses and expires in April 2022. The company currently leases their space in Naples, FL month-to-month for $2,300 per month. The company also has a -year lease agreement for 5,000 sq feet of office space at 100 Technology Way, Jeffersonville, IN 47130 for a monthly base rent of $2,291.67 beginning May 1, 2022, with an option to renew.
In considering its qualitative disclosure obligations under ASC 842-20-50-3, the Company examined its lease(s) for office space that have a fixed monthly rent with no variable lease payments. These lease(s) are for an office space with no right of use assets. These lease(s) do not provide for terms and conditions granting residual value guarantees by the Company, or any restrictions or covenants imposed by the lease for dividends or incurring additional financial obligations by the Company. The Company also elected a short-term lease exception policy and an accounting policy to not separate non-lease components from lease components for the facility lease, as the Company determined the right of use asset to be zero.
Legal Proceedings
From time to time, we may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect our financial condition, results of operations and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect us due to legal costs and expenses, diversion of management attention and other factors. We expense legal costs in the period incurred. We cannot assure you that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against us in the future, and these matters could relate to prior, current or future transactions or events. As of December 31, 2021 and 2020, there were no pending or threatened litigation against the Company.
NOTE 10. INCOME TAXES
The Company is elected to be taxed as an S Corporation for federal income tax purposes. As a result, its taxable income and loss are passed through to the shareholders at the end of each tax year.
On December 20, 2017, the US Congress passed the Tax Cut and Jobs Act. The new law was effective in 2018 and among its many provisions may impose additional reporting requirements on the Company. ASC Topic 740 provides guidance on the accounting for uncertainty in income taxes recognized in a company’s financial statements. Topic 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. At December 31, 2021, the Company had net operating loss carry forwards of $334,178 that maybe offset against future taxable income. No tax benefit has been reported in the December 31, 2021 or 2020 financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.
NOTE 11. SUBSEQUENT EVENTS
In August 2022, we entered into a loan agreement with an investor (the “Investor”) for a loan of up to $250,000 to help us pay certain offering expenses. As funds are advanced, the Company will issue a promissory note for the amount advanced plus a 10% original issue discount. The notes will be due on February 15, 2023, subject to the Company’s right to extend the note two times for three months each by issuing the investor shares of the Company’s common stock on each extension. In connection with the loan agreement, the Investor will receive warrants to purchase up to 200,000 shares of common stock (based on a $250,000 investment) at $ per share for a period of five years.
On April 1, 2022 Jacqueline von Zwehl executed an Employment Agreement (the “von Zwehl Employment Agreement”) for her service as our Chief Executive Officer. She will be paid a base salary of $325,000 per year upon completion of the company’s initial public offering and will be eligible to earn an annual bonus based on the achievement of certain goals and performance criteria established by our Board of Directors. For the fiscal years 2022-2025, the annual bonus will be 20% of the current base salary with a maximum payout of 150% based on target achievement. The employment is “at-will” and the von Zwehl Employment Agreement can be terminated any anytime, however, if she is terminated without cause or if she resigns for Good Reason (defined therein) she shall receive an amount equal to twelve months (12) of Executive’s then-current base salary (the “Severance Payout”). The Severance Payout is payable in equal installments over the subsequent 12-month period.
On August 6, 2021, the Company entered into a Business Service Development Agreement with Gerald Newman (“Newman”) in which the consultant will provide certain services to the Company. Pursuant to the agreement, Newman is entitled to receive shares of common stock equal to 5,000 per month for twelve months. The shares have not yet been issued as certain pre-conditions have not yet been met. of the total shares outstanding prior to this offering. Commencing upon the closing of the offering, Newman shall be entitled to a fee of $
On August 9, 2021, the Company entered into a service agreement in which the consultant will provide certain services to the Company. In exchange for the services, Greentree is entitled to receive an amount of shares of the Company’s common stock equal to of the total outstanding shares prior to this offering. In addition, Greentree shall receive warrants to purchase shares of common stock at $ per share. The shares and warrants have not yet been issued as certain pre-conditions have not yet been met.
Except to the above, the Company has evaluated subsequent events through the date of the financial statements were issued and determined there were no such events to report.
F-23 |
PART II — INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13. Other Expenses of Issuance and Distribution.
The following table sets forth all expenses to be paid by the registrant in connection with the issuance and distribution of the securities to be registered, other than underwriting discounts and commissions. All amounts shown are estimates except for the SEC registration fee:
SEC registration fee* | $ | 15,000 | ||
Legal fees and expenses* | $ | 465,000 | ||
Accounting fees and expenses* | $ | 60,000 | ||
Miscellaneous fees and expenses* | $ | 160,000 | ||
Total* | $ | 700,000 |
* To be filed by amendment.
Item 14. Indemnification of Directors and Officers.
Our certificate of incorporation limits the liability of directors to the maximum extent permitted by Delaware General Corporation Law (the “DGCL”). The DGCL provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors.
Our bylaws provide that we will indemnify our directors and officers to the fullest extent permitted by law, and may indemnify employees and other agents. Our bylaws also provide that we are obligated to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding.
Our bylaws, subject to the provisions of the DGCL contain provisions which allow the corporation to indemnify any person against liabilities and other expenses incurred as the result of defending or administering any pending or anticipated legal issue in connection with service to us if it is determined that person acted in good faith and in a manner which he or she reasonably believed was in the best interest of the corporation. Insofar as indemnification for liabilities arising under the Securities Act of 1933 as amended, or the Securities Act, may be permitted to our directors, officers and controlling persons, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
The limitation of liability and indemnification provisions in our bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might provide a benefit to us and our stockholders. Our results of operations and financial condition may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
At present, there is no pending litigation or proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.
Item 15. Recent Sales of Unregistered Securities.
On August 4, 2022, we entered into a loan agreement (the “Loan Agreement”) with Greentree Financial Group, Inc. (the “Investor”) for a loan of up to $250,000 to help us pay certain offering expenses. As funds are advanced, the Company will issue a promissory note (the “Note”) for the amount advanced plus a 10% original issue discount. The Note is on February 15, 2023, subject to the Company’s right to extend the note two times for three months each by issuing the investor 10,000 shares of the Company’s common stock on each extension. The Investor has the right to convert the unpaid principal amount and interest on the Note into shares of common stock at a price equal to 70% of the lowest closing price for the last five (5) trading days immediately prior to but not including the date of conversion. In connection with the Loan Agreement, the Investor will receive warrants to purchase up to 200,000 shares of common stock (based on a $200,000 investment) at $2.00 per share for a period of five years (the “Warrant”). The Investor was granted registration rights for a registration statement in connection with a subsequent offering, subject to certain exceptions. If after sixty (60) days of this offering (i) a registration statement for the common stock underlying the Warrants has gone effective, and is still effective, (ii) the 20-day volume-weighted daily average price of the Company’s common stock exceeds $6 per share, (iii) the average daily trading volume is at least 500,000 shares during such 20-day period, and (iv) an event of default under the Note has not occurred, then the Company will have the option for thirty (30) days to elect to call the Investor’s unexercised Warrants at a price per Warrant equal to $0.10 per Warrant; provided that, the Company provides the Investor with written notice of its intent to redeem, and the Investor has thirty (30) days after receipt of notice to elect to exercise the Warrants. The Warrants also contain an anti-dilution provision which proportionately adjusts the exercise price of the Warrants if the Company issues common stock or securities convertible into common stock at a price per share less than the exercise price.
On November 16, 2022, the Note was the Company and the Investor entered into amendment to the Note, pursuant to which the balance under the note may be converted into the Company’s common stock immediately upon the completion of the Company’s initial public offering or some other event that results in the Company’s common stock becoming publicly traded as opposed to the balance under the note being convertible into common stock immediately upon issuance.
On November 16, 2022, the Note was the Company and the Investor entered into amendment to the GT Warrant, pursuant to which the GT Warrants will not be exercisable until the Company’s initial public offering or some other event that results in the Company’s common stock becoming publicly traded as opposed to the GT Warrant being exercisable into common stock immediately upon issuance.
Item 16. Exhibits and Financial Statement Schedules.
(a) | Exhibits. The list of exhibits following the signature page of this registration statement is incorporated herein by reference. | |
(b) | Financial Statements. See page F-1 for an index to the financial statements and schedules included in the registration statement. |
II-1 |
Item 17. Undertakings.
(a) | The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. | |
(b) | Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. | |
(c) | The undersigned registrant hereby undertakes that: |
(1) | For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. | |
(2) | For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
(3) | For the purpose of determining liability under the Securities Act of 1933 to any purchaser, if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. | |
(4) | For the purpose of determining liability of a registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of an undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
(i) | Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; | |
(ii) | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by an undersigned registrant; | |
(iii) | The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and | |
(iv) | Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
II-2 |
EXHIBIT INDEX
* To be filed by amendment
68 |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in Naples, Florida, on the 8th day of December, 2022.
SCRIPPS SAFE, INC. | ||
By: | /s/ Jacqueline von Zwehl | |
Jacqueline von Zwehl | ||
Chief Executive Officer, Chairman of the Board of Directors and Director |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jacqueline von Zwehl and Craig Steinhoff, and each one of them, as their true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as they might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated below:
Signature | Title | Date | ||
/s/ Jacqueline von Zwehl | Chief Executive Officer, Chairman of the Board of Directors and | December 8, 2022 | ||
Jacqueline von Zwehl | Director (Principal Executive Officer) | |||
/s/ Craig Steinhoff | Chief Financial Officer | December 8, 2022 | ||
Craig Steinhoff | (Principal Financial and Accounting Officer) | |||
/s/ James Egan | Director | December 8, 2022 | ||
James Egan | ||||
/s/ Tim Theriault | Director | December 8, 2022 | ||
Tim Theriault | ||||
/s/ Steven Ruhl | Director | December 8, 2022 | ||
Steven Ruhl | ||||
/s/ Doug Balog | Director | December 8, 2022 | ||
Doug Balog |
69 |
Exhibit 3.1
CERTIFICATE OF INCORPORATION
OF
Scripps Safe Inc.
FIRST: The name of the corporation is: Scripps Safe Inc. (the “Corporation”).
SECOND: The Corporation’s registered office in the State of Delaware is located at 16192 Coastal Highway, Lewes, Delaware 19958, County of Sussex. The registered agent in charge thereof is Harvard Business Services, Inc.
THIRD: The purpose of the Corporation is to engage in any lawful activity for which corporations may be organized under the Delaware General Corporation Law (the “DGCL’’).
FOURTH: The Corporation is authorized to issue a total number of shares of 15,000,000 shares having a par value of $0.0100000 per share. All shares shall be common shares and of one class.
F1FTH: The business and affairs of the Corporation shall be managed by or under the direction of the board of directors (the “Board”), and the directors comprising the Board (the “Directors”) need not be elected by written ballot. The number of Directors on the Board shall be set by a resolution of the Board.
SIXTH: The Corporation shall exist perpetually unless otherwise decided by a majority of the Board.
SEVENTH: In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board is authorized to amend or repeal the bylaws.
EIGHTH: The Corporation reserves the right to amend or repeal any provision in this Certificate of incorporation in the manner prescribed by the laws of the State of Delaware.
NINTH: The incorporator is Harvard Business Services, Inc., the mailing address of which is 16192 Coastal Highway, Lewes, Delaware 19958.
TENTH: To the fullest extent permitted by the DGCL, a Director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a Director. No amendment to, modification of, or repeal of this item Tenth shall apply to or have any effect on the liability of a Director for or with respect to any acts or omissions of such Director occurring prior to such amendment. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of Directors, then this Certificate should be read to eliminate or limit the liability of a Director of the Corporation to the fullest extent permitted by the DGCL, as so amended.
I, the undersigned, for the purpose of forming a corporation under the laws of the State of Delaware do make and file this certificate, and do certify that the facts herein stated are true; and have accordingly signed below, this August 23, 2021.
Signed and attested to by: | /s/ Michael J. Bell | |
Harvard Business Service, Inc., Incorporator | ||
By: Michael J. Bell, President |
Exhibit 3.7
By-Laws
of
Scripps Safe Inc.
(the ‘‘Corporation’’),
a Delaware corporation
ARTICLE I - REGISTERED AGENT AND REGISTERED OFFICE
Section 1. Registered Office; Registered Agent: The registered office of the Corporation in the State of Delaware shall initially be 16192 Coastal Highway, in the city of Lewes, County of Sussex. The Board of Directors may determine to change such registered office of the Corporation in the State of Delaware in its discretion. The registered agent initially in charge thereof shall be Harvard Business Services. Inc., until such agent resigns or is removed by the Board of Directors.
Section 2. Other Offices: The Corporation may also have offices in such other States or jurisdictions as the Board of Directors may from time to time designate.
ARTICLE II - SEAL
Section 1. Corporate Seal: The Corporate Seal shall have inscribed thereon the name of the Corporation, the year of its organization and the words “Corporate Seal, Delaware” or “Seal Delaware”. The Board of Directors may define any additional features of the Seal or amend any features not required for such a Seal under the Delaware General Corporation Law (the “DGCL”), in its discretion. The Seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise, as may be prescribed by law or custom or by the Board of Directors.
ARTICLE III - STOCKHOLDERS MEETINGS
Section 1. Place of Meetings: Meetings of stockholders may be held at any place, either within or without the State of Delaware and the United States, as may be selected from time to time by the Board of Directors. In the discretion of the Board of Directors, meetings may also be held by means of telephonic, video, or other remote communication whereby each party can hear and be heard by the other parties as may be designated from time to time by a resolution of the Board of Directors and as set forth in the notice for the relevant meeting.
Section 2. Annual Meetings: The annual meeting of the stockholders for the election of members of the Board of Directors (each a “Director”) and for the transaction of such other business as may properly come before the meeting shall be held at such date, time and place, if any, as shall be determined by the Board of Directors and stated in the notice of the meeting. If no date for the annual meeting is established or said meeting is not held on the date established as provided above, a special meeting in lieu thereof may be held or there may be action by written consent of the stockholders on matters to be voted on at the annual meeting, and such special meeting or written consent shall have for the purposes of these By Laws or otherwise all the force and effect of an annual meeting.
Section 3. Special Meetings: Special meetings of the stockholders may be called at any time by the President, a resolution of the Board of Directors, or by stockholders entitled to cast at least one-fifth (l/5) of the votes which all stockholders are entitled to cast. Upon written request to the Corporation of any person or persons who have duly called a special meeting, it shall be the duty of the Secretary to fix the date, place and time of the meeting, and to give due notice thereof to all the persons entitled to vote at the meeting. Business at all special meetings shall be confined to the objects stated in the notice of the meeting and the matters immediately germane thereto.
Section 4. Notice of Meetings: Notice of the place, if any, date. hour, the record date for determining the stockholders entitled to vote at the meeting or the specific details for accessing a meeting held through any remote means of communication, if any, of every meeting of stockholders shall be given by the Corporation not less than ten (10) days nor more than sixty (60) days before the meeting (unless a different time is specified by law) to every stockholder entitled to vote at the meeting as of the record date set forth such purpose. Notices of special meetings shall also specify the purpose or purposes for which the meeting has been called. Notices of meetings to stockholders may be given by mailing the same, addressed to the stockholder entitled thereto, at such stockholder’s mailing address as it appears on the records of the Corporation and such notice shall be deemed to be given when deposited in the U.S. mail, postage prepaid. Without limiting the manner by which notices of meetings otherwise may be given effectively to stockholders, any such notice may also be effectively provided by means of electronic transmission (meaning an “Electronic Transmission” in accordance with Section 232 of the DGCL). Notice of any meeting need not be given to any stockholder who shall, either before or after the meeting, submit a waiver of notice or who shall attend such meeting, except when the stockholder attends for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of the meeting shall be bound by the proceedings of the meeting in all respects as if due notice thereof had been given.
Section 5. Adjournment: Any meeting of the stockholders, annual or special, may be adjourned from time to time by a vote of the majority of the shares present to reconvene at the same or some other place, if any, and notice need not be given of any such adjourned meeting if the time, place, if any, thereof, and the means of remote communication, if any, are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. If, after the adjournment, a new record date is fixed for stockholders entitled to vote at the adjourned meeting, the Board of Directors shall fix a new record date for notice of the adjourned meeting and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at the adjourned meeting as of the record date fixed for notice of the adjourned meeting.
Section 6. Quorum: A majority of the outstanding shares of the Corporation entitled to vote at a given meeting, represented in person or by proxy, shall constitute a quorum at such meeting of stockholders. If less than a majority of the outstanding shares entitled to vote at such meeting is represented at a meeting, a majority of the shares so represented may adjourn the meeting as set forth above in Section 5 at any time without further notice.
Section 7. Voting; Proxies: Unless otherwise required by law or the Certificate of Incorporation, the election of Directors shall be decided by a plurality of the votes cast at a meeting of the stockholders by the holders of stock entitled to vote in the election. Unless otherwise required by law, the Certificate of Incorporation, or these By-Laws, any matter, other than the election of Directors, brought before any meeting of stockholders shall be decided by the affim1ative vote of the majority of shares present in person or represented by proxy at the meeting and entitled to vote on the matter. Each stockholder entitled to vote at a meeting of stockholders or to express consent to corporate action in writing without a meeting may authorize another person or persons to act for such stockholder by proxy or by a transmission permitted by Section 212(c) of the DGCL, but no such proxy shall be voted or acted upon after three (3) years from its date, unless the proxy provides for a longer period. A proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by delivering to the Secretary of the Corporation a revocation of the proxy or a new proxy bearing a later date. Voting at meetings of stockholders need not be by written ballot. The Corporation shall not directly or indirectly vote any share of its own stock; provided, however, that the Corporation may vote shares which it holds in a fiduciary capacity to the extent permitted by law.
Section 8. Consent In Lieu of Meetings: Any action required to be taken at any annual or special meeting of stockholders of a Corporation, or any action which may be taken at any annual or special meeting of such stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent in writing (including one provided through Electronic Transmission), setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing.
Section 9. Setting the Record Date: In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the determination of stockholders entitled to vote at the adjourned meeting and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for the determination of stockholders entitled to vote therewith at the adjourned meeting. In order that the Corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting. the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. If no record date has been fixed by the Board of Directors, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting: (a) when no prior action by the Board of Directors is required by law, the record date for such purpose shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation by delivery (by hand, or by certified or registered mail, return receipt requested) to its registered office in the State of Delaware, its principal place of business. or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded and (b) if prior action by the Board of Directors is required by law, the record date for such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.
Section 10. List of Stockholders: The Corporation shall prepare a complete list of the stockholders entitled to vote at any meeting of stockholders (provided, however, if the record date for determining the stockholders entitled to vote is less than ten (10) days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the tenth (10th) day before the meeting date), arranged in alphabetical order, and showing the address of each stockholder and the number of shares of each class of capital stock of the Corporation registered in the name of each stockholder at least ten (10) days before any meeting of the stockholders. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, on a reasonably accessible electronic network if the information required to gain access to such list was provided with the notice of the meeting or during ordinary business hours, at the principal place of business of the Corporation for a period of at least ten (10) days before the meeting. If the meeting is to be held at a place, the list shall also be produced and kept at the time and place of the meeting the whole time thereof and may be inspected by any stockholder who is present. If the meeting is held solely by means of remote communication, the list shall also be open for inspection by any stockholder during the whole time of the meeting as provided by applicable law. Except as provided by applicable law, the stock ledger of the Corporation shall be the only evidence as to who are the stockholders entitled to examine the stock ledger and the list of stockholders or to vote in person or by proxy at any meeting of stockholders.
Section 11. Conduct of Meetings: The Board of Directors may adopt by resolution such rules and regulations for the conduct of the meeting of the stockholders as it shall deem appropriate. At every meeting of the stockholders, the President, or, in his or her absence or inability to act, the person whom the President shall appoint, shall act as chairman of, and preside at, the meeting. The Secretary or, in his or her absence or inability to act, the person whom the chairman of the meeting shall appoint to serve as secretary of the meeting, shall act as secretary of the meeting and keep the minutes thereof. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the chairman of any meeting of the stockholders shall have the right and authority to prescribe such rules, regulations, and procedures and to do all such acts as, in the judgment of such chairman, are appropriate for the proper conduct of the meeting. Such rules, regulations, or procedures, whether adopted by the Board of Directors or prescribed by the chairman of the meeting, may include, without limitation, the following: (a) the establishment of an agenda or order of business for the meeting; (b) the determination of when the polls shall open and close for any given matter to be voted on at the meeting; (c) rules and procedures for maintaining order at the meeting and the safety of those present; (d) limitations on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies or such other persons as the chairman of the meeting shall determine; (e) restrictions on entry to the meeting after the time fixed for the commencement thereof; and (f) limitations on the time allotted to questions or comments by participants.
ARTICLE IV - DIRECTORS
Section 1. Board Management: The business and affairs of the Corporation shall be managed by or under the direction of its Board of Directors. The Board of Directors shall consist of such number of persons as the Board of Directors shall determine from time to time, in its discretion. In the absence of the Board of Director’s determination to change such number, the Corporation shall have three (3) Directors. Each Director shall hold office until a successor is duly elected and qualified or until the Director’s earlier death, resignation, disqualification, or removal. Any Director may resign at any time by notice given in writing (including through Electronic Transmission) to the Corporation. Such resignation shall take effect at the date of receipt of such notice by the Corporation or at such later time as is therein specified. Verbal resignation shall not be deemed effective until confirmed by the Director in writing (including through Electronic Transmission) to the Corporation. Except as prohibited by applicable law or the Certificate of Incorporation, the stockholders entitled to vote in an election of Directors may remove any Director from office at any time, with, or without cause, by the affirmative vote of a majority in voting power thereof.
Section 2. Regular Meetings: Regular meetings of the Board of Directors may be held without notice at such times and at such places as may be determined from time to time by the Board of Directors or its chairman.
Section 3. Special Meetings: Special meetings of the Board of Directors may be called by the Chairman of the Board of Directors on five (5) days’ notice to all Directors, either personally or by mail, courier service, or through Electronic Transmission; special meetings may be called by the President or Secretary in like manner and on like notice by written request (including by request through Electronic Transmission) to the Chairman of the Board of Directors.
Section 4. Telephonic or Web Meetings: Board of Director’s meetings or committee meetings, regular or special, may be held by means of telephone conference or other communications equipment by means of which all persons participating in the meeting can hear each other and be heard, as may be determined by the Board of Directors. Attendance by a Director in a meeting through the relevant media pursuant to this Section 4 shall constitute presence in person at such meeting.
Section 5. Quorum: A majority of the total number of Directors shall constitute a quorum of any regular or special meetings of the Directors for the transaction of business.
Section 6. Voting: Except as otherwise expressly required by these By-Laws, the Certificate of Incorporation, or by applicable law, the vote of a majority of the Directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.
Section 7. Consent In Lieu of Meeting: Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if all Directors or members of such committee, as the case may be, consent thereto in writing (including through Electronic Transmission), and the consents are filed with the minutes of proceedings of the Board of Directors or committee in accordance with the DGCL.
Section 8. Board Committees: The Board of Directors may designate one or more committees, each committee to consist of one or more of the Directors of the Corporation. The Board of Directors may designate one or more Directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. If a member of a committee shall be absent from any meeting, or disqualified from voting thereat, the remaining member or members present at the meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent permitted by the DGCL, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it to the extent so authorized by the Board of Directors. Unless the Board of Directors provides otherwise, at all meetings of such committee, a majority of the then authorized members of the committee shall constitute a quorum for the transaction of business, and the vote of a majority of the members of the committee present at any meeting at which there is a quorum shall be the act of the committee. Each committee shall keep regular minutes of its meetings. Unless the Board of Directors provides otherwise, each committee designated by the Board of Directors may make, alter, and repeal rules and procedures for the conduct of its business. In the absence of such rules and procedures each committee shall conduct its business in the same manner as the Board of Directors conducts its business pursuant to this Article IV.
Section 9. Compensation: Directors may receive equity compensation or such fees as the Board of Directors may determine from time to time. In addition, a fixed sum per Board of Directors or committee meeting and any expenses of attendance may be allowed for attendance at each regular or special meeting. Nothing herein contained shall be construed to preclude any director from serving the Corporation as an officer or employee and receiving compensation therefore.
ARTICLE V -OFFICERS
Section 1. Executive Officers: The executive officers of the Corporation shall be chosen by the Board of Directors. The initial officers shall be: President, Secretary, and Treasurer. The Board may choose one or more Vice Presidents and such other officers as the Board of Directors shall deem necessary, and may delegate the selection of lesser officers to one or more executive officers of the Corporation. The Board of Directors may also choose a Chairman from among its own members. Any number of offices may be held by the same person, including a Director.
Section 2. Salaries: Salaries of all officers and agents of the Corporation shall be determined and fixed by the Board of Directors. The primary terms of such officers’ and agents’ compensation, responsibilities, obligations and other tem1s of employment shall be set forth in an employment agreement between the officer and the Corporation.
Section 3. Term of Office: Subject to the terms of any employment agreement between the Corporation and the officers, the officers of the Corporation shall serve at the pleasure of the Board of Directors and shall hold office until their successors are chosen and have qualified. Any officer or agent elected or appointed by the Board may be removed by the Board of Directors whenever, in its judgment the best interest of the Corporation will be served thereby.
Section 4. President: The President shall be chief executive officer of the Corporation, shall preside at all meetings of the stockholders, and shall have general and active management of the business of the Corporation. He or she may be an ex officio member of all committees if provided for by the Board of Directors, and shall have the general power and duties of supervision and management, the scope of which shall be set by the Board of Directors.
Section 5. Secretary: The Secretary shall attend all sessions of the Board of Directors and all meetings of the stockholders and act as clerk thereof, and record all votes of the Corporation and the minutes of all its transactions in a book to be kept for that purpose, and shall perform like duties for all the committees of the Board of Directors when required. He or she shall give, or cause to be given, notice of all meetings of the stockholders and of the Board of Directors, and such other duties as may be prescribed by the Board of Directors or President, under whose supervision shall be. He or she shall keep in safe custody the Seal of the Corporation, and when authorized by the Board of Directors, affix the same to any instrument requiring it.
Section 6. Treasurer: The Treasurer shall have custody of the corporate funds and securities and shall keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation and shall keep the moneys of the Corporation in a separate account to the credit of the Corporation. He or she shall disburse the funds of the Corporation as may be ordered by the Board, taking proper vouchers for such disbursements, and shall render to the President and Directors, at the regular meetings of the Board or whenever they may require it, an account of all his transactions as Treasurer and of the financial condition of the Corporation.
Section 7. Delegation; Customary Powers: In case any officer is absent, or for any other reason that the Board of Directors may deem sufficient, the President or the Board of Directors may delegate for the time being the powers or duties of such officer to any other officer or to any Director. Each officer of the Corporation shall have in addition to the duties and powers specifically set forth herein such duties and powers as are customa1ily incident to such officer’s office, and such duties and powers as may be designated from time to time by the Board of Directors.
ARTICLE VI - CORPORATE RECORDS
Section 1. Maintenance of Records: Any records administered by or on behalf of the Corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be maintained on any information storage device, method, or one or more electronic networks or databases (including one or more distributed electronic networks or databases); provided that the records so kept can be converted into clearly legible paper form within a reasonable time, and, with respect to the stock ledger, the records so kept comply with Section 224 of the DGCL. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to applicable law.
Section 2. Inspection Rights: Any stockholder of record, in-person or by attorney or other agent, shall, upon written demand under oath stating the purpose thereof, have the right during the usual hours of business to inspect for any proper purpose the Corporation’s stock ledger, a list of its stockholders, and its minute of Stockholder meetings for the past two (2) years. A proper purpose shall mean a purpose reasonably related to such person’s interest as a stockholder. In every instance where an attorney or other agent shall be the person who seeks the right to inspection, the demand under oath shall be accompanied by a power of attorney or such other writing which authorizes the attorney or other agent to so act on behalf of the stockholder. The demand under oath shall be directed to the Corporation at its registered office or at its principal place of business.
ARTICLE VII - STOCK CERTIFICATES, DIVIDENDS, ETC.
Section 1. Certification of Shares: The shares of stock of the Corporation may or may not be represented by ce1tificates; the Board of Directors may provide by resolution or resolutions that some or all of any class or series shall be uncertificated shares that may be evidenced by a book-entry system maintained by the registrar of such stock. If shares are represented by certificates, such certificates shall be in the form, other than bearer form, approved by the Board of Directors. The certificates representing shares of stock of each class shall be signed by, or in the name of, the Corporation by any two authorized officers of the Corporation. Any or all such signatures may be facsimiles. Although any officer, transfer agent, or registrar whose manual or facsimile signature is affixed to such a certificate ceases to be such officer, transfer agent, or registrar before such certificate has been issued, it may nevertheless be issued by the Corporation with the same effect as if such officer, transfer agent, or registrar were still such at the date of its issue.
Section 2. Transfers: Stock of the Corporation shall be transferable in the manner prescribed by law and in these by-laws. Any transfer of stock by a stockholder must be made in compliance with the Securities Act of 1933, as amended, as well as similar state securities laws. Transfers of stock shall be made on the books of the Corporation only by the holder of record thereof, by such person’s attorney lawfully constituted in w1iting and, in the case of certificated shares, upon the surrender of the certificate thereof, which shall be cancelled before a new certificate or uncertificated shares shall be issued. No transfer of stock shall be valid as against the Corporation for any purpose until it shall have been entered in the stock records of the Corporation by an entry showing from and to whom transferred. To the extent designated by the President or the Treasurer of the Corporation, the Corporation may recognize the transfer of fractional uncertificated shares, but shall not otherwise be required to recognize the transfer of fractional shares.
Section 3. Lost Certificates: The Board of Directors may direct a new certificate or uncertificated shares to be issued in place of any certificate theretofore issued by the Corporation alleged to have been lost, stolen, or destroyed upon the making of an affidavit of that fact by the owner of the allegedly lost, stolen, or destroyed certificate. When authorizing such issue of a new certificate or uncertificated shares, the Board of Directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of the lost, stolen, or destroyed certificate, or the owner’s legal representative to give the Corporation a bond sufficient to indemnify it against any claim that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen, or destroyed or the issuance of such new certificate or uncertificated shares.
Section 4. Dividends: Subject to applicable law and the Certificate of Incorporation, dividends upon the shares of capital stock of the Corporation may be declared by the Board of Directors at any regular or special meeting of the Board of Directors. Dividends may be paid in cash, in property, or in shares of the Corporation’s capital stock, unless otherwise provided by applicable law or the Certificate of Incorporation.
Section 5. Reserves: Before payment of any dividend there may be set aside out of the net profits of the corporation such sum or sums as the directors, from time to time, in their absolute discretion, think proper as a reserve fund to meet contingencies, or for equalizing dividends, or for repairing or maintaining the property of the corporation, or for such other purpose as the directors shall think conducive to the interests of the corporation, and the directors may abolish any such reserve in the manner in which it was created.
ARTICLE VIII- INDEMNIFICATION AND ADVANCEMENT
Section 1. Definitions: Solely for purposes of this Article VIII the following terms shall have the definitions set forth below:
(a) “Disinterested Director” means, with respect to each Proceeding in respect of which indemnification is sought hereunder, a Director of the Corporation who is not and was not a party to such Proceeding.
(b) “Expenses” means all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of expert witnesses, private investigators and professional advisors (including, without limitation, accountants and investment bankers), travel expenses, duplicating costs, printing and binding costs, costs of preparation of demonstrative evidence and other courtroom presentation aids and devices, costs incurred in connection with document review, organization, imaging and computerization, telephone charges, postage, delivery service fees, and all other disbursements, costs or expenses of the type customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settling or otherwise participating in, a Proceeding.
(c) “Non-Officer Employee” means any person who serves or has served as an employee or agent of the Corporation, but who is not or was not a Director or Officer:
(d) “Officer” means any person who serves or has served the Corporation as an officer appointed by the Board of Directors of the Corporation:
(e) “Proceeding” means any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or investigative.
Section 2. Indemnification of Directors and Officers: Subject to the operation of Section 4 of this Article VIII, each Director and Officer shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment) against any and all Expenses, judgments, penalties, fines and amounts reasonably paid in settlement that are incurred by such Director or Officer or on such Director’s or Officer’s behalf in connection with any threatened, pending or completed Proceeding or any claim, issue or matter therein, which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director’s or Officer’s status or conduct as such, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The rights of indemnification provided by this Section 2 shall continue as to a Director or Officer after he or she has ceased to be a Director or Officer and shall inure co the benefit of his or her heirs, executors, administrators and personal representatives.
Section 3. Indemnification of Non-Executive Employees: Subject to the operation of Section 4 of this Article VIII of these By-Laws, each Non-Officer Employee may, in the discretion of the Board of Directors of the Corporation, be indemnified by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended, against any or all Expenses, judgments, penalties. fines and amounts reasonably paid in settlement that are incurred by such Non-Officer Employee or on such Non-Officer Employee’s behalf in connection with any threatened, pending or completed Proceeding, or any claim, issue or matter therein, which such Non-Officer Employee is, or is threatened to be made, a party to or participant in by reason of such Non-Officer Employee’s status or conduct as such, if such Non-Officer Employee acted in good faith and in a manner such Non-Officer Employee reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The rights of indemnification provided by this Section 3 shall exist as to a Non-Officer Employee after he or she has ceased to be a Non-Officer Employee and shall inure to the benefit of his or her heirs, personal representatives, executors and administrators. Notwithstanding the foregoing, the Corporation may indemnify any Non-Officer Employee seeking indemnification in connection with a Proceeding initiated by such Non-Officer Employee only if such Proceeding was authorized by the Board of Directors of the Corporation.
Section 4. Good Faith: Unless ordered by a court, no indemnification shall be provided pursuant to this Article VIII to a Director, to an Officer or to a Non-Officer Employee unless a determination shall have been made that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal Proceeding, such person had no reasonable cause to believe his or her conduct was unlawful. Such determination shall be made by (a) a majority vote of the Disinterested Directors, even though less than a quorum of the Board of Directors, (b) a committee comprised of Disinterested Directors, such committee having been designated by a majority vote of the Disinterested Directors (even though less than a quorum), (c) if there are no such Disinterested Directors, or if a majority of Disinterested Directors so directs, by independent legal counsel in a written opinion, or (d) by the stockholders of the Corporation.
Section 5. Advancement of Expenses to Directors Prior to Final Disposition:
(a) The Corporation shall advance all Expenses incurred by or on behalf of any Director in connection with any Proceeding in which such Director is involved by reason of such Director’s Corporate Status within ten (10) days after the receipt by the Corporation of a written statement from such Director requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Director and shall be preceded or accompanied by an undertaking by or on behalf of such Director to repay any Expenses so advanced if it shall ultimately be determined that such Director is not entitled to be indemnified against such Expenses.
(b) If a claim for advancement of Expenses hereunder by a Director is not paid in full by the Corporation within ten (10) days after receipt by the Corporation of documentation of Expenses and the required undertaking, such Director may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and if successful in whole or in part, such Director shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such advancement of Expenses under this Article VIII shall not be a defense to the action and shall not create a presumption that such advancement is not permissible. The burden of proving that a Director is not entitled to an advancement of Expenses shall be on the Corporation.
(c) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Director has not met any applicable standard for indemnification set forth in the DGCL.
Section 6. Advancement of Expenses to Officers and Non-Officer Employees Prior to Final Disposition:
(a) The Corporation may, at the discretion of the Board of Directors of the Corporation. advance any or all Expenses incurred by or on behalf of any Officer and Non-Officer Employee in connection with any Proceeding in which such is involved by reason of such person’s status and/or actions as such upon the receipt by the Corporation of a statement or statements from such Officer or Non-Officer Employee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Officer and Non-Officer Employee and shall be preceded or accompanied by an undertaking by or on behalf of such to repay any Expenses so advanced if it shall ultimately be determined that such Officer or Non-Officer Employee is not entitled to be indemnified against such Expenses.
(b) In any suit brought by the Corporation to recover an advancement of Expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such Expenses upon a final adjudication that the Officer or Non-Officer Employee has not met any applicable standard for indemnification set forth in the DGCL.
Section 7. Contractual Nature of Rights:
(a) The foregoing provisions of this Article VIII shall be deemed to be a contract between the Corporation and each Director and Officer entitled to the benefits hereof at any time while this Article VIII is in effect, and any repeal or modification thereof shall not affect any rights or obligations then existing with respect to any state of facts then or theretofore existing or any Proceeding theretofore or thereafter brought based in whole or in part upon any such state of facts.
(b) If a claim for indemnification hereunder by a Director or Officer is not paid in full by the Corporation within sixty (60) days after receipt by the Corporation of a written claim for indemnification, such Director or Officer may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, such Director or Officer shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such indemnification under this Article VIII shall not be a defense to the action and shall not create a presumption that such indemnification is not permissible. The burden of proving that a Director or Officer is not entitled to indemnification shall be on the Corporation.
ARTICLE IX - AMENDMENTS
Section 1. These By-Laws may be supplemented. amended, or repealed by the Board or by a vote of stockholders entitled to cast at least a majority of the votes which all stockholders are entitled to cast thereon, at any regular or special meeting of the stockholders, duly convened after notice to the stockholders of that purpose; provided, that (a) the Board of Directors may not alter, amend or repeal any provision of these By Laws which under the DGCL, by the Certificate of Incorporation or by these By Laws requires action by the stockholders and (b) any alteration, amendment or repeal of these By Laws by the Board of Directors and any new By Law adopted by the Board of Directors may be altered, amended or repealed by the stockholders as set forth in this Section.
ARTICLE X - MISCELLANEOUS PROVISIONS
Section 1. Checks: All checks or demands for money and notes of the corporation shall be signed by such officer or officers as the Board of Directors may from time to time designate.
Section 2. Fiscal Year: The fiscal year of the Corporation shall be the calendar year, unless otherwise determined by the Board of Directors.
Section 3. Delaware Chancery Forum Selection: Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for: (a) any derivative action or proceeding brought on behalf of the Corporation, (b) any action asserting a claim for breach of a fiduciary duty owed by any Director, officer, employee or agent of the Corporation to the Corporation or the Corporation’s stockholders, (c) any action asserting a claim arising pursuant to any provision of the DGCL, the Certificate of Incorporation or these By-Laws or (d) any action asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein.
Section 4. Notice: Whenever notice is required to be given to any person by these By-Laws, such notice shall be deemed given effectively if given in person, by mail addressed to such person at such person’s address as it appears on the records of the Corporation, by facsimile, or by any means of Electronic Transmission.
Section 5. Waiver of Notice: Whenever any written notice is required by these by-laws, a waiver thereof in writing, signed by the person or persons entitled to such a notice, whether before or after the time stated therein, including a communication sent by means of Electronic Transmission bearing the name of the person or persons entitled to notice, shall be deemed equivalent to the giving of such notice. Attendance of a person either in person or by proxy at any meeting shall constitute a waiver of notice of such meeting, except where a person attends a meeting for the express purpose of objecting to the transaction of any business because the meeting was unlawfully convened.
* * * * *
Exhibit 10.1
Scripps Safe, Inc.
EMPLOYMENT AGREEMENT
This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into effective April 1, 2022 (the “Effective Date”), by Jacqueline Von Zwehl (“Executive”) and Scripps Safe, Inc. (the “Company”, together with Executive, the “Parties”).
RECITALS
A. Company desires to hire Executive as Chief Executive Officer to compensate Executive for Executive’s services to the Company; and
B. Executive wishes to be employed by the Company and provide services to the Company in return for certain compensation; and
C. Company and Executive desire to enter into this Agreement
Accordingly, in consideration of the mutual promises and covenants contained in this Agreement and for other good and valuable consideration, the sufficiency of which is acknowledged, the parties agree to the following:
1. DEFINITIONS.
1.1 “Affiliates” means, with respect to a Party, any entity which, directly or indirectly, is controlled by or is under common control with such Party.
1.2 “Board of Directors” or “Board” means the Board of Directors of the Company.
1.3 “Florida Office Location” means the current location of the Company’s offices in Naples, Florida, or such other location the Company may elect to relocate such offices.
1.4 “Cause” will be limited to mean the following:
(i) Willful misfeasance or nonfeasance by Executive that materially injures the reputation, business or business relationships of the Company or its Affiliates, or any of their respective officers, directors or employees and such action or failure is not remedied or reasonable steps to affect such remedy are not commenced within thirty (30) days following receipt of written notice;
(ii) Any act involving moral turpitude or conviction of a crime that reflects in some material fashion unfavorably upon the business or business relationships of the Company, its Affiliates, or any of its officers, directors or employees;
(iii) The willful and continued failure to perform substantially the Executive’s duties or to follow the reasonable direction of the principal executive within thirty (30) business days after receipt by Executive of written notice of such failure, other than by reason of Disability (as defined below) or approved leave of absence; or
(iv) Willful and prolonged absence from work by Executive, other than by reason of Disability, approved leave of absence, or otherwise in compliance with Company Policies, whether paid or unpaid.
1.5 “Code” will mean the Internal Revenue Code of 1986, as amended from time to time, and the regulations promulgated thereunder.
1.6 “Company Policies” will mean all policies and procedures of the Company and its Affiliates that are applicable to employees of the Company as they may be adopted, revised or deleted from time to time in the sole discretion of the Company or its Affiliates, as the case may be, in whatever form such policies and procedures (including all revisions and updates thereto) are made available to Executive after notification of such availability.
1.7 “Disability” will mean the earliest of the date on which Executive is deemed disabled under: (i) the long-term disability policy maintained by the Company; (ii) Code Section 22(e)(3); or (iii) the determination of the Social Security Administration. Notwithstanding the foregoing, Executive will not be considered to have suffered a Disability under subparagraph (ii) above if Executive timely provides medical certification from a qualified licensed physician that Executive is able to perform the essential functions of Executive’s position, with or without reasonable accommodation.
1.8 “Good Reason” will mean the occurrence of any of the following without Executive’s prior written consent:
(i) the removal of Executive as Chief Executive Officer of the Company, assignment to Executive of any duties or responsibilities materially inconsistent with Executive’s position, including any material diminution of Executive’s status, title, authority, duties or responsibilities or any other action that results in a material diminution in such status, title, authority, duties or responsibilities;
(ii) the reduction by five percent (5%) or more of Executive’s base salary or the reduction by five percent (5%) or more of the aggregate of Executive’s base salary and Incentive Compensation target cumulatively during any one year period, without Executive’s consent, or any action that materially adversely affects Executive’s overall compensation and benefits package, provided that the Company may change the benefits package if those changes are made on a non-discriminatory basis for all employees who participate in the benefits plans available to Executive;
(iii) the failure of the Company to pay to Executive any portion or installment of any salary, Incentive Compensation or deferred compensation within thirty (30) days of the date such compensation is due; or
(iv) requiring Executive perform her duties at a location outside of the Florida Office Location.
1.9 “Restricted Business” will mean the business of Business of the Company existing as of the Termination Date, which as of the date of this Agreement means the business of providing security and storage solutions for the pharmaceutical, healthcare, and drug industries.
1.9 “Termination Date” will mean Executive’s last day of employment, regardless of whether termination is on account of death, Disability, with or without Cause, or a resignation with or without Good Reason.
2. EMPLOYMENT BY THE COMPANY.
2.1 POSITION. Subject to the terms set forth in this Agreement, the Company agrees to employ Executive in the position of Chief Executive Officer and Executive hereby accepts such employment and position. During the term of Executive’s employment with the Company, Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention to the business of the Company.
2.2 Duties. Executive will report to the Board of Directors of the Company and will perform such duties as are normally associated with Executive’s position as are assigned to Executive from time to time. Executive will perform Executive’s duties under this Agreement at the Company’s Florida Office Location.
2.3 TERM. The term of this Agreement will run from the Effective Date until such time as it is terminated in accordance with the terms of this Agreement.
2.4 COMPANY POLICIES AND BENEFITS. The employment relationship between the parties will be subject to the Company Policies. Subject to any specific exceptions or conditions set forth in Section 3.3, Executive will be eligible to participate on substantially the same basis as similarly situated Executives in the Company’s benefit plans and programs in effect from time to time during Executive’s employment; provided, however, that participation and awards under any equity compensation or equity Incentive Compensation plan or program will be determined by the Board of Directors on an individual, case-by-case basis. All matters of eligibility for coverage or benefits under any benefit plan or program will be determined in accordance with the provisions of such plan or program. The Company reserves the right to change, alter, or terminate any benefit plan or program in its sole discretion; provided, however, that no such change, alteration or termination will change any vested or accrued benefits or rights of Executive. Notwithstanding the foregoing, in the event that the terms of this Agreement expressly provide Executive with benefits that differ from the Company’s generally available benefits, then the terms of this Agreement will control.
3. COMPENSATION AND BENEFITS.
3.1 SALARY. Executive will receive for Executive’s services to be rendered under this Agreement an initial annualized base salary of $180,000 (the “Base Salary”). Upon the company’s IPO on the NASDAQ, Executive’s annualized base salary will be increased to $325,000, subject to bi-annual review and adjustment from time to time by the Company. The Base Salary will be payable in accordance with Company’s standard payroll practices.
(a) Annual Bonus. Executive shall be eligible to earn annual bonus compensation based on the achievement of certain goals and performance criteria established by the Board. The Company agrees that Executive’s target annual bonus for fiscal year(s) 2022-2025 will be minimum of 20% of the current Base Salary with a maximum payout of up to 150% based on target achievement.
(b) Equity Incentive.
(1) Initial Grant. Executive is eligible to participate in the Company’s Incentive Stock Plan, subject to Board approval. Executive is eligible to receive equity bonuses and stock options.
3.2 EXPENSE REIMBURSEMENT. The Company will reimburse Executive for reasonable business expenses incurred by Executive during the period Executive is employed by the Company, in accordance with the Company’s standard expense reimbursement policy.
3.3 PAID TIME OFF. Executive is entitled to five weeks’ paid vacation during each calendar year. If Executive does not take the full vacation available in any year, the unused vacation may be carried over to the next calendar year, and Executive will be compensated for it.
3.4 BENEFITS. As provided in Section 2.4, Executive will receive benefits in accordance with the Company’s standard benefits plan and policies, as amended from time to time.
4. NON-COMPETITION; NON-SOLICITATION; CONFIDENTIALITY.
4.1 NON-COMPETITION. Executive acknowledges that Executive will gain extensive and valuable experiences and knowledge in the business conducted by the Company and its Affiliates and will have extensive contacts with customers of the Company and its Affiliates. Accordingly, in consideration of the mutual promises contained in this Agreement, Executive covenants and agrees with the Company that, during the term of this Agreement and for the Applicable Severance Payout Period (as defined in Section 7.2(c)) following the Executive’s Termination Date, Executive will not compete directly or indirectly with the Company or its Affiliates. Competing directly or indirectly with the Company and its Affiliates will mean engaging or having a material interest, directly or indirectly, as owner, employee, officer, director, partner, venturer, stockholder, capital investor, consultant, agent, principal, advisor or otherwise, either alone or in association with others, in the operation of any entity’s division or group which engages in the Restricted Business. Competing directly or indirectly with the Company or its Affiliates, as used in this Agreement, will not include having an ownership interest as an inactive investor, which for purposes of this Agreement will mean the beneficial ownership of less than five percent (5%) of the outstanding shares of any series or class of securities of any competitor of the Company, which shares are publicly traded in the securities markets. This Section 4.1 will cease to apply in the event the Company is in breach of any obligations to provide severance benefits in accordance with Section 7.2 and fails to cure such breach within twenty (20) days of receiving written notice of such breach from Executive. Executive agrees that any violation of this Section 4.1 by Executive, as determined by a court of law, will result in termination of the Company’s obligations to provide severance benefits under this Agreement and in the event of such termination, Executive will be required to repay to the Company any such severance benefits previously received.
4.2 NON-SOLICITATION. Executive acknowledges that Executive will have extensive contacts with employees and customers of the Company. Accordingly, in consideration of the mutual promises contained in this Agreement, Executive covenants and agrees that during the term of this Agreement, and for the Applicable Severance Payout Period following Executive’s Termination Date, Executive will not (i) solicit, raid, entice or induce any employee of the Company or its Affiliates to leave the employ of the Company or its Affiliates; (ii) interfere with the relationship of the Company or its Affiliates with any such employees, including, but not limited to, hiring such employee (except pursuant to a general solicitation which is not directed specifically to any such employees); or (iii) personally target or solicit customers of the Company or its Affiliates to purchase products or services in competition with the Company’s or its Affiliates products or services or to terminate a relationship with the Company or its Affiliates. This Section 4.2 will cease to apply in the event the Company is in breach of any obligations to provide severance benefits in accordance with Section 7.2 and fails to cure such breach within twenty (20) days of receiving notice of such breach from Executive. Executive agrees that any violation of this Section 4.2 by Executive, as determined by a court of law, will result in termination of the Company’s obligations to provide severance benefits hereunder and in the event of such termination, Executive will be required to repay to the Company any such severance benefits previously received.
4.3 CONFIDENTIALITY. Executive acknowledges that Executive will have access to certain information related to the business, operations, future plans and customers of the Company and its Affiliates, the disclosure or use of which could cause the Company substantial losses and damages. Accordingly, Executive acknowledges and affirms the terms and conditions of the confidentiality agreement signed by Executive with the Company on the date hereof in connection with Executive’s employment (the “Confidentiality Agreement”), which is incorporated by reference. The terms and conditions of Sections 4.1 and 4.2 will take precedence over any non-competition/non-solicitation provisions contained in the Confidentiality and Non-Compete Agreement
4.4 Derogatory Statements. During the term of this Agreement and for the Applicable Severance Payout Period (as defined in Section 7.2(c)) following the Executive’s Termination Date, each Party (on behalf of such Party and such Party’s Affiliates) agrees that such Party will not during such period make public statements in derogation of the other Party or its Affiliates; provided, that, the foregoing covenant regarding making public statements in derogation of the other Party or its Affiliates shall not restrict such Party from exercising protected rights to the extent that such rights cannot be waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency; provided, further, that such compliance does not exceed that required by the law, regulation, or order and such Party provides prompt written notice of any such order to the other Party.
5. OUTSIDE ACTIVITIES. Except with the prior written consent of the principal executive of the Company, Executive will not, while employed by the Company, undertake or engage in any other employment, occupation, consulting, advisory, or other business enterprise or business activities that would interfere with Executive’s responsibilities and the performance of Executive’s duties under this Agreement with the exception that engaging in charitable, civic, community activities and serving on boards of directors of charitable or civic organizations will not constitute interference, provided the time spent in such activities does not negatively impact Executive’s performance of Executive’s duties under this Agreement.
6. NO CONFLICT WITH EXISTING OBLIGATIONS. Executive represents that Executive’s performance of all the terms of this Agreement and as an executive of the Company does not and will not breach any agreement or obligation of any kind made prior to Executive’s employment by the Company, including agreements or obligations Executive may have with prior employers or entities for which Executive has provided services. Executive has not entered into, and Executive agrees that Executive will not enter into, any agreement or obligation, either written or oral, that conflicts with Executive’s obligations hereunder, it being acknowledged and agreed that Executive (i) shall not continue to perform any services under any agreement entered into prior to the date hereof without the Company’s prior written consent and (ii) has delivered true and complete copies of all such agreements to the Company prior to the date hereof.
7. TERMINATION OF EMPLOYMENT. Executive’s employment under this Agreement shall terminate:
(a) Resignation by Executive. Upon the effective date (if any) of Executive’s resignation;
(b) Termination by the Company for Cause. Immediately upon written notice by the Company to Executive for Cause;
(c) Death. Immediately upon the death of Executive; or
(d) Disability. Upon the date that is 10 days after the Company gives written notice to Executive stating that Executive’s employment is being terminated on account of Executive’s “Disability” (as defined below).
(e) Definitions. For purposes of this Agreement:
(1) “Cause” will exist if the Company determines that Executive willfully or through gross negligence acted or failed to act in a manner that materially damages the Company, any Affiliate, its stockholders or the Company’s or any Affiliate’s financial condition or reputation or involves fraud. Notwithstanding anything in this to the contrary, the failure of the Company or any Affiliate to achieve budgeted or projected financial or similar performance objectives shall not, in and of itself, be considered a breach of any obligation under this Agreement or to otherwise constitute “Cause” as defined herein.
(2) “Disability” shall be deemed to exist if Executive is unable, despite reasonable accommodation, to perform the essential functions of her current position due to physical illness, injury or other medical condition for a period of not less than six (6) full months in any 12-month period.
7.1 STANDARD TERMINATION PAYMENTS.
a. Salary and Reimbursements. Regardless of the reason for termination, the Company will pay Executive on the first regularly scheduled payroll date following Executive’s Termination Date any Base Salary accrued but unpaid as of Executive’s Termination Date, the value of any accrued paid time off unused by Executive as of Executive’s Termination Date, and any unpaid Expense Reimbursement, so long as the Expense Reimbursement complies with the Company guidelines for such requests.
7.2 SEVERANCE BENEFITS — TERMINATION WITH CAUSE/RESIGNATION
a. Company’s Right to Terminate. The Company will have the right to terminate Executive’s employment under this Agreement for any of the following reasons:
(i) upon Executive’s Disability in accordance with Section 7.3;
(ii) for Cause, by giving notice as described in Section 7.6;
b. Executive’s Right to Terminate. Executive will have the right to resign Executive’s employment with the Company at any time, as well as following an event constituting Good Reason.
c. Severance Benefits. In the event that the Company terminates Executive’s employment with Cause or Executive resigns for Good Reason, Executive will receive, in addition to the Standard Termination Payments, the following:
(i) Severance Payments. Provided that Executive delivers to the Company a fully executed and complete release (excluding the release of any obligations of the Company or its affiliates, or any claims Executive may have without revocation, in favor of the Company and its Affiliates, and in form and substance satisfactory to the Company (the “Release”) within thirty (30) days of Executive’s Termination Date (the “Execution Deadline”), the Company will provide to Executive (a) an amount equal to twelve (12) months of Executive’s then-current Base Salary. The Severance Payments will be payable in equal installment payments over the twelve (12) month period (“Applicable Severance Payout Period”) starting retroactively from the Termination Date in accordance with the Company’s regular bi-weekly paydays, or if different, in accordance with the Company’s customary payroll practices.
(ii) COBRA Benefits. In the event Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) in accordance with the COBRA materials that will be provided to Executive by the Company or the Company’s third party COBRA administrator, the Company will pay the Company’s portion (based upon the Company’s monthly premium subsidy immediately prior to the Termination Date) of Executive’s COBRA premium for the same medical, dental and vision benefit plan coverage (“Group Health Plan Coverage”) Executive and Executive’s dependents had as of the Termination Date for the Applicable Severance Payout Period, or until Executive elects to receive group medical, dental and vision insurance from another source, whichever occurs first. Payment of COBRA premiums (“COBRA Benefits”) will be made by the Company on Executive’s and Executive’s dependents behalf directly to the Group Health Plan’s COBRA administrator. Executive will be mailed a COBRA packet at her last known address. Such packet will contain additional information about Executive’s COBRA rights and responsibilities.
(iii) Severance Benefits Contingent on Execution of Release. Notwithstanding the foregoing, any Severance Payments that are otherwise payable before the Execution Deadline will be withheld pending Executive’s execution and delivery of the Release and will be paid on the payroll date immediately following the Execution Deadline. For the avoidance of doubt, Executive will forfeit the right to receive any Severance Payments or COBRA Benefits (to the extent such forfeiture of COBRA Benefits is permissible under applicable law) if Executive fails to deliver the Release by the Execution Deadline. For this forfeiture to take effect, the Release will not materially alter Executive’s rights to receive any payments or benefits under this Agreement; enlarge Executive’s obligations under this Agreement, including without limitation, Executive’s covenants of non-competition and non-solicitation; or impose material new obligations on Executive.
d. Compliance with Code Section 409A. The Company and Executive intend that (i) payments under Section 7.2(c)(i) will be made on account of an involuntary separation from service within the meaning of Treasury Regulation section 1.409A-1(n)(1) or a separation from service for good reason within the meaning of Treasury Regulation section 1.409A-1(n)(2), (ii) amounts paid under Section 7.2(c)(i) constitute separation pay exempt from Internal Revenue Code Section 409A under Treasury Regulation section 1.409A-1(b)(9)(iii), and (iii) Payments under Section 7.2(c)(ii) will be exempt from Code Section 409A as a non-taxable fringe benefit to Executive, but neither party will be liable to the other in the event any such payment receives different tax treatment. In the event any of these payments is determined to be deferred compensation subject to Internal Revenue Code Section 409A, the payments will comply with Section 7.7.
7.3 TERMINATION UPON DEATH OR DISABILITY OF EXECUTIVE.
a. Upon Executive’s death while employed pursuant to this Agreement, this Agreement will automatically terminate.
b. Subject to applicable state and federal law, the Company will at all times have the right, upon thirty (30) days written notice to Executive, to terminate this Agreement based on Executive’s Disability.
c. In the event Executive’s employment is terminated due to Executive’s death or Disability, the Company will pay to Executive or Executive’s heirs or estate all Standard Termination Payments together with any other compensation and benefits payable to Executive through the Executive’s Termination Date under any compensation or benefit plan, program or arrangement during such period. In addition, if Executive, or if Executive is deceased, a participant on Executive’s health insurance plan, elects COBRA coverage, the Company will pay its third party administrator the full cost of COBRA coverage for twelve (12) months from the Executive’s Termination Date.
7.4 Notice; Effective Date of Termination.
a. Termination of Executive’s employment pursuant to this Agreement will be effective on the earliest of:
(i) excluding a termination due to Executive’s death or Disability, the date on which the Company gives notice to Executive of Executive’s termination, with or without Cause, unless the Company specifies a later date, in which case, termination will be effective as of such later date;
(ii) the date of Executive’s death;
(iii) ten (10) days after the Company gives notice to Executive of Executive’s termination on account of Executive’s Disability; or
(iv) thirty (30) days after Executive gives written notice to the Company of Executive’s resignation, provided that the Company may set a termination date at any time between the date of notice and the 30th day thereafter (i.e., the effective date of resignation, but for this Section 7.5(a)), in which case the Executive’s resignation will be effective as of such earlier date (the date on which Executive’s resignation becomes effective, the “Actual Resignation Effective Date”).
b. In the event that notice of a termination is given orally, at the other party’s request, the party giving notice must provide written confirmation of such notice within five (5) business days of the request. In the event of a termination for Cause, written confirmation will specify the subsection(s) of the definition of Cause being relied on by the Company to support the decision to terminate for Cause, to afford Executive a reasonable opportunity to effect a cure, if permitted and possible under the applicable subsections of the definition of Cause. In the event of a resignation for Good Reason, written confirmation will specify the subsection(s) of the definition of Good Reason being relied on by Executive to support the decision to resign for Good Reason, to afford the Company a reasonable opportunity to cure under the applicable subsections of the definition of Good Reason.
7.5 COOPERATION WITH THE COMPANY AFTER TERMINATION OF EMPLOYMENT. Notwithstanding anything to the contrary contained herein, payment of the amounts specified in this Agreement is conditional upon Executive reasonably cooperating with the Company in connection with all matters relating to Executive’s employment with the Company, assisting the Company as reasonably requested in transitioning Executive’s responsibilities to Executive’s replacement, and Executive being available to answer questions and provide transition assistance to the Company through the end of the period during which Severance Benefits are to be paid. Following Executive’s Termination Date, such assistance will be provided at mutually acceptable times, and in reasonable amounts, taking into account other commitments that Executive may have. Executive agrees to use Executive’s best efforts to minimize any conflicts with other commitments to facilitate this assistance. The Company agrees to reimburse Executive for reasonable out of pocket, pre-approved expenses incurred in providing such assistance.
7.6 APPLICATION OF SECTION 280G. In the event that it is determined that the Severance Benefit payable to Executive pursuant to Section 7 of this Agreement, when added to any other payment or benefit to Executive from the Company that would be considered a “parachute payment” (a “Parachute Payment”), within the meaning of section 280G of the Code, would cause Executive to be considered to receive an “excess parachute payment” within the meaning of section 280G of the Code (an “Excess Parachute Payment”), the amount payable to Executive pursuant to Section 7 of this Agreement will be reduced to the maximum amount that, when added to any other Parachute Payments made to Executive, could be paid to Executive without causing Executive to receive an Excess Parachute Payment. Notwithstanding the foregoing, the Severance Benefit payable to Executive pursuant to Section 7 of this Agreement will not be reduced if (i) the net amount payable to Executive without the reduction described in the preceding sentence, but reduced by all Federal, state and local income and employment taxes payable by Executive on the Severance Benefit payable pursuant to this Agreement and all other Parachute Payments plus the excise tax payable on the Excess Parachute Payment pursuant to Section 4999 of the Code, is greater than (ii) the net amount that would be payable to Executive with the reduction described in the preceding sentence and reduced by all Federal, state and local income and employment taxes payable by Executive on the Severance Benefit payable pursuant to this Agreement and all other Parachute Payments. For purposes of this Section 7.7, Executive will be deemed to pay Federal income tax and employment taxes at the highest marginal rate of Federal income and employment taxation in the calendar year in which the Excess Parachute Payment would occur and state and local income taxes at the highest marginal rate of taxation in the state and locality of Executive’s residence in the calendar year in which the Excess Parachute Payment would be made, net of the reduction in Federal income taxes that Executive may obtain from the deduction of such state and local income taxes. In addition, all determinations to be made under this Section 7.7 will be made by the Company’s independent public accountant (the “Accounting Firm”) immediately before the date the Severance Benefit under Section 7 is to be paid. The Accounting Firm will provide its determinations and any supporting calculations and work papers both to the Company and to Executive within ten (10) days of such date, and any such determination by the Accounting Firm will be binding upon the Company and Executive.
7.7 DEFERRED COMPENSATION SUBJECT TO CODE SECTION 409A. Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement that constitute “deferred compensation” within the meaning of Code Section 409A will not commence in connection with Executive’s termination of employment unless and until Executive has also incurred a “separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h) (“Separation From Service”), unless the Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur additional tax under Code Section 409A. It is intended that each installment of Severance Benefits provided for in this Agreement is a separate “payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). For the avoidance of doubt, it is intended that Severance Benefits set forth in this Agreement satisfy, to the greatest extent possible, the exceptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5), and 1.409A-1(b)(9). If the Company (or, if applicable, the successor entity thereto) determines that any payments or benefits constitute “deferred compensation” under Code Section 409A and Executive is, on the termination of service, a “specified Executive” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences to Executive under Section 409A, the timing of the payments and benefits will be delayed until the earlier to occur of: (a) the date that is six (6) months and one day after Executive’s Separation From Service, or (b) the date of Executive’s death (such applicable date, the “Specified Executive Initial Payment Date”). On the Specified Executive Initial Payment Date, the Company (or the successor entity thereto, as applicable) will (i) pay to Executive a lump sum amount equal to the sum of the payments and benefits that Executive would otherwise have received through the Specified Executive Initial Payment Date if the commencement of the payment of such amounts had not been so delayed pursuant to this Section 7.7 and (ii) commence paying the balance of the payments and benefits in accordance with the applicable payment schedules set forth in this Agreement.
8. GENERAL PROVISIONS.
8.1 NOTICES. Any notice required or permitted under this Agreement will be given in writing by delivery in hand, express courier or by postage prepaid, United States first class mail; registered or certified mail, return receipt requested; facsimile at the party’s specified address; by email (including a confirmation of receipt); or as otherwise specified by a party. Notice will be effective upon receipt.
8.2 RIGHT TO INJUNCTIVE RELIEF. Executive agrees and acknowledges that a violation of the covenants contained in Section 4 of this Agreement will cause irreparable damage to the Company, and that it is and will be impossible to estimate or determine the damage that will be suffered by the Company in the event of breach by Executive of any such covenant. Therefore, Executive further agrees that, in the event of any violation or threatened violation of such covenants, the Company will be entitled to an injunction issued by any court of competent jurisdiction restraining such violation or threatened violation by Executive, such right to an injunction to be cumulative and in addition to whatever other remedies the Company may have.
8.3 Reserved
8.4 WAIVER. If either party should waive any breach of any provisions of this Agreement, such party will not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. It is agreed that no delay or omission to exercise any right, power or remedy accruing to either party, upon any breach, default or noncompliance by the other party under this Agreement will impair any such right, power or remedy, nor will it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent or approval of any kind or character on either party’s part of any breach, default or noncompliance under this Agreement or any waiver on such party’s part of any provisions or conditions of the Agreement must be in writing and will be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement by law, or otherwise afforded to either party, will be cumulative and not alternative.
8.5 WITHHOLDING. All amounts payable hereunder will be reduced by any and all federal, state, and local taxes imposed upon the Executive that are required to be paid or withheld by the Company.
8.6 COMPLETE AGREEMENT. This Agreement constitutes the entire agreement between Executive and the Company with regard to the subject matter hereof. This Agreement is the complete, final, and exclusive embodiment of the parties’ agreement with regard to this subject matter and supersede any prior oral discussions or written communications and agreements, including but not limited to any previous agreements. In the event of a conflict between this Agreement and any other agreement the provisions of this Agreement will control. This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in writing signed by Executive and an authorized officer of the Company. The parties may enter into, or may have entered into, separate agreement(s) related to stock options, stock awards or other matters relative to Executive’s service with the Company or its affiliates. These separate agreements govern (or may govern) other aspects of the relationship between the parties, have or may have provisions that survive termination of Executive’s employment under this Agreement, may be amended or superseded by the parties without regard to this Agreement and are enforceable according to their terms without regard to the enforcement provision of this Agreement, and it is not the intent of the Parties that this Agreement, the offer letter, or the Confidentiality Agreement modify or otherwise supersede the terms of such separate agreements.
8.7 COUNTERPARTS. This Agreement may be executed in separate counterparts, including facsimile, PDF, or other electronic counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.
8.8 HEADINGS. The headings of the sections hereof are inserted for convenience only and will not be deemed to constitute a part hereof nor to affect the meaning thereof.
8.9 SUCCESSORS AND ASSIGNS. The Company may assign this Agreement and its rights and obligations hereunder in whole, but not in part, to any company or other entity with or into which the Company may hereafter merge, consolidate, or be acquired by, or to which the Company may transfer all or substantially all of its assets. Executive may not assign or transfer this Agreement or any rights or obligations hereunder, other than to Executive’s estate upon Executive’s death.
8.10 CHOICE OF LAW / VENUE. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the internal, substantive laws of the State of Florida, as applied to agreements made and to be performed solely within the State of Florida and without regard to the principles of conflicts of laws of the State of Florida or of any other jurisdiction that would result in the application of the laws of any other jurisdiction to this Agreement. Any action brought to enforce this Agreement will be brought in Florida in a court of competent jurisdiction.
8.11 ATTORNEYS’ FEES. In any action brought to enforce this Agreement, the substantially prevailing party in such dispute will be entitled to recover from the losing party all reasonable fees, costs and expenses of enforcing any right of such substantially prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys, which will include, without limitation, all fees, costs and expenses of appeal.
[Remainder of Page Intentionally Blank, Signature Page Follows]
IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year first written above.
Company: Scripps Safe, Inc. | ||
Name: | /s/ Jacqueline von Zwehl | |
Title: | President and CEO |
[Signature Page to Employment Agreement]
Exhibit 10.2
Gerald R. Newman & Associates
162 N. Hamel Drive
Suite 101
Beverly Hills, California 90211
Tel. (310) 871-3996
Fax (310) 289-1015
Email gman90211@gmail.com
August 6, 2021
PERSONAL AND CONFIDENTIAL
Scripps Safe, Inc.
9051 Tamiami Trial N Suite 201
Naples, Florida 34108
Attn: Jacqueline Anz - Chief Executive Officer
Dear Ms. Jacqueline Anz,
This Business Services Development Agreement (the “Agreement”) confirms the terms and conditions of the engagement of Gerald R. Newman, (“CONSULTANT”) by Scripps Safe, Inc.., a Florida Corporation (the “Company”) to render certain professional services to the Company.
Whereas, CONSULTANT has assisted hundreds of companies over the past 40 years with business development, including helping both private and public companies with improving valuation, strategic relationships, acquisitions, licensing, recruiting key personnel, improving domestic/international distribution, public company resources, both as a consultant and/or business attorney (now recently retired), and
Whereas, CONSULTANT has of July 9, 2021, commenced to assist the Company with general business consulting, strategic relationships and the recruiting of certain key personnel, and
Whereas, CONSULTANT and the Company desire to memorialize their prior oral agreement with this written Business Services Development Agreement,
NOW THEREFOR, FOR ADEQUATE CONSIDERATION, THE PARTIES HEREBY AGREE AS FOLLOWS:
1. | Business Goals of the Company |
(a) | The CEO of the Company has indicated that she would like assistance in building value for the Company by having: |
1) | New customer acquisition opportunities that could be beneficial to the Company | |
2) | Intellectual Property (IP) acquisition and licensing opportunities that could be beneficial to the Company | |
3) | New product opportunities that could be beneficial to the Company | |
4) | New domestic and international distribution channels that could be beneficial to the Company | |
5) | New advertising and marketing opportunities that could be beneficial to the Company | |
6) | Service providers who can assist the Company in the process of obtaining a NASDAQ listing, including an experienced and available PCAOB Auditor, an experienced and available SEC Attorney, and an experienced and available NASDAQ Process Coordinator. | |
7) | Service providers to assist with Company Public Press Releases | |
8) | Service providers to assist with Company Investor Relations | |
9) | Service providers who can assist with opening Stock Brokerage Accounts for thousands of the Company’s shareholders | |
10) | Such other assistance the Company and the CONSULTANT may agree upon during the term of the CONSULTANT’S engagement. |
2. | CONSULTANT’S services, if requested, to Assist the Company with its Business Goals |
(a) | Sales goals - at the request of the CEO review the Company sales plans, resources, personnel requirements and potential challenges. Offer such advice and referral of experts as may be helpful | |
(b) | Business acquisition opportunities - CONSULTANT has over the years established connections with business brokers and M&A firms, both domestic and international, and is familiar with the relevant databases of such opportunities established business connections with patent attorneys and licensing attorneys and is familiar with the relevant databases of such opportunities | |
(c) | Intellectual Property (IP) acquisition and licensing- CONSULTANT has over the years | |
(d) | New product opportunities - CONSULTANT has over the years established business connections with new product developers and has access to the relevant databases. | |
(e) | New domestic and international distribution channels - CONSULTANT has owned, operated and partnered in various businesses and has become familiar with domestic and international distribution channels on a worldwide basis |
(f) | New advertising and marketing opportunities -CONSULTANT has owned and operated a national advertising and marketing firm, including print, radio, TV, digital and nationwide informercials (one of which did over $100 million in sales) | |
(g) | Service providers who can assist with a Nasdaq listing |
1) | PCAOB Auditor - CONSULTANT has sourced an experienced and available Auditor and the Company has the opportunity to enter into an agreement with the Auditor that it deems acceptable. CONSULTANT will continue to work with the Auditor and the Company to make sure the audit is completed in a timely and professional manner. | |
2) | SEC Attorney- CONSULTANT has sourced an experienced and available SEC Attorney and the Company has the opportunity to enter into an agreement with the Attorney that it deems acceptable. CONSULTANT will continue to work with the SEC attorney and the Company to make sure the necessary legal process for a NASDAQ listing is completed in a timely and professional manner. | |
3) | NASDAQ Process Coordinator-CONSULTANT has sourced an experienced and available NASDAQ Process Coordinator and the Company has the opportunity to enter into an agreement with the NASDAQ Process Coordinator that it deems acceptable. CONSULTANT will continue to work with the NASDAQ Process Coordinator to make sure the necessary NASDAQ listing process is completed in a timely and professional manner (for details see 1), below). |
(h) | Service provider for Public Press Releases - CONSULTANT has advised numerous public companies and has business connections with various firms that write and publish public company press releases | |
(i) | Service provider for Investor Relations - CONSULTANT has advised numerous public companies and has business connections with various Investor Relations firms | |
G) | Service provider for shareholder Stock Brokerage Accounts - CONSULTANT has assisted the shareholders of various public companies to open Stock Brokerage Accounts including a company CONSULTANT took public and that at the time had four thousand individual investors |
1) | Details: NASDAQ financial requirements coordinator, underwriter negotiator, and NASDAQ listing process supervisor for the Company (the “NASDAQ Process Coordinator”) working in conjunction with the CONSULTANT will: |
● | Assist the Company in responding to comments from the NASDAQ Listing Qualifications Staff, if requested; |
● | Assist the Company in preparing a Code of Conduct applicable to all directors, officers and employees, including but not limited to, insiders trading policies, if requested; |
● | Assist the Company in preparing employment agreements for all directors and executive officers, if requested; |
● | Assist the Company to setup the Company’s nomination system for all directors; |
● | Advise and assist the Company in the conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with United States GAAP (Generally Accepted Accounting Principles); |
● | Review and advise the Company on all documents and accounting systems relating to its finances and transactions, with the purpose of bringing such documents and systems into compliance with United States GMP or disclosures required by SEC; |
● | Provide necessary consulting services and support as a liaison for the Company to third-party service providers, including coordination amongst the Company and their related attorneys, CPAs and the transfer agent; |
● | Provide management training to the senior management of the Company, pertaining to usual and customary practices for public companies with business plans similar to the Company’s business plan; |
● | Assist the Company with Edgarization of initial Public Offering related filings with the United States Securities and Exchange Commission, including Forms S-1, XBRL Filings for financial statements, footnotes. |
3. Services Fees. The Company agrees to pay CONSULTANT for the services set forth in this Agreement a professional service fee (“Services Fee” or “Securities”) consisting of:
Common Shares: Four and nine/tenths Percent (4.9%) of the fully diluted equity of the Company as measured by the capital equity table immediately prior to listing on NASDAQ. The Company will issue a ‘true-up,’ if necessary, within thirty days prior to its expected NASDAQ listing day. The common shares will be issued within fifteen days from the satisfaction of the following: (1) conversion of the Company to a “C” corporation; (2) amendment of the Company’s articles of incorporation to authorize a sufficient number of shares to issue the common shares; (each of the foregoing conditions may hereinafter be referred to as the “Pre-IPO Conditions”).
Warrants: The Company shall grant CONSULTANT five-year warrants to purchase 1,000,000 shares of the Company’s common stock at Sl.00 per share. All warrants will vest 30 days prior to an expected going public transaction. The Form of Warrants is attached hereto as Exhibit B.
Considering that the Company is in the process of finalizing its capitalization, the Company is authorized to reduce the CONSULTANT’S warrants so that the Consultant beneficially owns no more than 9.95% of the Company’s capital stock when combined with granted stock and vested warrants as of the time of listing as a public company. The Company will issue the warrants within fifteen days after all of the Pre-IPO Conditions are met.
Leak-out Transition Fee. It is contemplated that CONSULTANT will be under a stock lock-up/leak-out agreement once the Company is listed as a public company, therefore CONSULTANT shall be entitled to be paid as a 1099 independent contractor on the first of each month the sum of five thousand dollars ($5,000.00) first commencing when the Company is publicly listed and ending twelve (12) months thereafter.
1. | Except as provided by the vesting provisions of the warrants, the Services Fee shall be deemed fully earned upon satisfaction of all of the Pre-IPO Conditions. The Consultant makes no representations with respect to the success of his and the Company’s efforts to achieve their above stated Business Goals. |
u. | In addition to any fees that may be payable to CONSULTANT under this Agreement, the Company agrees to reimburse CONSULTANT, upon request made from time to time, for its reasonable and actual out-of-pocket expenses incurred in connection with CONSULTANT’s activities under this Agreement, including the reasonable fees and travel expenses for the meetings on behalf of the Company. All such fees, expenses and costs will be pre-approved by the Company in writing, and billed at any time by CONSULTANT and are payable by the Company when invoiced. Upon expiration of the Agreement any unreimbursed fees and expenses will be immediately due and payable. |
4. | Term. The term of this Agreement shall commence on July 25, 2021, and end on July 24, 2023 (the “Term”). This Agreement may be renewed upon mutual written agreement of the parties hereto. Any obligation pursuant to this Paragraph 4, and pursuant to Paragraphs 3 (payment of fees), 5 (indemnification), 6 (matters relating to engagement), 7 (governing law); 8 (attorney fees) and 11 (miscellaneous) hereof, shall survive the termination or expiration of this Agreement. As stated in the foregoing sentence, the parties specifically agree that in the event the Company terminates this Agreement prior to expiration of the Term, the full Service Fee shall become immediately due and payable. |
5. Indemnification. Each party agrees to indemnify the other and its respective affiliates against third-party claims with regard to the matters contemplated herein; provided, however, that the indemnifying party will have no indemnification obligations to the other if the damages arose as a result of the negligence, willful misconduct, or fraud of the indemnified party.
6. Matters Relating to Engagement. The Company acknowledges that CONSULTANT has been retained solely to provide the services set forth in this Agreement.
In rendering such services, CONSULTANT shall act as an independent contractor, and any duties of CONSULTANT arising out of its engagement hereunder shall be owed solely to the Company. The Company further acknowledges that CONSULTANT may perform certain of the services described herein through one or more of its affiliates, and provide similar services for other non-competitive companies. Consultant acknowledges that they will devote sufficient ti.me to performing its services under the Agreement.
The Company acknowledges and agrees that in connection with the performance of CONSULTANTs services hereunder (or any other services) that neither CONSULTANT nor any of its employees will be providing the Company with legal, tax or accounting advice or guidance (and no advice or guidance provided by CONSULTANT or its employees to the Company should be construed as such) and that neither CONSULTANT nor its employees hold itself or themselves out to be advisors as to legal, tax, accounting, financing or regulatory matters in any jurisdiction, nor will the CONSULTANT be responsible for obtaining any investments in the Company. CONSULTANT may retain attorneys and accountants that are for CONSULTANT’s benefit, and CONSULTANT may recommend a particular law firm, accounting/audit firm, broker-dealer/ Investment Banking firm, Investor Relations firm, or digital marketing firm to be engaged by the Company. However, CONSULTANT makes no recommendation as to the outcome of such referrals, nor does CONSULTANT guarantee or warrant the work product of any referral. The Company shall consult with its own legal, tax, accounting and financial advisors concerning all matters and advice rendered by CONSULTANT to the Company, and the Company shall be responsible for making its own independent investigation and appraisal of the risks, benefits and suitability of the advice and guidance given by CONSULTANT to the Company. Neither CONSULTANT nor its employees shall have any responsibility or liability whatsoever to the Company or its affiliates with respect thereto.
The Company recognizes and confirms that in performing its duties pursuant to this Agreement, CONSULTANT will be using and relying on data, material, and other information furnished by the Company, a third-party provider, or their respective employees and representatives (“the Information”). The Company will cooperate with CONSULTANT and will furnish CONSULTANT with all Information concerning the Company and any financial information or organizational or transactional information which CONSULTANT deems appropriate, and Company will provide CONSULTANT with access to the Company’s officers, directors, employees, independent accountants and legal counsel for the purpose of performing CONSULTANTs obligations pursuant to this Agreement.
The Company hereby agrees and represents that all Information furnished to CONSULTANT pursuant to this Agreement shall be accurate and complete in all material respects at the time provided, and that, if the Information becomes materially inaccurate, incomplete or misleading during the term of CONSULTANTs engagement hereunder, the Company shall promptly advise CONSULTANT in writing. Accordingly, CONSULTANT assumes no responsibility for the accuracy and completeness of the Information. In rendering its services, CONSULTANT will be using and relying upon the Information without independent verification evaluation thereof.
7. Representations and Warranties by CONSULTANT. CONSULTANT, by his acceptance of the Securities he agrees to accept for payment, represents and warrants to Company as follows:
(a) CONSULTANT is acquiring the Securities he agrees to accept for payment with the intent to hold as an investment and not with a view of distribution.
(b) CONSULTANT is an “accredited investor” within the definition contained in Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”), and is acquiring the Securities for its own account, for investment, and not with a view to, or for sale in connection with, the distribution thereof or of any interest therein. CONSULTANT has adequate net worth and means of providing for his current needs and contingencies and is able to sustain a complete loss of the investment in the Securities, and has no need for liquidity in such investment. CONSULTANT, himself or through his officers, employees or agents, has sufficient knowledge and experience in financial and business matters to be capable of evaluating the merits and risks of an investment such as an investment in the Securities, and CONSULTANT, either alone or through his officers, employees or agents, has evaluated the merits and risks of the investment in the Securities.
(c) CONSULTANT acknowledges and agrees that it is acquiring the Securities hereunder based upon his own inspection, examination and determination with respect thereto as to all matters, and without reliance upon any express or implied representations or warranties of any nature, whether in writing, orally or otherwise, made by or on behalf of or imputed to the Company.
(d) CONSULTANT has no contract, arrangement or understanding with any broker, finder, investment bank, financial intermediary, or similar agent with respect to any of the transactions contemplated by this Agreement.
8. Governing Law, Consent to Jurisdiction, Attorney Fees. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida, without regard to conflict of laws provisions. All disputes arising out of or in connection with this agreement, or in respect of any legal relationship associated with or derived from this agreement, shall only be heard in any competent court residing in Collier County, Florida. Each party agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any manner provided by law. Each party further waives any objection to venue in any such action or proceeding on the basis of inconvenient forum. Each party agrees that any action on or proceeding brought against the other shall only be brought in such courts. If any party institutes any legal suit, action, or proceeding against the other party to enforce this Agreement (or obtain any other remedy regarding any breach of this Agreement), the prevailing party in the suit, action, or proceeding is entitled to receive, and the non-prevailing party shall pay, in addition to all other remedies to which the prevailing party may be entitled, the costs and expenses incurred by the prevailing party in conducting or defending the suit, action, or proceeding, including reasonable and actual attorneys’ fees and expenses, and court costs, even if not recoverable by law (including, without limitation, all fees, taxes, costs, and expenses incident to appellate, bankruptcy, and post- judgment proceedings).
9. No Brokers. The Company represents and warrants to CONSULTANT that there are no brokers, representatives, service providers under this Agreement or other persons which have an interest in compensation due to CONSULTANT from any services contemplated herein.
10. Authorization. The Company and CONSULTANT represent and warrant that each has all requisite power and authority, and all necessary authorizations, to enter into and carry out the terms and provisions of this Agreement and the execution, delivery and performance of this Agreement does not breach or conflict with any agreement, document or instrument (including third-party contracts, wills, court orders, regulatory orders, etc.) to which it is a party or bound.
11. Miscellaneous. This Agreement constitutes the entire understanding and agreement between the Company and CONSULTANT with respect to the subject matter hereof and supersedes all prior understandings or agreements between the parties with respect thereto, whether oral or written, express or implied. Any amendments or modifications must be executed in writing by both parties. This Agreement and all rights, liabilities and obligations hereunder shall be binding upon and inure to the benefit of each party’s successors, but may not be assigned without the prior written approval of the other party. If any provision of this Agreement shall be held or made invalid by a statute, rule, regulation, decision of a tribunal or otherwise, the remainder of this Agreement shall not be affected thereby and, to this extent, the provisions of this Agreement shall be deemed to be severable. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but such counterparts shall, together, constitute only one instrument. The descriptive headings of the paragraphs of this Agreement are inserted for convenience only, do not constitute a part of this Agreement and shall not affect in any way the meaning or interpretation of this Agreement. CONSULTANT hereby discloses that he is a retired attorney, in good standing, whose Bar license in California is currently non-active; he is not providing legal services under this Agreement nor being paid for such by the Company.
12. Previous Agreement. CONSULTANT and the Company having previously entered into a Non-Disclosure and Non-Circumvention Agreement, regarding persons hired by the Company, CONSULTANT agrees to issue a full and complete release and waiver to the Company upon CONSULTANT receiving the shares and warrants herein provided for in this Agreement.
Please confirm that the foregoing correctly sets forth our agreement by signing below in the space provided, placing your initials on the bottom left of each page and returning this Agreement to CONSULTANT fully executed, which shall constitute a binding agreement as of the date first above written.
CONSULTANT
By: | /s/ Gerald R. Newman | |
Name: | Gerald R. Newman, an individual |
AGREED TO AND ACCEPTED
DATE: AUGUST 06, 2021
SCRIPPS SAFE, INC. | ||
By: | /s/ Jacqueline von Zwehl | |
Name: | Jacqueline Anz (aka Von Zwehl) | |
Title: | Chief Executive Officer/President/Founder |
AGREED TO AND ACCEPTED
DATE: Aug 06, 2021
Exhibit B
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER AND REASONABLY APPROVED BY THE COMPANY), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.
COMMON STOCK PURCHASE WARRANT
Number of shares: 1,000,000 |
Holder: Gerald R. Newman |
Exercise Price per Share: $1.00 |
Warrant No. 2021-001 |
Expiration Date: July 31, 2026 |
Issue Date: August 6, 2021 |
FOR VALUE RECEIVED, SCRIPPS SAFE, INC., a Nevada corporation (in organization) (the “Company”), hereby certifies that Gerald R. Newman., or its designated assigns (the “Warrant Holder”), is entitled to purchase the securities set forth below.
This Warrant entitles the Warrant Holder to purchase from the Company at any time after the Issue Date and before the Expiration Date ONE MILLION (1,000,000) shares (the “Warrant Shares”) of common stock (the “Common Stock”) of the Company at an exercise price of ONE DOLLAR 00/00 CENTS (US$1.00) per share (as adjusted from time to time as provided in Section 7 hereof, the “Exercise Price”), at any time and from time to time from and after the Issue Date and through and including 5:00 p.m. New York time on the Expiration Date.
This Warrant is being issued pursuant to that certain Services Agreement, dated as of August 6, 2021 by and between the Company and the Warrant Holder, (the “Services Agreement”). Capitalized terms used herein but not otherwise defined herein, shall have the meanings given to them in the Services Agreement. This Warrant will vest 30 days prior to an expected going public transaction and can only be exercised if the Company is listed on a national stock exchange.
This Warrant is subject to the following terms and conditions:
1. Registration of Warrant. The Company shall register this Warrant upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Warrant Holder hereof from time to time. The Company may deem and treat the registered Warrant Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Warrant Holder, and for all other purposes, unless provided notice to the contrary in accordance herewith.
2. Investment Representation. The Warrant Holder by accepting this Warrant represents that the Warrant Holder is acquiring this Warrant for its own account or the account of an affiliate for investment purposes and not with the view to any offering or distribution and that the Warrant Holder will not sell or otherwise dispose of this Warrant or the underlying Warrant Shares in violation of applicable securities laws. The Warrant Holder acknowledges that the certificates representing any Warrant Shares will bear a legend indicating that they have not been registered under the United States Securities Act of 1933, as amended (the “1933 Act”) and may not be sold by the Warrant Holder except pursuant to an effective registration statement or pursuant to an exemption from registration requirements of the 1933 Act and in accordance with federal and state securities laws. If this Warrant was acquired by the Warrant Holder pursuant to the exemption from the registration requirements of the 1933 Act afforded by Regulation S thereunder, the Warrant Holder acknowledges and covenants that this Warrant may not be exercised by or on behalf 0f a Person during the one year distribution compliance period (as defined in Regulation S) following the date hereof. “Person” means an individual, partnership, firm, limited liability company, trust, joint venture, association, corporation, or any other legal entity.
3. Validity of Warrant and Issue of Shares. The Company represents and warrants that this Warrant has been duly authorized and validly issued and warrants and agrees that all of Warrant Shares that may be issued upon the due exercise of the rights represented by this Warrant will, when issued upon such exercise, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issue thereof. The Company further warrants and agrees that during the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant.
4. Registration of Transfers and Exchange of Warrants.
a. Subject to compliance with the legend set forth on the face of this Warrant, the Company shall register the transfer of this Warrant, or any portion of this Warrant, in the Warrant Register, upon delivery by the Warrant Holder to the Company, pursuant to Section 10 of (i) this Warrant, and (ii) a duly completed and executed written assignment. Upon any such registration or transfer, a new warrant to purchase Common Stock, in substantially the form of this Warrant (any such new warrant, a “New Warrant”), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Warrant Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance of such transferee of all of the rights and obligations of a Warrant Holder of a Warrant.
b. This Warrant is exchangeable, upon the surrender hereof by the Warrant Holder to the office of the Company specified in or pursuant to Section 10 for one or more New Warrants, evidencing in the aggregate the right to purchase the number of Warrant Shares which may then be purchased hereunder. Any such New Warrant will be dated the date of such exchange, and will have the same Expiration Date as the original Warrant for which the New Warrant was exchanged.
5. Exercise of Warrants.
a. Exercise of this Warrant shall be made upon delivery to the Company pursuant to Section 10, of (i) this Warrant; (ii) a duly completed and executed election notice, in the form attached hereto (the “Election Notice”) and (iii) payment of the Exercise Price. Payment of the Exercise Price may be made at the option of the Warrant Holder either (a) in cash, wire transfer or by certified or official bank check payable to the order of the Company equal to Exercise Price per share in effect at the time of exercise multiplied by the number of Warrant Shares specified in the Election Notice, or (b) through a cashless exercise provided in Section S(b) below. The Company shall promptly (but in no event later than three (3) business days after the “Date of Exercise,” as defined herein) issue or cause to be issued and cause to be delivered to the Warrant Holder in such name or names as the Warrant Holder may designate in the Election Notice, a certificate for the Warrant Shares issuable upon such exercise, with such restrictive legend as required by the 1933 Act, as applicable. Any person so designated by the Warrant Holder to receive Warrant Shares shall be deemed to have become holder of record of such Warrant Shares as of the Date of Exercise of this Warrant. All Warrant Shares delivered to the Warrant Holder the Company covenants, shall upon due exercise of this Warrant, be duly authorized, validly issued, fully paid and non-assessable.
b. If the closing price per share of the Common Stock (as quoted by the NASDAQ or other principal trading market, if applicable) reported on the day immediately preceding the Date of Exercise (the “Fair Market Value”) of one share of Common Stock is greater than the Exercise Price of one Warrant Share (at the date of calculation as set forth below), in lieu of exercising this Warrant for cash, the Warrant Holder may elect to receive that number of Warrant Shares computed using the following formula:
X=Y (A-B)
A
Where X= the number of shares of Common Stock to be issued to the Warrant Holder
Y= the number of shares of Warrant Shares purchasable under this Warrant or, if only a portion of this Warrant is being exercised, the portion of this Warrant being exercised (at the date of such calculation)
A= Fair Market Value
B= Exercise Price (as adjusted to the date of such calculation)
For purposes of Rule 144 promulgated under the 1933 Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction in the manner described above shall be deemed to have been acquired by the Warrant Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued.
c. A “Date of Exercise” means the date on which the Company shall have received (i) this Warrant (or any New Warrant, as applicable), (ii) the Election Notice (or attached to such New Warrant) appropriately completed and duly signed, and (iii) payment of the Exercise Price (if this Warrant is exercised on a cash basis) for the number of Warrant Shares so indicated by the Warrant Holder to be purchased.
d. This Warrant shall be exercisable at any time and from time to time for such number of Warrant Shares as is indicated in the attached Form of Election to Purchase. If less than all of the Warrant Shares which may be purchased under this Warrant are exercised at any time, the Company shall issue or cause to be issued, at its expense, a New Warrant evidencing the right to purchase the remaining number of Warrant Shares for which no exercise has been evidenced by this Warrant.
e. Notwithstanding any other provision of this Warrant, the Warrant Holder may not exercise this Warrant if such exercise would cause Warrant Holder’s beneficial ownership (as defined by Section 13(d) of the Securities Exchange Act of 1934, as amended) of the Common Stock of the Company to exceed 4.9% of its total issued and outstanding Common Stock or voting shares. Upon not less than sixty-one (61) days advance written notice, at any time or from time to time, the Warrant Holder at its sole discretion, may waive this provision of this Warrant.
f. Notwithstanding any other provision of this Warrant, the Warrant Holder may not exercise this Warrant if such exercise would cause Warrant Holder’s beneficial ownership (as defined by Section 13(d) of the Securities Exchange Act of 1934, as amended) of the Common Stock of the Company to exceed 9.9% of its total issued and outstanding Common Stock or voting shares.
6. Common Share Issuance. Upon receipt by the Company of a written request from Warrant Holder to exercise any portion of any Warrant, subject to any limitations on exercise contained in any Warrant, the Company shall have three (3) business days (“Delivery Date”) to request issuance of the shares of Common Stock rightfully listed in such request. If the Company fails to timely deliver the shares through willful failure or deliberate hindrance, the Company shall pay to Warrant Holder in immediately available funds $1,000.00 per day past the Delivery Date that the shares are actually issued. Any amounts due under this Section shall be paid by the fifth (5th) day of the month following the month in which they accrued. The Company agrees that the right to exercise its Warrants is a valuable right to Warrant Holder and a material consideration of it entering this Agreement. The parties agree that it would be impracticable and extremely difficult to ascertain the amount of actual damages caused by a failure of the Company to timely deliver shares as required hereby. Therefore, the parties agree that the foregoing liquidated damages provision represents reasonable compensation for the loss which would be incurred by the Warrant Holder due to any such breach. The parties agree that this Section is not intended to in any way limit Warrant Holder’s right to pursue other remedies, including actual damages and/or equitable relief.
7. Adjustment of Exercise Price and Number of Shares. The character of the shares of stock or other securities at the time issuable upon exercise of this Warrant and the Exercise Price therefor, are subject to adjustment upon the occurrence of the following events:
a. Adjustment for Reorganization, Consolidation, Merger, Etc. In case of any consolidation or merger of the Company with or into any other corporation, entity or person, or any other corporate reorganization, in which the Company shall not be the continuing or surviving entity of such consolidation, merger or reorganization (any such transaction being hereinafter referred to as a “Reorganization”), then, in each case, the Holder of this Warrant, on exercise hereof at any time after the consummation or effective date of such Reorganization (the “Effective Date”), shall receive, in lieu of the shares of stock or other securities at any time issuable upon the exercise of the Warrant issuable on such exercise prior to the Effective Date, the stock and other securities and property (including cash) to which such Holder would have been entitled upon the Effective Date if such holder had exercised this Warrant immediately prior thereto (all subject to further adjustment as provided in this Warrant). The Company shall ensure that the surviving entity in any Reorganization specifically assumes the Company’s obligations under this Warrant.
b. Exercise Price Adjustment. If at any time the Company grants, issues or sells any Common Stock, options to purchase Common Stock, securities convertible into Common Stock or rights relating to Common Stock (the “Purchase Rights”) to any person, entity, association, or other organization other than the Holder, at a price per share less than the Exercise Price, then the Exercise Price hereof shall be proportionately reduced to match the price per share of the Purchase Rights. For purposes of clarification, if the exercise price of the Warrant Shares is $1.50, and if the Company sells Common Stock at $1.00 per share at any time after the date hereof, then the Exercise Price of Holder’s Warrant Shares would be adjusted to $1.00. Notwithstanding, the Exercise Price may not exceed $1.50 per share in any case.
c. Adjustments for Stock Dividends; Combinations, Etc. In case the Company shall do any of the following (an “Event”):
(i) declare a dividend or other distribution on its Common Stock payable in Common Stock of the Company,
(ii) subdivide the outstanding Common Stock pursuant to a stock split or otherwise, or
(iii) reclassify its Common Stock, then the number of shares of Common Stock or other securities at the time issuable upon exercise of this Warrant shall be appropriately adjusted to reflect any such Event; however, there shall be no adjustment to the Exercise Price or issuable Warrant Shares in the event of a reverse stock split or other reduction in the authorized Common Stock of the Company.
d. Certificate as to Adjustments. In case of any adjustment or readjustment in the price or kind of securities issuable on the exercise of this Warrant, the Company will promptly give written notice thereof to the holder of this Warrant in the form of a certificate, certified and confirmed by the Board of Directors of the Company, setting forth such adjustment or readjustment and showing in reasonable detail the facts upon which such adjustment or readjustment is based.
8. Registration Rights. If, after the date hereof, the Company shall prepare and file with the United States Securities and Exchange Commission (the “Commission”) a registration statement relating to an offering for its own account or the account of others under the 1933 Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the 1933 Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Company shall send to the Warrant Holder written notice of such determination and, unless the Warrant Holder objects to the registration of the Warrant Shares or any part thereof in writing within ten (10) calendar days after receipt of such notice, the Company shall include in such registration statement all of the Warrant Shares, subject to customary cutbacks applicable to all holders of registration rights. To the extent not all of the Warrant Shares may be included for registration in the registration statement, as a result of the Commission’s application of Rule 415 under the 1933 Act, priority in such registration statement will be given to the other Common Stock included therein in preference to the Warrant Shares except no preference shall be given to shares held by affiliates. The obligations of the Company under this Section may be waived by the Warrant Holder. Notwithstanding anything to the contrary herein, the registration rights granted to the Warrant Holder shall not be applicable for such times as such Warrant Shares may be sold by the Holder thereof without restriction pursuant to Rule 144 of the 1933 Act.
9. Fractional Shares. The Company shall not be required to issue or cause to be issued fractional Warrant Shares on the exercise of this Warrant. The number of full Warrant Shares that shall be issuable upon the exercise of this Warrant shall be computed on the basis of the aggregate number of Warrants Shares purchasable on exercise of this Warrant so presented. If any fraction of a Warrant Share would, except for the provisions of this Section 8, be issuable on the exercise of this Warrant, the Company shall, at its option, (i) pay an amount in cash equal to the Exercise Price multiplied by such fraction or (ii) round the number of Warrant Shares issuable, up to the next whole number.
10. Notice. All notices and other communications hereunder shall be in writing and shall be deemed to have been given (i) on the date they are (a) delivered if delivered in person or (b) sent, if sent by email; (ii) on the date initially received if delivered by facsimile transmission followed by registered or certified mail confirmation; (iii) on the date delivered by an overnight courier service; or (iv) on the third business day after it is mailed by registered or certified mail, return receipt requested with postage and other fees prepaid as follows:
If to the Company:
SCRIPPS SAFE, INC.
9051 Tamiami Trail N, Suite 201
Naples, Florida 34108
Email Address: janz@scripps-safe.com
If to the Warrant Holder:
Gerald R. Newman 162 N. Hamel Dr.
Beverly Hills, CA 90211
Email Address: gman902l l@gmail.com
Attn: Gerald R. Newman
11. Miscellaneous.
a. This Warrants is being granted pursuant to the terms of that certain Services Agreement, dated as of August 6, 2021 by and between the Company and the Warrant Holder. If not otherwise defined herein, all capitalized terms herein shall have the meanings given to them in the Services Agreement. Further, all of the terms, representations, warranties, agreements, covenants and conditions set forth in the Services Agreement are incorporated herein by reference. To the extent that there is a conflict between any condition, term or provision of this Warrant and the Services Agreement, the conditions, terms, and provisions set forth herein shall specifically supersede the conflicting conditions, provisions and/or terms in the Services Agreement.
b. This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and permitted assigns. This Warrant may be amended only in writing and signed by the Company and the Warrant Holder. Holder may assign this Warrant without consent from the Company but in accordance with the restrictions herein.
c. Nothing in this Warrant shall be construed to give to any person or corporation other than the Company and the Warrant Holder any legal or equitable right, remedy or cause of action under this Warrant; this Warrant shall be for the sole and exclusive benefit of the Company and the Warrant Holder.
d. This Warrant shall be governed by, construed and enforced in accordance with the internal laws of the State of Florida without regard to the principles of conflicts of law thereof.
e. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.
f. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonably substitute therefore, and upon so agreeing, shall incorporate such substitute provision in this Warrant.
g. The Warrant Holder shall not, by virtue hereof, be entitled to any voting or other rights of a shareholder of the Company, either at law or equity, and the rights of the Warrant Holder are limited to those expressed in this Warrant.
IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by the authorized officer as of the date first above stated.
SCRIPPS SAFE, INC. | ||
By: | /s/ Jacqueline Anz | |
Name: | Jacqueline Anz | |
Title: | Chief Executive Officer | |
Dated: | August 6, 2021 |
FORM OF ELECTION TO PURCHASE
(To be executed by the Warrant Holder to exercise the right to purchase shares of Common Stock under the foregoing Warrant)
To: SCRIPPS SAFE, INC.
The undersigned, pursuant to the provisions set forth in the attached Warrant, hereby irrevocably elects to purchase (check applicable box):
☐ | _________ shares of the Common Stock covered by such Warrant; or |
☐ | the maximum number of shares of Common Stock covered by such Warrant pursuant to the cashless exercise procedure set forth therein. |
The undersigned herewith makes payment of the full purchase price for such shares at the price per share provided for in such Warrant, which is$ ______________. Such payment takes the form of (check applicable box or boxes):
☐ | $ in lawful money of the United States; and/or |
☐ | the cancellation of such portion of the attached Warrant as is exercisable for a total of __________ shares of Common Stock (using a Fair Market Value of $ per share for purposes of this calculation); and/or |
☐ | the cancellation of such number of shares of Common Stock as is necessary, in accordance with the formula set forth in Section 5 of the Warrant, to exercise this Warrant with respect to the maximum number of shares of Common Stock purchasable pursuant to the cashless exercise procedure set forth in Section 5. |
After application of the cashless exercise feature as described above, shares of Common Stock are required to be delivered pursuant to the instructions below.
The undersigned represents and warrants that all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant to registration of the Common Stock under the Securities Act of 1933, as amended (the “Securities Act”), or pursuant to an exemption from registration under the Securities Act.
Name of Warrant Holder: | ||
(Print). | ||
(By:). | ||
(Name:) | ||
(Title:) | ||
Signatures must conform in all respects to the name of the Warrant Holder on the face of the Warrant. |
Exhibit 10.3
August 9, 2021
PERSONAL AND CONFIDENTIAL
Scripps Safe Inc.
9051 Tamiami Trail N, Suite 201
Naples, FL 34108
Attn: Jacqueline Anz – Chief Executive Officer
Dear Ms. Anz,
This service agreement (“Agreement”) confirms the terms and conditions of the engagement of Greentree Financial Group, Inc. (“Greentree”) by Scripps Safe Inc., a Florida Corporation (the “Company”) to render certain professional services to the Company.
1. | Services. Greentree agrees to perform the following services: |
(a) | Assist the Company in responding to comments from the NASDAQ Listing Qualifications Staff, if requested; |
(b) | Assist the Company in preparing a Code of Conduct applicable to all directors, officers and employees, including but not limited to, insiders trading policies, if requested; |
(c) | Assist the Company in preparing employment agreements for all directors and executive officers, if requested; |
(d) | Assist the Company to setup the Company’s nomination system for all directors; |
(e) | Advise and assist the Company in the conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with United States GAAP (Generally Accepted Accounting Principles); |
(f) | Review and advise the Company on all documents and accounting systems relating to its finances and transactions, with the purpose of bringing such documents and systems into compliance with United States GAAP or disclosures required by SEC; |
(g) | Provide necessary consulting services and support as a liaison for the Company to third-party service providers, including coordination amongst the Company and their related attorneys, CPAs and the transfer agent; |
(h) | Provide management training to the senior management of the Company, pertaining to usual and customary practices for public companies with business plans similar to the Company’s business plan; |
(i) | Assist the Company with Edgarization of Initial Public Offering related filings with the United States Securities and Exchange Commission, including Forms S-1 and XBRL Filings for the financial statements and footnotes; |
2. Fees. The Company agrees to pay Greentree for its services a professional service fee (“Service Fee” or “Securities”) of:
Common Shares: Three Percent (3%) of the fully diluted equity of the company as measured by the capital equity table immediately prior to listing on NASDAQ or any other Exchange, with a ‘true-up’ amount to be delivered within thirty days prior to its expected listing day. The common shares will be issued within fifteen days from the satisfaction of all of the following: (1) the conversion of the Company to a “C” corporation; (2) amendment of the Company’s articles of incorporation to authorize a sufficient number of shares to issues the common shares (each of the foregoing conditions may hereinafter be referred to as the “Pre-IPO Conditions”).
Warrants: The Company shall grant Greentree five-year warrants to purchase 400,000 shares of the Company’s common stock at $2.00 per share. These warrants will vest 30 days prior to an expected going public transaction, and will be issued within fifteen days after all of the Pre-IPO Conditions are met. The form of warrants is attached hereto as Exhibit B. Notwithstanding anything to the contrary herein, in no event will the total ownership from the warrants and common shares issued pursuant to this Agreement result in Greentree exceeding 9.99% of the Company’s total issued equity, and the warrant will be equitable adjusted as necessary prior to vesting.
In addition to the initial Service Fee, Greentree and the Company may enter into additional agreements such as bridge financing agreements or annual service agreements as mutually acceptable to Greentree and the Company.
Note:
i. | Except as provided by the vesting provisions of the warrants, the Service Fee shall be deemed fully earned upon signing this Agreement. |
ii. | In addition to any fees that may be payable to Greentree under this Agreement, the Company agrees to reimburse Greentree, upon request made from time to time, for its reasonable out-of-pocket expenses incurred in connection with Greentree’s activities under this Agreement, including the reasonable fees and travel expenses for the meetings on behalf of the Company. All such fees, expenses and costs will be pre-approved by the Company in writing, and billed at any time by Greentree and are payable by the Company when invoiced. Upon expiration of the Agreement any unreimbursed fees and expenses will be immediately due and payable. |
3. Term. The term of this Agreement shall commence on signing of this Agreement and end on March 31, 2022 (the “Term”). This Agreement may be renewed upon mutual written agreement of the parties hereto. This agreement may be terminated by the Company prior to its expiration or services being rendered with 45 days prior written notice to Greentree. Any obligation pursuant to this Paragraph 3, and pursuant to Paragraphs 2 (payment of fees), 4 (indemnification), 5 (matters relating to engagement), 7 (governing law); 8 (attorney fees) and 11 (miscellaneous) hereof, shall survive the termination or expiration of this Agreement. As stated in the foregoing sentence, the parties specifically agree that in the event the Company terminates this Agreement prior to expiration of the Term, the full Service Fee shall become immediately due and payable.
4. Indemnification. Each party agrees to indemnify the other and its respective affiliates against third-party claims with regard to matters contemplated herein; provided, however, that the indemnifying party will have no indemnification obligations to the other if the damages arose as a result of the negligence, willful misconduct, or fraud of the indemnified party.
5. Matters Relating to Engagement. The Company acknowledges that Greentree has been retained solely to provide the services set forth in this Agreement.
In rendering such services, Greentree shall act as an independent contractor, and any duties of Greentree arising out of its engagement hereunder shall be owed solely to the Company. The Company further acknowledges that Greentree may perform certain of the services described herein through one or more of its affiliates.
The Company acknowledges that Greentree is a consulting firm that is engaged in providing consulting services. The Company acknowledges and agrees that in connection with the performance of Greentree’s services hereunder (or any other services) that neither Greentree nor any of its employees will be providing the Company with legal, tax or accounting advice or guidance (and no advice or guidance provided by Greentree or its employees to the Company should be construed as such) and that neither Greentree nor its employees hold itself or themselves out to be advisors as to legal, tax, accounting or regulatory matters in any jurisdiction. Greentree may retain attorneys and accountants that are for Greentree’s benefit, and Greentree may recommend a particular law firm or accounting firm to be engaged by the Company and may pay the legal expenses or accounting expenses associated with that referral on behalf of the Company, after full disclosure to the Company and the Company’s consent that Greentree make such payment on its behalf. However, Greentree makes no recommendation as to the outcome of such referrals. The Company shall consult with its own legal, tax, accounting and other advisors concerning all matters and advice rendered by Greentree to the Company, and the Company shall be responsible for making its own independent investigation and appraisal of the risks, benefits and suitability of the advice and guidance given by Greentree to the Company. Neither Greentree nor its employees shall have any responsibility or liability whatsoever to the Company or its affiliates with respect thereto.
The Company recognizes and confirms that in performing its duties pursuant to this Agreement, Greentree will be using and relying on data, material, and other information furnished by the Company, a third party provider, or their respective employees and representatives (“the Information”). The Company will cooperate with Greentree and will furnish Greentree with all Information concerning the Company and any financial information or organizational or transactional information which Greentree deems appropriate, and Company will provide Greentree with access to the Company’s officers, directors, employees, independent accountants and legal counsel for the purpose of performing Greentree’s obligations pursuant to this Agreement.
The Company hereby agrees and represents that all Information furnished to Greentree pursuant to this Agreement shall be accurate and complete in all material respects at the time provided, and that, if the Information becomes materially inaccurate, incomplete or misleading during the term of Greentree’s engagement hereunder, the Company shall promptly advise Greentree in writing. Accordingly, Greentree assumes no responsibility for the accuracy and completeness of the Information. In rendering its services, Greentree will be using and relying upon the Information without independent verification evaluation thereof.
6. Representations and Warranties by Greentree. Greentree, by its acceptance of the Promissory Note, represents and warrants to Company as follows:
(a) Greentree is acquiring the Promissory Note with the intent to hold as an investment and not with a view of distribution.
(b) Greentree is an “accredited investor” within the definition contained in Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”), and is acquiring the Promissory Note for its own account, for investment, and not with a view to, or for sale in connection with, the distribution thereof or of any interest therein. Greentree has adequate net worth and means of providing for its current needs and contingencies and is able to sustain a complete loss of the investment in the Promissory Note, and has no need for liquidity in such investment. Greentree, itself or through its officers, employees or agents, has sufficient knowledge and experience in financial and business matters to be capable of evaluating the merits and risks of an investment such as an investment in the Securities, and Greentree, either alone or through its officers, employees or agents, has evaluated the merits and risks of the investment in the Promissory Note.
(c) Greentree acknowledges and agrees that it is acquiring the Promissory Note hereunder based upon its own inspection, examination and determination with respect thereto as to all matters, and without reliance upon any express or implied representations or warranties of any nature, whether in writing, orally or otherwise, made by or on behalf of or imputed to the Company.
(d) Greentree has no contract, arrangement or understanding with any broker, finder, investment bank, financial intermediary or similar agent with respect to any of the transactions contemplated by this Agreement.
(e) Greentree understands that in lieu of this Promissory Note, Greentree has the right to receive an up-front cash payment prior to Greentree rendering services to the Company pursuant to the Advisory Agreement. It is further acknowledged and agreed that the value of the Promissory Note, or the securities into which it may be converted, at any given time, could be less than the value of the Service Fee had Greentree elected an up-front payment, and Greentree accepts the investment risk associated therewith.
7. Governing Law and Consent to Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida, without regard to conflict of laws provisions. All disputes arising out of or in connection with this agreement, or in respect of any legal relationship associated with or derived from this agreement, shall only be heard in any competent court residing in Collier County, Florida. Each party agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any manner provided by law. Each party waives any objection to venue in any such action or proceeding on the basis of inconvenient forum. Each party agrees that any action on or proceeding brought against the other shall only be brought in such courts. If any party institutes any legal suit, action, or proceeding against the other party to enforce this Agreement (or obtain any other remedy regarding any breach of this Agreement), the prevailing party in the suit, action, or proceeding is entitled to receive, and the non-prevailing party shall pay, in addition to all other remedies to which the prevailing party may be entitled, the costs and expenses incurred by the prevailing party in conducting or defending the suit, action, or proceeding, including reasonable and actual attorneys’ fees and expenses, and court costs, even if not recoverable by law (including, without limitation, all fees, taxes, costs, and expenses incident to appellate, bankruptcy, and post-judgment proceedings.)
8. No Brokers. The Company represents and warrants to Greentree that there are no brokers, representatives or other persons which have an interest in compensation due to Greentree from any services contemplated herein.
9. Authorization. The Company and Greentree represent and warrant that each has all requisite power and authority, and all necessary authorizations, to enter into and carry out the terms and provisions of this Agreement and the execution, delivery and performance of this Agreement does not breach or conflict with any agreement, document or instrument (including contracts, wills, agreements, records and wire receipts, etc.) to which it is a party or bound.
10. Miscellaneous. This Agreement constitutes the entire understanding and agreement between the Company and Greentree with respect to the subject matter hereof and supersedes all prior understandings or agreements between the parties with respect thereto, whether oral or written, express or implied. Any amendments or modifications must be executed in writing by both parties. This Agreement and all rights, liabilities and obligations hereunder shall be binding upon and inure to the benefit of each party’s successors but may not be assigned without the prior written approval of the other party. If any provision of this Agreement shall be held or made invalid by a statute, rule, regulation, decision of a tribunal or otherwise, the remainder of this Agreement shall not be affected thereby and, to this extent, the provisions of this Agreement shall be deemed to be severable. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but such counterparts shall, together, constitute only one instrument. The descriptive headings of the Paragraphs of this Agreement are inserted for convenience only, do not constitute a part of this Agreement and shall not affect in any way the meaning or interpretation of this Agreement.
Please confirm that the foregoing correctly sets forth our agreement by signing below in the space provided and returning this Agreement to Greentree for execution, which shall constitute a binding agreement as of the date first above written.
Thank you. We look forward to a mutually rewarding relationship.
GREENTREE FINANCIAL GROUP, INC. | ||
By: | /s/ R. Chris Cottone | |
Name: | R. Chris Cottone | |
Title: | Vice President | |
AGREED TO AND ACCEPTED | ||
DATE: AUGUST 9, 2021 | ||
SCRIPPS SAFE INC. | ||
By: | /s/ Jacqueline Anz | |
Name: | Jacqueline Anz | |
Title: | Chief Executive Officer | |
AGREED TO AND ACCEPTED | ||
DATE: AUGUST 9, 2021 |
Exhibit B
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER AND REASONABLY APPROVED BY THE COMPANY), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.
—————————————
COMMON STOCK PURCHASE WARRANT
Number of shares: 400,000 | Holder: Greentree Financial Group, Inc. |
Exercise Price per Share: $2.00 | Warrant No. 2021-001 |
Expiration Date: July 23, 2026 | Issue Date: July 23, 2021 |
FOR VALUE RECEIVED, Scripps Safe Inc., a Florida corporation (the “Company”), hereby certifies that Greentree Financial Group, Inc., or its designated assigns (the “Warrant Holder”), is entitled to purchase the securities set forth below.
This Warrant entitles the Warrant Holder to purchase from the Company at any time after the Issue Date and before the Expiration Date FOUR HUNDRED THOUSAND (400,000) shares (the “Warrant Shares”) of common stock (the “Common Stock”) of the Company at an exercise price of TWO DOLLAR (US$2.00) per share (as adjusted from time to time as provided in Section 7 hereof, the “Exercise Price”), at any time and from time to time from and after the Issue Date and through and including 5:00 p.m. New York time on the Expiration Date.
This Warrant is being issued pursuant to that certain Services Agreement, dated as of July 23, 2021, by and between the Company and the Warrant Holder, (the “Services Agreement”). Capitalized terms used herein but not otherwise defined herein, shall have the meanings given to them in the Services Agreement.
This Warrant is subject to the following terms and conditions:
1. Registration of Warrant. The Company shall register this Warrant upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Warrant Holder hereof from time to time. The Company may deem and treat the registered Warrant Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Warrant Holder, and for all other purposes, unless provided notice to the contrary in accordance herewith.
2. Investment Representation. The Warrant Holder by accepting this Warrant represents that the Warrant Holder is acquiring this Warrant for its own account or the account of an affiliate for investment purposes and not with the view to any offering or distribution and that the Warrant Holder will not sell or otherwise dispose of this Warrant or the underlying Warrant Shares in violation of applicable securities laws. The Warrant Holder acknowledges that the certificates representing any Warrant Shares will bear a legend indicating that they have not been registered under the United States Securities Act of 1933, as amended (the “1933 Act”) and may not be sold by the Warrant Holder except pursuant to an effective registration statement or pursuant to an exemption from registration requirements of the 1933 Act and in accordance with federal and state securities laws. If this Warrant was acquired by the Warrant Holder pursuant to the exemption from the registration requirements of the 1933 Act afforded by Regulation S thereunder, the Warrant Holder acknowledges and covenants that this Warrant may not be exercised by or on behalf of a Person during the one year distribution compliance period (as defined in Regulation S) following the date hereof. “Person” means an individual, partnership, firm, limited liability company, trust, joint venture, association, corporation, or any other legal entity.
3. Validity of Warrant and Issue of Shares. The Company represents and warrants that this Warrant has been duly authorized and validly issued and warrants and agrees that all of Warrant Shares that may be issued upon the due exercise of the rights represented by this Warrant will, when issued upon such exercise, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issue thereof. The Company further warrants and agrees that during the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant.
4. Registration of Transfers and Exchange of Warrants.
a. Subject to compliance with the legend set forth on the face of this Warrant, the Company shall register the transfer of this Warrant, or any portion of this Warrant, in the Warrant Register, upon delivery by the Warrant Holder to the Company, pursuant to Section 10 of (i) this Warrant, and (ii) a duly completed and executed written assignment. Upon any such registration or transfer, a new warrant to purchase Common Stock, in substantially the form of this Warrant (any such new warrant, a “New Warrant”), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Warrant Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance of such transferee of all of the rights and obligations of a Warrant Holder of a Warrant.
b. This Warrant is exchangeable, upon the surrender hereof by the Warrant Holder to the office of the Company specified in or pursuant to Section 10 for one or more New Warrants, evidencing in the aggregate the right to purchase the number of Warrant Shares which may then be purchased hereunder. Any such New Warrant will be dated the date of such exchange, and will have the same Expiration Date as the original Warrant for which the New Warrant was exchanged.
5. Exercise of Warrants.
a. Exercise of this Warrant shall be made upon delivery to the Company pursuant to Section 10, of (i) this Warrant; (ii) a duly completed and executed election notice, in the form attached hereto (the “Election Notice”) and (iii) payment of the Exercise Price. Payment of the Exercise Price may be made at the option of the Warrant Holder either (a) in cash, wire transfer or by certified or official bank check payable to the order of the Company equal to Exercise Price per share in effect at the time of exercise multiplied by the number of Warrant Shares specified in the Election Notice, or (b) through a cashless exercise provided in Section 5(b) below. The Company shall promptly (but in no event later than three (3) business days after the “Date of Exercise,” as defined herein) issue or cause to be issued and cause to be delivered to the Warrant Holder in such name or names as the Warrant Holder may designate in the Election Notice, a certificate for the Warrant Shares issuable upon such exercise, with such restrictive legend as required by the 1933 Act, as applicable. Any person so designated by the Warrant Holder to receive Warrant Shares shall be deemed to have become holder of record of such Warrant Shares as of the Date of Exercise of this Warrant. All Warrant Shares delivered to the Warrant Holder the Company covenants, shall upon due exercise of this Warrant, be duly authorized, validly issued, fully paid and non-assessable.
b. If the closing price per share of the Common Stock (as quoted by the NASDAQ or other principal trading market, if applicable) reported on the day immediately preceding the Date of Exercise (the “Fair Market Value”) of one share of Common Stock is greater than the Exercise Price of one Warrant Share (at the date of calculation as set forth below), in lieu of exercising this Warrant for cash, the Warrant Holder may elect to receive that number of Warrant Shares computed using the following formula:
X=Y (A-B)
A
Where X= the number of shares of Common Stock to be issued to the Warrant Holder
Y= the number of shares of Warrant Shares purchasable under this Warrant or, if only a portion of this Warrant is being exercised, the portion of this Warrant being exercised (at the date of such calculation)
A= Fair Market Value
B= Exercise Price (as adjusted to the date of such calculation)
For purposes of Rule 144 promulgated under the 1933 Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction in the manner described above shall be deemed to have been acquired by the Warrant Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued.
c. A “Date of Exercise” means the date on which the Company shall have received (i) this Warrant (or any New Warrant, as applicable), (ii) the Election Notice (or attached to such New Warrant) appropriately completed and duly signed, and (iii) payment of the Exercise Price (if this Warrant is exercised on a cash basis) for the number of Warrant Shares so indicated by the Warrant Holder to be purchased.
d. This Warrant shall be exercisable at any time and from time to time for such number of Warrant Shares as is indicated in the attached Form of Election to Purchase. If less than all of the Warrant Shares which may be purchased under this Warrant are exercised at any time, the Company shall issue or cause to be issued, at its expense, a New Warrant evidencing the right to purchase the remaining number of Warrant Shares for which no exercise has been evidenced by this Warrant.
e. Notwithstanding any other provision of this Warrant, the Warrant Holder may not exercise this Warrant if such exercise would cause Warrant Holder’s beneficial ownership (as defined by Section 13(d) of the Securities Exchange Act of 1934, as amended) of the Common Stock of the Company to exceed 4.9% of its total issued and outstanding Common Stock or voting shares. Upon not less than sixty-one (61) days advance written notice, at any time or from time to time, the Warrant Holder at its sole discretion, may waive this provision of this Warrant.
f. Notwithstanding any other provision of this Warrant, the Warrant Holder may not exercise this Warrant if such exercise would cause Warrant Holder’s beneficial ownership (as defined by Section 13(d) of the Securities Exchange Act of 1934, as amended) of the Common Stock of the Company to exceed 9.9% of its total issued and outstanding Common Stock or voting shares.
6. Common Share Issuance. Upon receipt by the Company of a written request from Warrant Holder to exercise any portion of any Warrant, subject to any limitations on exercise contained in any Warrant, the Company shall have three (3) business days (“Delivery Date”) to request issuance of the shares of Common Stock rightfully listed in such request. If the Company fails to timely deliver the shares through willful failure or deliberate hindrance, the Company shall pay to Warrant Holder in immediately available funds $1,000.00 per day past the Delivery Date that the shares are actually issued. Any amounts due under this Section shall be paid by the fifth (5th) day of the month following the month in which they accrued. The Company agrees that the right to exercise its Warrants is a valuable right to Warrant Holder and a material consideration of it entering this Agreement. The parties agree that it would be impracticable and extremely difficult to ascertain the amount of actual damages caused by a failure of the Company to timely deliver shares as required hereby. Therefore, the parties agree that the foregoing liquidated damages provision represents reasonable compensation for the loss which would be incurred by the Warrant Holder due to any such breach. The parties agree that this Section is not intended to in any way limit Warrant Holder’s right to pursue other remedies, including actual damages and/or equitable relief.
7. Adjustment of Exercise Price and Number of Shares. The character of the shares of stock or other securities at the time issuable upon exercise of this Warrant and the Exercise Price therefor, are subject to adjustment upon the occurrence of the following events:
a. Adjustment for Reorganization, Consolidation, Merger, Etc. In case of any consolidation or merger of the Company with or into any other corporation, entity or person, or any other corporate reorganization, in which the Company shall not be the continuing or surviving entity of such consolidation, merger or reorganization (any such transaction being hereinafter referred to as a “Reorganization”), then, in each case, the Holder of this Warrant, on exercise hereof at any time after the consummation or effective date of such Reorganization (the “Effective Date”), shall receive, in lieu of the shares of stock or other securities at any time issuable upon the exercise of the Warrant issuable on such exercise prior to the Effective Date, the stock and other securities and property (including cash) to which such Holder would have been entitled upon the Effective Date if such holder had exercised this Warrant immediately prior thereto (all subject to further adjustment as provided in this Warrant). The Company shall ensure that the surviving entity in any Reorganization specifically assumes the Company’s obligations under this Warrant.
b. Exercise Price Adjustment. If at any time the Company grants, issues or sells any Common Stock, options to purchase Common Stock, securities convertible into Common Stock or rights relating to Common Stock (the “Purchase Rights”) to any person, entity, association, or other organization other than the Holder, at a price per share less than the Exercise Price, then the Exercise Price hereof shall be proportionately reduced to match the price per share of the Purchase Rights. For purposes of clarification, if the exercise price of the Warrant Shares is $2.00, and if the Company sells Common Stock at $0.50 per share at any time after the date hereof, then the Exercise Price of Holder’s Warrant Shares would be adjusted to $0.50. Notwithstanding, the Exercise Price may not exceed $2.00 per share in any case.
c. Adjustments for Stock Dividends; Combinations, Etc. In case the Company shall do any of the following (an “Event”):
(i) declare a dividend or other distribution on its Common Stock payable in Common Stock of the Company,
(ii) subdivide the outstanding Common Stock pursuant to a stock split or otherwise, or
(iii) reclassify its Common Stock, then the number of shares of Common Stock or other securities at the time issuable upon exercise of this Warrant shall be appropriately adjusted to reflect any such Event; however, there shall be no adjustment to the Exercise Price or issuable Warrant Shares in the event of a reverse stock split or other reduction in the authorized Common Stock of the Company.
d. Certificate as to Adjustments. In case of any adjustment or readjustment in the price or kind of securities issuable on the exercise of this Warrant, the Company will promptly give written notice thereof to the holder of this Warrant in the form of a certificate, certified and confirmed by the Board of Directors of the Company, setting forth such adjustment or readjustment and showing in reasonable detail the facts upon which such adjustment or readjustment is based.
8. Registration Rights. If, after the date hereof, the Company shall prepare and file with the United States Securities and Exchange Commission (the “Commission”) a registration statement relating to an offering for its own account or the account of others under the 1933 Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the 1933 Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Company shall send to the Warrant Holder written notice of such determination and, unless the Warrant Holder objects to the registration of the Warrant Shares or any part thereof in writing within ten (10) calendar days after receipt of such notice, the Company shall include in such registration statement all of the Warrant Shares, subject to customary cutbacks applicable to all holders of registration rights. To the extent not all of the Warrant Shares may be included for registration in the registration statement, as a result of the Commission’s application of Rule 415 under the 1933 Act, priority in such registration statement will be given to the other Common Stock included therein in preference to the Warrant Shares except no preference shall be given to shares held by affiliates. The obligations of the Company under this Section may be waived by the Warrant Holder. Notwithstanding anything to the contrary herein, the registration rights granted to the Warrant Holder shall not be applicable for such times as such Warrant Shares may be sold by the Holder thereof without restriction pursuant to Rule 144 of the 1933 Act.
9. Fractional Shares. The Company shall not be required to issue or cause to be issued fractional Warrant Shares on the exercise of this Warrant. The number of full Warrant Shares that shall be issuable upon the exercise of this Warrant shall be computed on the basis of the aggregate number of Warrants Shares purchasable on exercise of this Warrant so presented. If any fraction of a Warrant Share would, except for the provisions of this Section 8, be issuable on the exercise of this Warrant, the Company shall, at its option, (i) pay an amount in cash equal to the Exercise Price multiplied by such fraction or (ii) round the number of Warrant Shares issuable, up to the next whole number.
10. Notice. All notices and other communications hereunder shall be in writing and shall be deemed to have been given (i) on the date they are (a) delivered if delivered in person or (b) sent, if sent by email; (ii) on the date initially received if delivered by facsimile transmission followed by registered or certified mail confirmation; (iii) on the date delivered by an overnight courier service; or (iv) on the third business day after it is mailed by registered or certified mail, return receipt requested with postage and other fees prepaid as follows:
If to the Company:
Scripps Safe Inc.
9051 Tamiami Trail N, Suite 201
Naples, FL 34108
Attn: Jacqueline Anz
If to the Warrant Holder:
Greentree Financial Group, Inc.
7951 S.W. 6th Street, Suite 216
Plantation, Florida 33324
Email Address: chriscottone@gtfinancial.com
Attn: R. Chris Cottone
11. Miscellaneous.
a. This Warrants is being granted pursuant to the terms of that certain Services Agreement, dated as of July 23, 2021 by and between the Company and the Warrant Holder. If not otherwise defined herein, all capitalized terms herein shall have the meanings given to them in the Services Agreement. Further, all of the terms, representations, warranties, agreements, covenants and conditions set forth in the Services Agreement are incorporated herein by reference. To the extent that there is a conflict between any condition, term or provision of this Warrant and the Services Agreement, the conditions, terms, and provisions set forth herein shall specifically supersede the conflicting conditions, provisions and/or terms in the Services Agreement.
b. This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and permitted assigns. This Warrant may be amended only in writing and signed by the Company and the Warrant Holder. Holder may assign this Warrant without consent from the Company but in accordance with the restrictions herein.
c. Nothing in this Warrant shall be construed to give to any person or corporation other than the Company and the Warrant Holder any legal or equitable right, remedy or cause of action under this Warrant; this Warrant shall be for the sole and exclusive benefit of the Company and the Warrant Holder.
d. This Warrant shall be governed by, construed and enforced in accordance with the internal laws of the State of Florida without regard to the principles of conflicts of law thereof.
e. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.
f. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonably substitute therefore, and upon so agreeing, shall incorporate such substitute provision in this Warrant.
g. The Warrant Holder shall not, by virtue hereof, be entitled to any voting or other rights of a shareholder of the Company, either at law or equity, and the rights of the Warrant Holder are limited to those expressed in this Warrant.
IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by the authorized officer as of the date first above stated.
Scripps Safe Inc. | ||
By: | /s/ Jacqueline Anz | |
Name: | Jacqueline Anz | |
Title: | Chief Executive Officer |
FORM OF ELECTION TO PURCHASE
(To be executed by the Warrant Holder to exercise the right to purchase shares of Common Stock under the foregoing Warrant)
To: Scripps Safe Inc.
The undersigned, pursuant to the provisions set forth in the attached Warrant, hereby irrevocably elects to purchase (check applicable box):
☐ | ________ shares of the Common Stock covered by such Warrant; or |
☐ | the maximum number of shares of Common Stock covered by such Warrant pursuant to the cashless exercise procedure set forth therein. |
The undersigned herewith makes payment of the full purchase price for such shares at the price per share provided for in such Warrant, which is $___________. Such payment takes the form of (check applicable box or boxes):
☐ | $__________ in lawful money of the United States; and/or |
☐ | the cancellation of such portion of the attached Warrant as is exercisable for a total of _______ shares of Common Stock (using a Fair Market Value of $_______ per share for purposes of this calculation); and/or |
☐ | the cancellation of such number of shares of Common Stock as is necessary, in accordance with the formula set forth in Section 5 of the Warrant, to exercise this Warrant with respect to the maximum number of shares of Common Stock purchasable pursuant to the cashless exercise procedure set forth in Section 5. |
After application of the cashless exercise feature as described above, _____________ shares of Common Stock are required to be delivered pursuant to the instructions below.
The undersigned represents and warrants that all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant to registration of the Common Stock under the Securities Act of 1933, as amended (the “Securities Act”), or pursuant to an exemption from registration under the Securities Act.
Name of Warrant Holder: | ||
(Print) | ||
(By:) | ||
(Name:) | ||
(Title:) | ||
Signatures must conform in all respects to the name of the Warrant Holder on the face of the Warrant. |
Exhibit 10.4
AMENDMENT NO. 1 TO CONSULTING AGREEMENT
Amendment No. 1 to Consulting Agreement, dated as of July 13, 2022 (the “Amendment”), between Scripps Safe, Inc., a Delaware Corporation, (the “Company”), and Gerald R. Newman (“Consultant”, and together with the Company, the “Parties”, and each, a “Party”).
WHEREAS, the Parties have entered into a Consulting Agreement dated as of August 6, 2021 (the “Existing Agreement”), and desire to amend the Existing Agreement on the terms and subject to the conditions set forth herein.
NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
1. Definitions. Capitalized terms used and not defined in this Amendment have the respective meanings assigned to them in the Existing Agreement.
2. Amendments to the Existing Agreement. The Existing Agreement is hereby amended as follows:
(a) Section 3 of the Existing Agreement is hereby deleted in its entirety and replaced with the following:
“3. Services Fees. The Company agrees to pay CONSULTANT for the services set forth in this Agreement a professional service fee (“Service Fee” or “Securities”) consisting of:
Common Shares: Eight Percent (8%) of the fully diluted equity of the Company as measured by the capital equity table immediately prior to listing on the NASDAQ. The Company will issue a ‘true-up’, if necessary, within thirty days prior to its expected NASDAQ listing day. The common shares will be issued within fifteen days from the satisfaction of the following: 1) conversion of the Company to a “C” corporation; (2) amendment of the Company’s articles of incorporation to authorize a sufficient number of shares to issue the common shares; (each of the foregoing conditions may hereinafter be referred to as the “Pre-IPO Conditions”). In the event that the IPO is not consummated within two years of the date hereof no Common Shares shall be issued but the CONSULTANT shall still be entitled to the $5,000 per month for 12 months from such date less the $10,000 prepaid.
Lock Up Period. CONSULTANT shall be under a stock lock-up period commencing as of the date the common shares are issued to this Agreement and ending six (6) months from the date the Company is listed as a public company. CONSULTANT shall be entitled to be paid as a 1099 independent contractor on the first of each month the sum of five thousand dollars ($5,000.00), first commencing when the Company is publicly listed and ending twelve (12) months thereafter, with ten thousand ($10,000.00) pre-paid within ten (10) days upon the closing of the Company’s pre-IPO contemplated bridge financing.
i. The Services Fee shall be deemed fully earned upon satisfaction of all of the Pre-IPO Conditions. The Consultant makes no representations with respect to the success of his and the Company’s efforts to achieve their above stated Business Goals.
ii. In addition to any fees that may be payable to CONSULTANT under this Agreement, the Company agrees to reimburse CONSULTANT, upon request made from time to time, for its reasonable and actual out-of-pocket expenses incurred in connection with CONSULTANT’s activities under this Agreement, including the reasonable fees and travel expenses for the meetings on behalf of the Company. All such fees, expenses and costs will be pre-approved by the Company in writing, and billed at any time by CONSULTANT and are payable by the Company when invoiced. Upon expiration of the Agreement any unreimbursed fees and expenses will be immediately due and payable.”
3. Except as expressly set forth herein, the Existing Agreement is unmodified and remains in full force and effect and the execution of this Amendment does not and shall not constitute an amendment of any other rights to which the parties are entitled pursuant to the Existing Agreement.
[SIGNATURE PAGE FOLLOWS]
IN WITNESS WHEREOF, the Parties have executed this Amendment on the date first written above.
SCRIPPS SAFE, INC. | ||
By: | /s/ Jacqueline Anz | |
Name: | Jacqueline Anz | |
Title: | Chief Executive Officer | |
CONSULTANT | ||
By: | /s/ Gerald R. Newman | |
Name: | Gerald R. Newman |
Exhibit 10.5
Loan Agreement
LOAN AGREEMENT
This Loan Agreement (“Agreement”) is made and entered into in this 4th day of August 2022 (“Effective Date”), by and between Scripps Safe Inc., a Delaware corporation, its successors and assigns (the “Company”), and Greentree Financial Group, Inc., a Florida corporation (the “Lender”).
RECITALS
WHEREAS, the Company is in need of capital for Initial Public Offering related expenses and the Lender has agreed to provide up to $250,000.00 of such capital according to the terms hereof; and
WHEREAS, the Lender and Company are entering into this Agreement to establish terms by which the Lender, in their sole discretion, may fund Loans, as set forth herein and therein the related Note, described below.
AGREEMENT
NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and other good and valuable consideration, the sufficiency of which is acknowledged by the Lender and Company (each “party” and, collectively, “parties”), the parties hereby agree as follows:
1. LOANS; PROMISSORY NOTE. The Lender shall loan the Company up to $250,000 (the “Principal Amount”) with a 10% original issuance discount, pursuant to the terms hereof; provided, nothing herein or otherwise shall obligate Lender to make any future loans to the Company. All sums advanced pursuant to the terms of this Agreement (a “Loan”) shall be evidenced by a separate 10% convertible promissory note (the “Note”), in substantially the form set forth as Exhibit A hereto. The Note shall be convertible into shares of the Company’s common stock (the “Common Stock”) pursuant to the terms contained in the Note. All covenants, conditions and agreements contained herein are made a part of the Note, unless modified therein.
a. Unless stated otherwise in the Note, the Note will automatically mature on February 15, 2023. However, the Parties acknowledge and agree that the Company may extend such maturity date by up to an additional six (6) months, to be in two extensions of three (3) months each, provided that at the time of each such extension, the Company is required, five (5) days prior to the applicable Extension deadline, to issue the Lender 10,000 shares of the Company’s common stock, and therefore a total of 20,000 shares of the Company’s common stock for both three (3) month Extensions.
b. At the Effective Date, the Lender agrees to a net deposit of $112,500 ($125,000 face value of the Loan less the applicable original issue discount) in the Company’s attorney’s escrow account which will be released to the Company to pay certain expenses related to the Company’s proposed Initial Public Offering. The balance of the Loan Amount will be paid to the Company upon presentment of invoices that need to be paid in connection with the Initial Public Offering. In the event that the Company requests an advance be made to cover an Initial Public Offering Expense and the Lender refuses to make such advance the amount of Warrants issued under section 2 shall be reduced pro rata based on the amount actually advanced at such time. All sums advanced pursuant to this Agreement shall bear simple interest from the date the Loan is made until paid in full at an interest rate of ten percent (10%) per annum. The accrued interest shall not compound and will be calculated on the basis of a 360-day year. Interest shall be paid by the Company quarterly. In the Event of a Default (as defined in the Note), the Note will bear simple interest at an annual rate of 18%, which shall become the new rate of interest on this Note.
2. WARRANTS. Upon signing this Agreement at the Effective Date, the Company shall simultaneously issue to the Lender at the Effective Date, a warrant in substantially the form annexed hereto as Exhibit B (the “Warrant”) to purchase an aggregate of 200,000 shares of Common Stock (the “Warrant Shares”) at an exercise price of $2.00 per share (the “Exercise Price”). The Warrant shall be cashless exercisable for a period of five (5) years from the issue date specified on the face of such Warrant until and unless the underlying common shares are registered by the Company in an effective registration statement as set forth in Section 5, and such registration statement stays effective, in which event the Warrants shall be exercisable only on a cash basis. The Warrants shall have Down Round Protection meaning that prior to exercise, if at any time the Company grants, issues or sells any Common Stock, options to purchase Common Stock, securities convertible into Common Stock or rights relating to Common Stock (the “Purchase Rights”) to any person, entity, association, or other organization other than the Lender, at a price per share less than the Exercise Price, then the Exercise Price hereof shall be proportionately reduced to match the price per share of the Purchase Rights. For purposes of clarification, if the Company sells Common Stock at $1.00 per share at any time after the date hereof but prior to exercise, then the Exercise Price of Lender’s Warrant Shares would be adjusted to $1.00. Notwithstanding, the Exercise Price may not exceed $2.00 per share except in the event of a reverse stock split after the Company’s Initial Public Offering in which event it would be adjusted pro-rata..
The issuance of Purchase Rights shall not constitute a Down Round for purposes of this Agreement in the event of: (i) the exercise or issuance of stock options or the conversion of convertible securities in each case issued to employees and directors of the Company pursuant to a plan, agreement or arrangement approved by the Board of Directors of the Company; (ii) a dividend or distribution payable to holders of capital stock of the Company; (iii) a subdivision (by stock split, recapitalization or otherwise) of outstanding shares of the Company into a greater number of shares; or (iv) the issuance of shares pursuant to a currently outstanding security. Each of these events shall be an “Exempt Issuance”.
3. PREPAYMENT. The Company may, at its option, at any time and from time to time, prepay all or any part of the principal balance of this Note before the Maturity Date, without any penalty. In the event of prepayment, the Lender shall retain the Warrants
4. ALLOWANCE FOR LEGAL FEE. There will be a $5,000 allowance for Lender’s legal fees paid by the Company and deducted from Lender’s payment.
5. REGISTRATION RIGHTS. If, after the date hereof and the Company’s Initial Public Offering, the Company shall prepare and file with the United States Securities and Exchange Commission (the “Commission”) a registration statement relating to an offering for its own account or the account of others under the 1933 Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the 1933 Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Company shall send to the Warrant Holder written notice of such determination and, unless the Warrant Holder objects to the registration of the Warrant Shares or any part thereof in writing within ten (10) calendar days after receipt of such notice, the Company shall include in such registration statement all of the Warrant Shares, subject to customary cutbacks applicable to all holders of registration rights. To the extent not all of the Warrant Shares may be included for registration in the registration statement, as a result of the Commission’s application of Rule 415 under the 1933 Act, priority in such registration statement will be given to the other Common Stock included therein in preference to the Warrant Shares except no preference shall be given to shares held by affiliates. The obligations of the Company under this Section may be waived by the Warrant Holder. Notwithstanding anything to the contrary herein, the registration rights granted to the Warrant Holder shall not be applicable for such times as such Warrant Shares may be sold by the Holder thereof without restriction pursuant to Rule 144 of the 1933 Act.
6. REPRESENTATIONS AND WARRANTIES BY THE COMPANY. In order to induce Lender to enter into this Agreement and to make the Loans provided for herein, Company represents and warrants to Lender as follows:
a. Organization, Good Standing and Power. The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware and has the requisite corporate power to own, lease and operate its properties and assets and to conduct its business as it is now being conducted. The Company has one wholly owned subsidiary incorporated in the state of Florida.
b. Non-Shell Status. The Company is not now or ever been a shell as that term is defined in Rule 405 of the Securities Act.
c. Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and perform this Agreement, the Note, and the Warrants (all such documents together with all amendments, schedules, exhibits, annexes, supplements and related items, to each such document shall hereinafter be collectively referred to as, the “Transaction Documents”). The execution, delivery and performance of the Transaction Documents by the Company, and the consummation by it of the transactions contemplated in, have been duly and validly authorized by all necessary corporate action. The Transaction Documents, when executed and delivered, will constitute valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application.
d. Disclosure. None of the Transaction Documents nor any other document, certificate or instrument furnished to the Lender by or on behalf of the Company in connection with the transactions contemplated by the Transaction Documents contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements made herein or therein, in the light of the circumstances under which they were made herein or therein, not misleading.
e. Adequate Shares. The Company will at all times have authorized and reserved a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by the respective Warrants and Note.
f. Periodic Filings. The Company at all times required will remain current in its reporting requirements with the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and maintain its continued listing of the Company’s common stock on NASDAQ Global Market.
g. Additional Issuances. Except for the transactions contemplated by the Transaction Documents, the Company, for a period of twelve (12) months from the date hereof, will not issue, grant or sell any security with a variable conversion or exercise rate.
7. REPRESENTATIONS AND WARRANTIES BY LENDER. Lender, by the acceptance of this Note, represents and warrants to Company as follows:
a. Lender is acquiring the Note with the intent to hold as an investment and not with a view of distribution.
b. Lender is an “accredited investor” within the definition contained in Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”), and is acquiring the Note for its own account, for investment, and not with a view to, or for sale in connection with, the distribution thereof or of any interest therein. Lender has adequate net worth and means of providing for its current needs and contingencies and is able to sustain a complete loss of the investment in the Note, and has no need for liquidity in such investment. Lender, itself or through its officers, employees or agents, has sufficient knowledge and experience in financial and business matters to be capable of evaluating the merits and risks of an investment such as an investment in the Securities, and Lender, either alone or through its officers, employees or agents, has evaluated the merits and risks of the investment in the Note.
c. Lender acknowledges and agrees that it is purchasing the Note hereunder based upon its own inspection, examination and determination with respect thereto as to all matters, and without reliance upon any express or implied representations or warranties of any nature, whether in writing, orally or otherwise, made by or on behalf of or imputed to the Company.
8. LIQUIDATED DAMAGES.
a. Upon receipt by the Company of a written request from Lender to convert any amount due under any Note or to exercise any portion of any Warrant, subject to any limitations on conversion or exercise contained in any Note and/or Warrant, the Company shall have three (3) business days (“Delivery Date”) to issue the shares of Common Stock rightfully listed in such request. If the Company fails to timely deliver the shares, the Company shall pay to Lender in immediately available funds $1,000.00 per day past the Delivery Date that the shares are actually issued. Any amounts due under this Section shall be paid by the fifth (5th) day of the month following the month in which they accrued or, at the option of Lender, may be added to the principal under any Note. The Company agrees that the right to convert the Note or exercise its Warrants is a valuable right to Lender and a material consideration of it entering this Agreement. The parties agree that it would be impracticable and extremely difficult to ascertain the amount of actual damages caused by a failure of the Company to timely deliver shares as required hereby. Therefore, the parties agree that the foregoing liquidated damages provision represents reasonable compensation for the loss which would be incurred by the Lender due to any such breach. The parties agree that this Section is not intended to in any way limit Lender’s right to pursue other remedies, including actual damages and/or equitable relief.
b. The Company and Lender hereto acknowledge and agree that the sums payable as Liquidated Damages under subsection 8(a) above shall constitute liquidated damages and not penalties and are in addition to all other rights of the Lender, including the right to call a default under the Securities Purchase Agreement. The parties further acknowledge that (i) the amount of loss or damages likely to be incurred is incapable or is difficult to precisely estimate, (ii) the amounts specified in such subsections bear a reasonable relationship to, and are not plainly or grossly disproportionate to, the probable loss likely to be incurred in connection with any failure by the Company to obtain or maintain the effectiveness of a registration statement, (iii) one of the reasons for the Company and the Lender reaching an agreement as to such amounts was the uncertainty and cost of litigation regarding the question of actual damages, and (iv) the Company and the Lender are sophisticated business parties and have been represented by sophisticated and able legal counsel and negotiated this Agreement at arm’s length.
9. CONVERSION COSTS. The Company agrees to reimburse Lender’s certificate processing cost by adding $1,500 to the principal for each note conversion effected by Lender provided that each such conversion is for no less than $50,000.
10. EVENTS OF DEFAULT. An event of default will occur if any of the following circumstances occur (each an “Event of Default”):
a. Any representation or warranty made by Company in this Agreement or in connection with any Warrant or Note, or in any financial statement, or any other statement furnished by Company to Lender is untrue in any material respect at the time when made or becomes untrue.
b. Default by Company in the observance or performance of any other covenant or agreement contained in this Agreement.
c. Default by Company under the terms of any Note or Warrant or any other third party note or warrant that exceeds a value of $50,000.
d. Filing by Company of a voluntary petition in bankruptcy seeking reorganization, arrangement or readjustment of debts, or any other relief under the Bankruptcy Code as amended or under any other insolvency act or law, state or federal, now or hereafter existing.
e. Filing of an involuntary petition against Company in bankruptcy seeking reorganization, arrangement or readjustment of debts, or any other relief under the Bankruptcy Code as amended, or under any other insolvency act or law, state or federal, now or hereafter existing, and the continuance thereof for sixty (60) days undismissed, unbonded or undischarged.
f. Company liquidates, transfers, sells or assigns substantially its assets or elects to wind down its operations or dissolve.
g. The Company fails to maintain irrevocable TA instruction or file with the Company’s transfer agent along with a reserve of common shares sufficient to satisfy the Note based on a then hypothetical conversion scenario per the terms of the Note.
h. The Company fails to maintain DTC or DWAC eligibility.
i. The Company fails to stay current in its SEC reporting obligations or maintain its continued listing of the Company’s common stock on NASDAQ Global Market.
j. The Company fails to deliver Lender the shares of Common Stock rightfully listed in any Conversion Notice or any Warrants Exercise Notice within three (3) business days.
k. The Company breaches any other agreement it has with Lender or his assigns.
l. The Company interferes with Lender’s or its assigns’ efforts to remove the restrictive legend from the Common Stock issued as a result of conversion of any Note when Lender or his assign has provided a reasoned attorney opinion letter opining that the shares are eligible to have the legend removed pursuant to Rule 144 or otherwise.
11. REMEDIES. There will be no cure period available for the Event of Default as defined in subsection 10(d) and 10(e); Upon the occurrence of any Event of Default, and provided such Event of Default as defined in subsection 10(a) through 10(c), and 10(f) through 10(l), has not been cured by the Company within five (5) business days after the occurrence of such Event of Default (except a payment default of any interest, principal and/or other amount when due, of which no cure period is available), the Holder, may, by written notice to the Company, declare all or any portion of the unpaid Principal Amount due to Holder, together with all accrued interest thereon, immediately due and payable (without advanced notice as may otherwise by required hereunder); provided that upon the occurrence of an Event of Default as set forth in paragraph (d) or paragraph (e) hereof, all or any portion of the unpaid Principal Amount due to Holder, together with all accrued interest thereon, shall immediately become due and payable without any such notice. Holder shall also have all other remedies available under law and equity. There shall be a late charge equal to 18% of the amount of any unpaid principal plus any interest accrued as of the due date.
12. NOTICE. Any and all notices, demands, advance requests or other communications required or desired to be given hereunder by any party shall be in writing and shall be validly given or made to another party if (i) personally served, (ii) sent by email on the date such email is sent (provided confirmation of such email being sent is provided upon request) (iii) deposited in the United States mail, postage prepaid, return receipt requested, or (iv) by facsimile with confirmation receipt. Notice hereunder is to be given as follows:
If to the Company:
Scripps Safe Inc.
9051 Tamiami Trail N, Suite 201
Naples, FL 34108
Attn: Jacqueline Anz
If to the Lender:
Greentree Financial Group, Inc.
7951 S.W. 6th Street, Suite 216
Plantation, Florida 33324
Attn: R. Chris Cottone
13. GENERAL PROVISIONS. All representations and warranties made in the Transaction Documents shall survive the execution and delivery of this Agreement and the making of any Loans hereunder. This Agreement will be binding upon and inure to the benefit of Company and Lender, their respective successors and assigns.
14. ENTIRE AGREEMENT. The Transaction Documents contain the entire agreement of the parties and supersedes and replaces all prior discussions, negotiations and representations of the parties. No party shall rely upon any oral representations in entering into this agreement, such oral representations, if any, being expressly denied by the party to whom they are attributed and it being the intention of the parties to limit the terms of this Agreement to those matters contained herein in writing. However, incorporated Note shall be deemed controlling at all times with regards to any inconsistent or changed terms or amendments contained therein.
15. BINDING EFFECT. This agreement is binding upon and inures to the benefit of the parties hereto, their heirs, personal representatives, successors and assigns. Lender may assign their rights hereunder without prior permission from the Company.
16. GOVERNING LAW AND CONSENT TO JURISDICTION. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida, without regard to conflict of law provisions. All disputes arising out of or in connection with this Agreement, or in respect of any legal relationship associated with or derived from this Agreement, shall only be heard in any competent court residing in Broward County, Florida. The Company agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any manner provided by law. The Company further waives any objection to venue in any such action or proceeding on the basis of inconvenient forum. The Company agrees that any action on or proceeding brought against the Lender shall only be brought in such courts.
17. ATTORNEYS FEES. In the event the Lender hereof shall refer this Agreement to an attorney to enforce the terms hereof, the Company agrees to pay all the costs and expenses incurred in attempting or effecting the enforcement of the Lender’s rights, including reasonable attorney’s fees, whether or not suit is instituted.
18. AMENDMENT. The terms of this Agreement may not be amended, modified, or eliminated without written consent of the parties.
19. SEVERABILITY. Every provision of this Agreement is intended to be severable. If any term or provision thereof is illegal or invalid for any reason whatsoever, such illegality or invalidity shall not affect the validity or legality of the remainder of this Agreement.
20. CONSTRUCTION. Section and paragraph headings are for convenience only and do not affect the meaning or interpretation of this Agreement. No rule of construction or interpretation that disfavors the party drafting this Agreement or any of its provisions will apply to the interpretation of this Agreement. Instead, this Agreement will be interpreted according to the fair meaning of its terms.
21. FURTHER ASSURANCES. Each party hereto agrees to do all things, including execute, acknowledge and/or deliver any documents which may be reasonably necessary, appropriate or desirable to effectuate the transactions contemplated herein pursuant to terms and conditions of this Agreement.
IN WITNESS WHEREOF, the parties hereto enter into this Loan Agreement which is effective as of the date first written.
Company: | Lender: | |||
Scripps Safe, Inc. | Greentree Financial Group, Inc. | |||
By: | /s/ Jacqueline Anz | By: | /s/ R. Chris Cottone | |
Name: | Jacqueline Anz | Name: | R. Chris Cottone | |
Title: | Chief Executive Officer | Title: | Vice President | |
8/4/2022 | 8/5/2022 |
EXHIBIT A
NOTE FORM
EXHIBIT B
WARRANT FORM
Exhibit 10.6
AMENDMENT NO. 1 TO CONVERTIBLE NOTE
Amendment No. 1 to that certain convertible note dated August 4, 2022 dated as of November 16, 2022 (the “Amendment”), between Scripps Safe, Inc., a Delaware Corporation, (the “Company”), and Greentree Financial Group, Inc., (“Greentree”, and together with the Company, the “Parties”, and each, a “Party”).
WHEREAS, the Parties have entered into a Loan Agreement dated as of August 4, 2022, pursuant to which Greentree has agreed to loan the Company up to $250,000 (the “Existing Agreement”) and desire to amend the convertible note dated August 4, 2022 (the “Existing Note”) issued in connection with the Existing Agreement on the terms and subject to the conditions set forth herein.
NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
1.Definitions. Capitalized terms used and not defined in this Amendment have the respective meanings assigned to them in the Existing Note.
2. Amendments to the Existing Note. The Existing Note is hereby amended as follows:
(a) Section 3.1 of the Existing Note is hereby amended to provide that the balance under the Existing Note may be converted into the Company’s common stock immediately upon the completion of the Company’s IPO or some other event that results in the Company’s common stock becoming publicly traded as opposed to the balance under the Existing Note being convertible into common stock immediately upon issuance.
3. Except as expressly set forth herein, the Existing Agreement and Existing Note are unmodified and remain in full force and effect and the execution of this Amendment does not and shall not constitute an amendment of any other rights to which the parties are entitled pursuant to the Existing Agreement or Existing Note.
[SIGNATURE PAGE FOLLOWS]
IN WITNESS WHEREOF, the Parties have executed this Amendment on the date first written above.
SCRIPPS SAFE, INC. | ||
By | /s/ Jacqueline Anz | |
Name: | Jacqueline Anz | |
Title: | Chief Executive Officer | |
GREENTREE FINANCIAL GROUP, INC. | ||
By | /s/ Robert Chris Cottone | |
Name: | Robert Chris Cottone | |
Title: | Vice President |
2 |
Exhibit 10.7
AMENDMENT NO. 1 TO WARRANT
Amendment No. 1 to that certain warrant dated August 4, 2022 dated as of November 16, 2022 (the “Amendment”), between Scripps Safe, Inc., a Delaware Corporation, (the “Company”), and Greentree Financial Group, Inc., (“Greentree”, and together with the Company, the “Parties”, and each, a “Party”).
WHEREAS, the Parties have entered into a Loan Agreement dated as of August 4, 2022, pursuant to which Greentree has agreed to loan the Company up to $250,000 (the “Existing Agreement”) and desire to amend the warrant dated August 4, 2022 to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $2.00 per share (the “Existing Warrant”) issued in connection with the Existing Agreement on the terms and subject to the conditions set forth herein.
NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
1. Definitions. Capitalized terms used and not defined in this Amendment have the respective meanings assigned to them in the Existing Warrant.
2. Amendments to the Existing Warrant. The Existing Warrant is hereby amended as follows:
(a) The pre-amble to the Existing Warrant shall be hereby amended to provide that the Warrants shall not be exercisable until the Company’s IPO or some other event that results in the Company’s common stock becoming publicly traded as opposed to the Warrant being exercisable into common stock immediately upon issuance.
3. Except as expressly set forth herein, the Existing Agreement and Existing Warrant are unmodified and remain in full force and effect and the execution of this Amendment does not and shall not constitute an amendment of any other rights to which the parties are entitled pursuant to the Existing Agreement or Existing Warrant
[SIGNATURE PAGE FOLLOWS]
IN WITNESS WHEREOF, the Parties have executed this Amendment on the date first written above.
SCRIPPS SAFE, INC. | ||
By | /s/ Jacqueline Anz | |
Name: | Jacqueline Anz | |
Title: | Chief Executive Officer | |
GREENTREE FINANCIAL GROUP, INC. | ||
By | /s/ Robert Chris Cottone | |
Name: | Robert Chris Cottone | |
Title: | Vice President |
2 |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated August 22, 2022 relating to the consolidated financial statements which appeared in Scripps Safe, Inc.’s Annual Report on Form S-1 for the years ended December 31, 2021 and 2020 and the reference to our firm under the caption “Experts” in the Registration Statement.
/s/ M&K CPA’s, PLLC
www.mkacpas.com
Houston, TX
December 8, 2022
Exhibit 107
Calculation of Filing Fee Tables
Form
S-1
(Form Type)
Scripps
Safe, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type | Security Class Title |
Fee Calculation or Carry Forward Rule |
Maximum Aggregate Offering Price(1)(2) |
Fee Rate | Amount
of Registration Fee |
|||||||||||||||
Newly Registered Securities | ||||||||||||||||||||
Fees to Be Paid | Equity | Common Stock, par value $0.0001 per share(3) | 457 | (o) | $ | 17,250,000 | $110.20 per $1,000,000 |
$ | 1,900.95 | |||||||||||
Underwriter Warrants(4) | 457 | (g) | — | — | — | |||||||||||||||
Common stock issuable upon exercise of Underwriter Warrants(5) | 457 | (o) | $ | 1,620,000 | $110.20 per $1,000,000 |
$ | 178.52 | |||||||||||||
Total Offering Amounts | $ | 18,870,000 | $110.20 per $1,000,000 |
$ | 2,079.47 | |||||||||||||||
Total Fees Previously Paid | — | |||||||||||||||||||
Total Fee Offsets | — | |||||||||||||||||||
Net Fee Due | $ | 2,079.47 |
(1) | Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) of the Securities Act of 1933, as amended. Includes shares to be sold upon exercise of the underwriters’ option to purchase additional shares. |
(2) | Pursuant to Rule 416, the securities being registered hereunder include such indeterminate number of additional securities as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions. |
(3) | Includes shares of common stock which may be issued on exercise of a 45-day option granted to the underwriters to cover over-allotments. |
(4) | No fee pursuant to Rule 457(g) under the Securities Act of 1933, as amended. |
(5) | As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o), the proposed maximum aggregate offering price of the Underwriter Warrants is $1,620,000, which is equal to 9.0% of the aggregate number of shares of common stock sold in this offering, excluding the overallotment option, at an exercise price equal to 120% of the public offering price per share. |